Document:

EX-10.16

 Exhibit 10.16 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  
 

 
 EXECUTION COPY 

RESEARCH COLLABORATION, OPTION 

AND EXCLUSIVE LICENSE AGREEMENT 

by and between 
 MERCK
SHARP & DOHME CORP. 
 and 

AMBRX, INC. 

 

 
  

 RESEARCH COLLABORATION, OPTION 

AND EXCLUSIVE LICENSE AGREEMENT 

THIS RESEARCH COLLABORATION, OPTION AND EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), effective as of June 13, 2012
(the “Effective Date”), by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey, (“Merck”) and AMBRX, INC., a corporation organized and existing under the
laws of the State of Delaware (“Ambrx”). 
 RECITALS: 

WHEREAS, Ambrx has developed Ambrx Know-How (as hereinafter defined) and has rights to Ambrx Patent Rights (as hereinafter defined);

 WHEREAS, Merck and Ambrx desire to enter into a research collaboration to identify and optimize polypeptide drug conjugates which
are developed against one or more of the Selected Targets (as hereinafter defined), using, among other things Ambrx’s ReCODETM Technology (as hereinafter defined) and/or EuCODETM Technology (as hereinafter defined), upon the terms and
conditions set forth herein; 
 WHEREAS, Merck desires to obtain a license under the Ambrx Patent Rights and Ambrx Know-How upon the
terms and conditions set forth herein, and Ambrx desires to grant such a license, in order to conduct the research collaboration activities; 

WHEREAS, Merck desires to have certain options, exercisable at Merck’s sole discretion, to obtain an exclusive license under the
Ambrx Patent Rights and Ambrx Know-How to further develop and commercialize the polypeptide drug conjugates, including against one or more of the Selected Targets, resulting from the research collaboration for use in the Field (as hereinafter
defined) in the Territory (as hereinafter defined), and Ambrx desires to grant Merck such options, upon the terms and conditions set forth herein; and 

WHEREAS, upon exercise by Merck of its option(s), Merck shall have the right to exercise the exclusive licenses under the Ambrx Patent
Rights and Ambrx Know-How to research, develop, make, have made, use, sell, offer for sale, export and import Compounds (as hereinafter defined) and Products (as hereinafter defined) for use in the Field in the Territory, and Ambrx desires to grant
such licenses, upon the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing premises and the
mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless specifically set forth to the contrary herein, the following terms shall have the respective meanings set forth below: 

	 	1.1	“Act” shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§ 301 et seq., and/or the Public Health Service Act, 42 U.S.C. §§ 262 et
seq., as such may be amended from time to time. 

  

	 	1.2	“Affiliate” shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by or is under common control with such Person. A Person shall be deemed
to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of such Person, whether through the ownership of fifty percent (50%) or more of the voting securities of such
Person, by contract or otherwise. 

  

	 	1.3	“Agreement” shall have the meaning set forth in the introductory paragraph to this Agreement. 

  

	 	1.4	“Ambrx” shall have the meaning set forth in the introductory paragraph to this Agreement. 

  

	 	1.5	“Ambrx Background Know-How” shall mean all information and materials, including discoveries, improvements, processes, methods, protocols, formulas, compositions of matter, data, inventions,
know-how (including any Linker Technology) and/or trade secrets, patentable or otherwise, which (i) are Controlled by Ambrx or any of its Affiliates as of the Effective Date or during the Research Program Term, (ii) are not generally known
and (iii) are necessary or reasonably useful either (a) in connection with the performance of activities under the Research Program and/or (b) in connection with the research, development, manufacture, marketing, use or sale of
Compound(s) or Product(s) in the Territory. [***] For clarity, the use of “Affiliate” in this definition shall exclude any Third Party that becomes an Affiliate of Ambrx after the
Effective Date due to a Change of Control involving Ambrx and such Third Party; provided that (i) such Affiliate does not engage in Research Program activities under this Agreement and (ii) for clarity, in all cases, all information and
materials included within the “Ambrx Background Know-How” prior to the time that such Change of Control occurs shall continue to be included in “Ambrx Background Know-How” following such Change of Control. 

 

	 	1.6	“Ambrx Collaboration Information and Inventions” shall mean all Collaboration Information and Inventions, patentable or otherwise, that are conceived, discovered, developed, invented, reduced to
practice and/or otherwise made under the Research Program solely by employees of Ambrx (or any of its Affiliates) or other persons (not employed by Merck (or any of its Affiliates)) acting on behalf of Ambrx (or any of its Affiliates).

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 2
- 

	 	1.7	“Ambrx Know How” shall mean, the Ambrx Background Know-How, the Ambrx Collaboration Information and Inventions and Ambrx’s rights in Joint Collaboration Information and Inventions.

  

	 	1.8	“Ambrx Patent Rights” shall mean any and all Patent Rights in the Territory which are Controlled by Ambrx or any of its Affiliates as of the Effective Date or during the Term and which
(i) claim or cover any Compound and/or Product or the research, development, manufacture, marketing, use or sale thereof;(ii) claim or cover Ambrx Know-How (including any Ambrx Collaboration Information and Inventions or Ambrx’s
rights in Joint Collaboration Information and Inventions); or (iii) claim or cover ReCODETM Modification or EuCODETM Modification. [***] 

  

	 	1.9	“Ambrx Third Party License Agreements” shall mean the Scripps License. 

  

	 	1.10	“Applicable Laws” shall mean the applicable laws of any jurisdiction which are applicable to any of the Parties or their respective Affiliates in carrying out activities hereunder or to which any
of the Parties or their respective Affiliates in carrying out the activities hereunder is subject, and shall include all statutes, enactments, acts of legislature, laws, ordinances, rules, regulations, notifications, guidelines, policies,
directions, directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local authority or other governmental entity in such jurisdictions, including the Act. 

 

	 	1.11	“Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.

  

	 	1.12	“Calendar Year” shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31. 

 

	 	1.13	“Cancer” shall mean a disease in humans primarily characterized by uncontrolled growth or spread of abnormal and anaplastic cells, metastases, neoplasm, malignant tumors and/or invasion by
abnormal and anaplastic cells into tissues. [***]. 

  

	 	1.14	“Change of Control” shall mean [***] 

  

	 	1.15	“Clinical Trial” shall mean a Phase I Clinical Trial, Phase II Clinical Trial, or Phase III Clinical Trial, as applicable. 

 

	 	1.16	“Collaboration Information and Inventions” shall mean any protocol, formula, data, know-how, information, trade secret, process, method, composition of matter [***], compound [***], material,
article of manufacture, discovery, invention or finding, patentable or otherwise, that is first conceived, discovered, developed, invented, reduced to practice and/or otherwise made (as would be necessary to establish inventorship under United
States patent law (regardless of where the applicable activities occurred)) in performance of the Research Program. For clarity, “Collaboration Information and Inventions” shall exclude Patent Rights. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 3
- 

	 	1.17	“Combination Product” shall mean a Product which includes one or more active ingredients other than a Compound in combination with a Compound. All references to Product in this Agreement shall be
deemed to include Combination Product. 

  

	 	1.18	“Commercially Reasonable Efforts” shall mean[***]. 

  

	 	1.19	“Committee” shall mean the joint research committee established to facilitate the Research Program, as more fully described in Section 2.4.1. 

 

	 	1.20	“Compound” shall mean any and all (a) polypeptide drug conjugates Discovered in performance of a Research Program with Primary Activity directed against the applicable Selected Target and
(b) any subsequent modifications or derivatives of such polypeptide drug conjugate under subsection (a) that still maintain Primary Activity directed against the applicable Selected Target, whether modified or derived during or after the
Research Program. [***]. 

  

	 	1.21	“Confidential Information” shall mean any and all proprietary and/or confidential information and data, including all scientific, pre-clinical, clinical, regulatory, manufacturing, marketing,
financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement. 

 

	 	1.22	“Control”, “Controls” or “Controlled by” shall mean with respect to any Patent Rights, know-how or other intellectual property assets or other items or rights,
as applicable, the possession of (whether by ownership or license or other right, other than pursuant to a license under this Agreement), or the ability of a Party to grant access to, or a license or sublicense of, such item or right as provided for
herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense. 

 

	 	1.23	“Discover” shall mean, [***] 

  

	 	1.24	“EuCODETM Modification” shall mean the design, creation, modification and/or generation of compounds against a Target through the incorporation, substitution or addition of one or more
non-naturally encoded amino acids (i.e., amino acids other than the 20 naturally-encoded amino acids), including non-naturally encoded amino acids providing one or more points of site-specific attachment for a drug, into the amino acid sequence of
the polypeptide comprising such compounds against a Target using EuCODETM Technology. 

  

	 	1.25	“EuCODETM Technology” shall mean Ambrx Patent Rights and Ambrx Know-How (i) necessary for performing EuCODETM Modification and/or (ii) directed to or 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 4
- 

	 	
necessary for expressing, or chemically modifying, Compounds resulting from EuCODETM Modification. 

  

	 	1.26	“Field” shall mean the use of Compound and Product [***]. 

  

	 	1.27	“Filing” of an NDA (or IND, as applicable) shall mean the acceptance by a Regulatory Authority of an NDA (or IND, as applicable) for filing; provided that such Regulatory Authority has not issued
a refusal to file letter or a letter identifying deficiencies for which the Regulatory Authority will suspend its review following submission of the filing. 

  

	 	1.28	“First Commercial Sale” shall mean, with respect to a given Product in a given country in the Territory[***]. 

 

	 	1.29	“Full Time Equivalent” or “FTE” shall mean the equivalent of a full-time scientist’s work time over a Calendar Year consisting of a total of one thousand seven hundred and
sixty (1760) hours per Calendar Year of work devoted to, and directly related to, conducting activities under the Research Program in accordance with this Agreement. Any individual who devotes less than one thousand seven hundred and sixty
(1760) hours per Calendar Year to conducting activities under the Research Program shall be treated as an FTE on a pro-rata basis taking into account the actual number of hours worked on conducting activities under the Research Program divided
by one thousand seven hundred and sixty (1760) hours. No individual may be charged at greater than one (1) FTE in a given Calendar Year. 

  

	 	1.30	“FTE Rate” shall mean [***]. 

  

	 	1.31	“GLP” or “Good Laboratory Practice” shall mean the applicable then-current standards for laboratory activities for pharmaceuticals or biologicals, as set forth in the Act, as
amended from time to time, together with any similar standards of good laboratory practice as are required by any Regulatory Authority in the Territory. 

  

	 	1.32	“Improvement to Ambrx Background Technology” shall mean any Collaboration Information and Invention which is an improvement, modification, alteration or enhancement of any Ambrx Background
Know-How (including any Improvement to Ambrx Linker Technology Solely Developed by Ambrx). Notwithstanding the foregoing, “Improvement to Ambrx Background Technology” shall exclude any Collaboration Information and Invention that is
(i) an Improvement to Ambrx Linker Technology (other than an Improvement to Ambrx Linker Technology Solely Developed by Ambrx), [***] and/or (iii) a Selected Target, Compound or Product (or specifically related to, or applicable to, a
Selected Target, Compound or Product). 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 5
- 

	 	1.33	“Improvement to Ambrx Linker Technology” shall mean any Collaboration Information and Invention which is an improvement, modification, alteration or enhancement of any Linker Technology within
the Ambrx Background Know-How. 

  

	 	1.34	“Improvement to Ambrx Linker Technology Solely Developed by Ambrx” shall mean any Improvement to Ambrx Linker Technology that is conceived, discovered, developed, invented, reduced to practice
and/or otherwise made under the Research Program solely by employees of Ambrx (or any of its Affiliates) or other persons (not employed by Merck (or any of its Affiliates)) acting on behalf of Ambrx (or any of its Affiliates). 

 

	 	1.35	“Improvement to Merck Background Technology” shall mean any [***] 

  

	 	1.36	“Improvement to Merck Linker Technology” shall mean any [***] 

  

	 	1.37	“IND” shall mean an Investigational New Drug application, Clinical Study Application, Clinical Trial Exemption, or similar application or submission for approval to conduct human clinical
investigations filed with or submitted to the applicable Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

  

	 	1.38	“IND-Enabling Pharmacology and Toxicology Study” shall mean a genotoxicity, acute toxicology, safety pharmacology and sub-chronic toxicology study, in species that satisfy applicable regulatory
requirements, using applicable GLP, that meets the standard necessary for submission as part of an IND filing with the applicable Regulatory Authority[***]. 

  

	 	1.39	“Initiates” or “Initiation” shall mean, with respect to a Clinical Trial, the administration of the first dose to a patient in such Clinical Trial. 

 

	 	1.40	“Joint Collaboration Information and Inventions” shall mean all Collaboration Information and Inventions, patentable or otherwise, that are conceived, discovered, developed, invented, reduced to
practice and/or otherwise made under the Research Program jointly by employee(s) of Merck and/or its Affiliate and/or a Third Party acting on behalf of Merck or its Affiliate, on the one hand, and employee(s) of Ambrx and/or its Affiliate and/or a
Third Party acting on behalf of Ambrx or its Affiliate, on the other hand. 

  

	 	1.41	“Joint Patent Rights” shall mean all Patent Rights to the extent claiming patentable Joint Collaboration Information and Inventions. 

 

	 	1.42	“Linker Technology” shall mean [***]. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 6
- 

	 	1.43	“Major Markets” shall mean the following countries: the United States, Japan, the United Kingdom, France, Germany, Italy and Spain. 

 

	 	1.44	“Major Market in the EU” shall mean any one of the following countries: the United Kingdom, France, Germany, Italy or Spain. 

 

	 	1.45	“Marketing Authorization” shall mean all approvals from the relevant Regulatory Authority necessary to market and sell a Product in a given country in the Territory (including all applicable
pricing and governmental reimbursement approvals legally required to sell Product in such country). 

  

	 	1.46	“Merck” shall have the meaning set forth in the introductory paragraph to this Agreement. 

  

	 	1.47	“Merck Background Know-How” shall mean [***]. 

  

	 	1.48	“Merck Collaboration Information and Inventions” shall mean all Collaboration Information and Inventions, patentable or otherwise, that are conceived, discovered, developed, invented, reduced to
practice and/or otherwise made under the Research Program solely by employees of Merck (or any of its Affiliates) or other persons (not employed by Ambrx (or any of its Affiliates)) acting on behalf of Merck (or any of its Affiliates).

  

	 	1.49	“Merck Know-How” shall mean the Merck Background Know-How, the Merck Collaboration Information and Inventions and Merck’s rights in Joint Collaboration Information and Inventions.

  

	 	1.50	“Merck Patent Rights” shall mean any and all Patent Rights in the Territory which are Controlled by Merck or any of its Affiliates and which claim or cover Merck Know-How (including Merck
Collaboration Information and Inventions and Merck’s rights in Joint Collaboration Information and Inventions). 

  

	 	1.51	“Merck Proprietary Molecule” shall mean [***]. 

  

	 	1.52	“Merck Reversion Technology” shall mean [***]. 

  

	 	1.53	“NDA” shall mean a New Drug Application, Biologics License Application, Worldwide Marketing Application, Marketing Authorization Application, filing pursuant to Section 510(k) of the Act, or
similar application or submission for Marketing Authorization of a Product filed with a Regulatory Authority to obtain marketing approval for a biological, pharmaceutical or diagnostic product in a given country or group of countries.

  

	 	1.54	“Net Sales” shall mean the [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 7
- 

	 	(a)	[***] 

  

	 	(b)	[***] 

  

	 	(c)	[***] 

  

	 	(d)	[***] 

  

	 	(e)	[***] 

  

	 	(f)	[***] 

  

	 	(g)	[***] 

 [***] 

[***] 
  

	 	1.55	“Option(s)” shall have the meaning set forth in Section 3.6.1(c) of this Agreement. 

  

	 	1.56	“Option Exercise Date” shall mean the date that Merck exercises a given Option (if any) as set forth in Section 3.6.1. 

 

	 	1.57	“Party” shall mean Merck or Ambrx, individually, and “Parties” shall mean Merck and Ambrx, collectively. 

 

	 	1.58	“Patent Rights” shall mean (i) patents and patent applications in the Territory (which for the purposes of this Agreement shall be deemed to include certificates of invention and
applications for certificates of invention) and (ii) any and all divisionals, continuations, continuations-in-part, reissues, renewals, substitutions, registrations, re-examinations, revalidations, extensions, supplementary protection
certificates and the like of any such patents and patent applications, and any and all foreign equivalents of the foregoing in the Territory. 

  

	 	1.59	“Person” means any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any
other entity not specifically listed herein. 

  

	 	1.60	“Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(a), as may be amended, or the foreign equivalent thereof.

  

	 	1.61	“Phase II Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(b), as may be amended, or the foreign equivalent thereof.

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 8
- 

	 	1.62	“Phase III Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(c), as may be amended, or the foreign equivalent thereof.

  

	 	1.63	“Preclinical Proof of Concept” shall mean that a given Compound has successfully met the criteria, as reasonably determined by Merck, set forth in the applicable Research Plan as the proof of
concept criteria. 

  

	 	1.64	“Primary Activity” shall mean [***]. 

  

	 	1.65	“Product” shall mean any pharmaceutical or biological preparation in final form containing a Compound for any and all uses in the Field, including any Combination Product. For clarity, different
formulations or dosage strengths of a given Product shall be considered the same Product for purposes of this Agreement. 

  

	 	1.66	“Program Linker Technology” shall mean any Linker Technology that is a Collaboration Information and Invention. 

 

	 	1.67	“ReCODETM Modification” shall mean the design, creation, modification and/or generation of compounds against a Target through the incorporation, substitution or addition of one or more
non-naturally encoded amino acids (i.e., amino acids other than the 20 naturally-encoded amino acids), including non-naturally encoded amino acids providing one or more points of site-specific attachment for a drug, into the amino acid sequence of
the polypeptide comprising such compounds against a Target using ReCODETM Technology. 

  

	 	1.68	“ReCODETM Technology” shall mean Ambrx Patent Rights and Ambrx Know-How (i) necessary for performing ReCODETM Modification and/or (ii) directed to or necessary for expressing,
or chemically modifying, Compounds resulting from ReCODETM Modification. 

  

	 	1.69	“Regulatory Authority” shall mean any applicable government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of a Product in the
Territory, including, in the United States, the United States Food and Drug Administration and any successor governmental authority having substantially the same function. 

 

	 	1.70	“Related Party” shall mean each of Merck, its Affiliates, and their respective sublicensees (which term does not include distributors), as applicable. 

 

	 	1.71	“Research [***]” shall mean [***]. 

  

	 	1.72	“Research [***]” shall mean [***]. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 9
- 

	 	1.73	“Research [***]” shall mean [***]. 

  

	 	1.74	“Research [***]” shall mean [***]. 

  

	 	1.75	“Research [***]” shall mean [***]. 

  

	 	1.76	“Research [***]” shall mean [***]. 

  

	 	1.77	“Research [***]” shall mean [***]. 

  

	 	1.78	“Research [***]” shall mean [***]. 

  

	 	1.79	“Research [***]” shall mean [***]. 

  

	 	1.80	“Research [***]” shall mean [***]. 

  

	 	1.81	“Research [***]” shall mean [***]. 

  

	 	1.82	“Research [***]” shall mean [***]. 

  

	 	1.83	“Reversion Combination Product” shall mean a Reversion Product which includes one or more active ingredients other than a Reversion Compound in combination with a Reversion Compound.

  

	 	1.84	“Reversion Compound” shall mean [***] 

  

	 	1.85	“Reversion Product” shall mean any pharmaceutical or biological preparation in final form containing a Reversion Compound for any and all uses in the Field, including any Reversion Combination
Product. For clarity, once a given Product becomes a Reversion Product, it shall no longer be considered a “Product” for purposes of this Agreement. 

  

	 	1.86	“Royalty Products” shall mean [***], as applicable. 

  

	 	1.87	“Scripps License” shall mean that certain License Agreement by and between The Scripps Research Institute (“Scripps”) and Ambrx, dated as of August 26, 2003, as amended by
Amendment No. 1, dated December 19, 2005, and as the same may be amended from time to time in accordance with this Agreement. 

  

	 	1.88	“Selected Target” shall mean [***] 

  

	 	1.89	“Target” shall mean [***] 

  

	 	1.90	“Target [***]” shall mean [***]. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
10 - 

	 	1.91	“Target [***]” shall mean [***]. 

  

	 	1.92	“Target [***]” shall mean [***]. 

  

	 	1.93	“Target [***]” shall mean [***]. 

  

	 	1.94	“Target [***]” shall mean [***]. 

  

	 	1.95	“Target [***]” shall mean [***]. 

  

	 	1.96	“Territory” shall mean all of the countries in the world, and their territories and possessions. 

  

	 	1.97	“Third Party” shall mean an entity other than Merck and its Affiliates, and Ambrx and its Affiliates. 

  

	 	1.98	[***]. 

  

	 	1.99	[***]. 

  

	 	1.100	“Valid Patent Claim” shall mean [***]. 

  

	 	1.101	“Violation” shall mean that a Party or any of its officers or directors or any other personnel (or other permitted agents of such Party performing activities hereunder) has been:
(1) convicted of any of the felonies identified among the exclusion authorities listed on the U.S. Department of Health and Human Services, Office of Inspector General (OIG) website, including 42 U.S.C. 1320a-7(a)
(http://oig.hhs.gov/exclusions/authorities.asp); (2) identified in the OIG List of Excluded Individuals/Entities (LEIE) database (http://exclusions.oig.hhs.gov/) or the U.S. General Services Administration’s list of Parties Excluded from
Federal Programs (http://www.epls.gov); or (3) listed by any US Federal agency as being suspended, debarred, excluded or otherwise ineligible to participate in Federal procurement or non-procurement programs, including under 21 U.S.C. 335a
(http://www.fda.gov/ora/compliance_ref/debar/) (each of (1), (2) and (3) collectively the “Exclusions Lists”). 

  

	 	1.102	Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement: 

  

			
	 Term
	  	 Section

		
	“AAA”	  	10.6.1
	“Additional Third Party Licenses”	  	5.5.7
	“Ambrx Compound Patent Rights”	  	7.2.1

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
11 - 

			
	“Ambrx Indemnified Parties”	  	9.1
	“Code”	  	8.4(g)
	“Development/Commercialization Milestones”	  	5.4.2
	[***]	  	5.4.2
	[***]	  	5.4.2
	[***]	  	5.4.2
	[***]	  	5.4.2
	[***]	  	5.4.2
	“Eliminated FTE”	  	5.2.3
	“Excluded Claim”	  	10.6.6
	“Excluded Targets”	  	2.1.1
	“Exclusions Lists”	  	1.101
	“Human Materials”	  	2.2.2
	“Indemnified Party”	  	9.3
	“Indemnifying Party”	  	9.3
	“License Payments”	  	5.9
	“Materials”	  	2.9
	“Merck Indemnified Parties”	  	9.2
	“Officials”	  	2.12.2
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	“Option Outside Date”	  	3.6.1(c)
	“Payment”	  	2.12.2
	“Project Leader”	  	2.4.3
	“Providers”	  	2.2.2
	“Research Milestones”	  	5.4.1
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	“Royalty Period”	  	5.5.4
	“Safety/Efficacy Termination”	  	8.2
	“Sensitive Information”	  	10.2
	“Taxes”	  	5.9
	“Target Identification Date”	  	2.1.1
	“Target Identification Notice”	  	2.1.1
	“Term”	  	8.1

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
12 - 

			
	“Third Party Research Costs”	  	5.2.1
	“[***] Sublicense”	  	3.2

 ARTICLE 2 

RESEARCH PROGRAM 
  

	 	2.1	General; Research Plans and Selected Targets 

  

	 	2.1.1	Identification of Selected Targets. The Parties hereby agree and acknowledge that Target 1 has been identified by the Parties and is more particularly described on Schedule 1.90. Within [***] after
the Effective Date, Merck shall identify a [***]), which Targets may be chosen by Merck in its sole discretion; provided, however, that such Targets are not otherwise identified on Schedule 2.1.1 (the “Excluded Targets”);
[***] Merck shall notify Ambrx thereof in writing (each such notice, a “Target Identification Notice”, and the date of delivery of such notice with respect to a given Target, the “Target Identification Date”, as
applicable). 

  

	 	2.1.2	Creation of Initial Research Plans. The Parties hereby acknowledge and agree that the initial Research Plan 1 for the activities under Research Program 1 is attached hereto as Schedule 1.72. [***].

  

	 	2.1.3	Research Program in General. Ambrx and Merck shall engage in the [***] upon the terms and conditions set forth in this Agreement and as directed by the Committee. The activities to be undertaken in the
course of the Research Program shall be set forth in [***], any or all of which Research Plans may be amended from time to time by the Committee as set forth herein. Each Research Plan shall provide that, subject to Section 2.4.1, Ambrx shall
solely be responsible for (a) making the research quantities of recombinant polypeptides incorporating non-active amino acids under the applicable Research Program for use in such Research Program and (b) EuCODETM Modification
activities and ReCODETM Modification activities involving the use or application of EuCODETM Technology or ReCODETM Technology under the Research Plan (subject to Section 2.5.2) for the applicable Research Program, in each case,
through the earlier of (i) the applicable Option Outside Date for such Research Program or (ii) the exercise of the applicable Option by Merck for such Research Program. 

 

	 	2.2	Conduct of Research 

  

	 	2.2.1	 Activities and Efforts. Ambrx and Merck each shall use Commercially Reasonable Efforts to accomplish the objectives of the Research
Program, 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
13 - 

	 	
including to perform all activities to be performed by such Party as set forth in the applicable Research Plan, and in connection therewith, each Party shall maintain and utilize sufficient
equipment, laboratories, offices and other facilities, and use personnel with sufficient skills and experience, in each case, as are required to accomplish the Research Program in accordance with the terms of this Agreement and the Research Plans,
as applicable. 

  

	 	2.2.2	Compliance. Ambrx and Merck each shall conduct the Research Program in compliance with all Applicable Laws. In addition, if animals are used in research under a Research Program hereunder, the Parties will
comply with the Animal Welfare Act or any other applicable local, state, national and international laws and regulations relating to the care and use of laboratory animals, and are encouraged to use the highest standards, such as those set forth in
the Guide for the Care and Use of Laboratory Animals (NRC, 1996), for the humane handling, care and treatment of such research animals. Any animals which are used in the course of a Research Program, or products derived from those animals, such as
eggs or milk, will not be used for food purposes, nor will these animals be used for commercial breeding purposes. In addition, if any human cell lines, tissue, human clinical isolates or similar human-derived materials (“Human
Materials”) have been or are to be collected and/or used in a Research Program, each Party represents and warrants (i) that it has complied, or shall comply, with all Applicable Laws relating to the collection and/or use of the Human
Materials and (ii) that it has obtained, or shall obtain, all necessary approvals and appropriate informed consents, in writing, for the collection and/or use of such Human Materials, and such Party shall provide documentation of such approvals
and consents to the other upon request. Each Party further represents and warrants that such Human Materials may be used as contemplated in this Agreement without any obligations to the individuals or entities (“Providers”) who
contributed the Human Materials, including any obligations of compensation to such Providers or any other Third Party for the intellectual property associated with, or commercial use of, the Human Materials for any purpose. Each Party shall notify
the other Party in writing of any deviations from applicable regulatory or legal requirements. Each Party hereby certifies that it has not employed or otherwise used in any capacity, and will not employ or otherwise use in any capacity, the services
of any person debarred under United States law, including but not limited to Section 21 USC 335a, or foreign equivalent thereof, in performing any portion of the Research Program. Each Party shall notify the other Party in writing immediately
if any such debarment occurs or comes to its attention, and shall, with respect to any person or entity so debarred promptly remove such person or entity from performing any Research Program activities, function or capacity related to the Research
Program. 

  

	 	2.2.3	 Subcontractors. Merck shall be entitled to utilize the services of its Affiliates and Third Parties to perform its Research Program
activities. Ambrx shall be entitled to utilize the services of its Affiliates to perform its Research Program activities; Ambrx shall be entitled to utilize the services of Third Parties to perform its

  
 - 14 - 

	 	
Research Program activities only upon Merck’s prior written consent, not to be unreasonably withheld, or as specifically set forth in the applicable Research Plan. Notwithstanding any such
consent, each Party shall remain at all times fully liable for its respective responsibilities under the Research Program. In all cases, the rights granted to any subcontractor shall be subject and subordinate to the applicable terms and conditions
of this Agreement. The applicable Party engaging a subcontractor shall oversee the performance by its subcontractors of the subcontracted activities in a manner that would be reasonably expected to result in their timely and successful completion of
such activities, and such Party shall remain responsible and primarily and fully liable for the performance of such activities in accordance with this Agreement. Each Party hereby expressly waives any requirement that the other Party exhaust any
right, power or remedy, or proceed against such subcontractor for any obligation or performance hereunder, prior to proceeding directly against the Party engaging such subcontractor. The Party engaging a subcontractor shall ensure compliance with
the applicable terms of this Agreement by any such subcontractor with respect to the applicable activities to be performed by such subcontractor hereunder, including with respect to provisions on confidentiality and intellectual property ownership
and compliance with legal requirements. Without limiting the foregoing, to the extent that a Party utilizes Third Party contractors to perform Research Program activities, such Party shall ensure that such Third Party contractors are obligated to
assign rights to any Collaboration Information and Inventions made by such Third Party contractors so that such rights can be conveyed in accordance with the terms and conditions of this Agreement, including Section 2.7. 

 

	 	2.3	Use of Research Funding 

 Ambrx shall apply the research funding it receives from
Merck under this Agreement to carry out its Research Program activities in accordance with the applicable Research Plan and the terms and conditions of this Agreement. 
  

	 	2.4	Joint Research Committee 

 The Parties hereby establish a committee to facilitate
the Research Program as follows: 
  

	 	2.4.1	 Composition of the Joint Research Committee. The Research Program shall be conducted under the direction of a joint research committee
(the “Committee”) comprised of three (3) representatives of Merck and three (3) representatives of Ambrx. Each Party shall provide the other with a list of its initial members of the Committee no later than thirty
(30) days after the Effective Date, and each Party may change its representatives to the Committee from time to time, in its sole discretion, effective upon notice to the other Party of such change. These representatives shall have appropriate
technical credentials, experience and knowledge, and ongoing familiarity with the Research Program. Additional representatives or consultants may from time to time, by mutual consent of the

  
 - 15 - 

	 	
Parties, be invited to attend Committee meetings, subject to such representative’s or consultant’s written agreement to comply with the requirements of Section 4.1. The Committee
shall be chaired by a representative of Merck, who shall prepare written draft minutes of all Committee meetings within twenty (20) days following such meetings, and shall circulate such minutes to the Committee members. Merck shall issue final
minutes within twenty (20) days following receipt of Ambrx’s written comments. Decisions of the Committee shall be made unanimously by the representatives, with each Party having a single vote. In the event that the Committee cannot or
does not, after good faith efforts, reach agreement on an issue, the issue will be communicated [***] who shall endeavor to facilitate a resolution of such issue. If the Parties have not resolved such issue within ten (10) business days
following the communication of the issue to them, then the resolution and/or course of conduct shall be determined by Merck, in its sole discretion (and such matter shall not be subject to dispute resolution pursuant to Section 10.6); [***] or
(iii) resolve any dispute regarding payments hereunder. In making such final decision, the [***] shall consider any comments from Ambrx and such decision shall be consistent with the general goals of the applicable Research Program. Each Party
shall bear its own expenses related to the attendance of such meetings by its representatives. 

  

	 	2.4.2	 Meetings and Responsibilities. The Committee shall meet in accordance with a schedule established by mutual written agreement of the
Parties, but no less frequently than once per Calendar Quarter, with the location for such meetings alternating between Ambrx and Merck facilities (or such other location as may be determined by the Committee). Alternatively, the Committee may meet
by means of teleconference, videoconference or other similar communications equipment. The Committee shall be responsible for directing the Research Program and making decisions and determinations in connection therewith, including (i) to
create and approve [***], (ii) to amend any of the Research Plans (including with respect to any extension periods as set forth in Section 5.3), (iii) to review and coordinate the Parties’ activities under the Research Program,
(iv) to confer regarding the status of the Research Program and the progress under the Research Program, (v) to review relevant data under the Research Program, (vi) to consider and advise on any technical issues that arise under the
Research Program, (vii) to consider issues of priority of activities under the Research Program, (viii) to discuss intellectual property strategy and other intellectual property matters under the Research Program, and to discuss matters
related to Merck Background Know-How, Merck Patent Rights, Ambrx Background Know-How and Ambrx Patent Rights, which a Party proposed to make available or has made available for use in connection with performance of activities under the Research
Program, and to discuss other relevant Third Party intellectual property rights, and (ix) to review and advise on any budgetary and economic matters relating to the Research Program (including to allocate resources across the projects and to

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
16 - 

	 	
determine the number of FTEs needed to conduct the Research Program activities). 

  

	 	2.4.3	Project Leaders. Merck and Ambrx each shall appoint a person (a “Project Leader”) from the Committee to coordinate its part of the Research Program. The Project Leaders shall be the
primary contact between the Parties with respect to the Research Program. Each Party shall notify the other within thirty (30) days of the Effective Date of the appointment of its Project Leader and shall notify the other Party as soon as
practicable upon changing this appointment. 

  

	 	2.4.4	Limitations on Authority of the Committee. The Committee will have solely the roles and responsibilities assigned to it in this Article 2. The Committee will have no authority to amend, modify or waive
compliance with this Agreement (provided that for clarity, the Committee shall have the right to amend or modify the Research Plans as set forth in this Section 2.4). In addition, the Committee will have no authority to amend, modify or limit
Merck’s final decision-making authority with respect to the development and commercialization of Compound and Product as set forth in this Agreement. 

  

	 	2.4.5	Disbandment of Committee. Upon completion (or earlier termination) of a given Research Program, the Committee shall have no further authority with respect to the Compounds (or Reversion Compounds, as
applicable) Discovered under such Research Program, and all further research and development thereof hereunder shall be in accordance with Section 3.8. Upon completion (or earlier termination) of all Research Programs, the Committee shall be
disbanded and shall have no further authority with respect to the activities hereunder, and all further research and development of Compounds (or Reversion Compounds, as applicable) hereunder shall be in accordance with Section 3.8.

  

	 	2.5	Exchange of Information 

  

	 	2.5.1	Ambrx Background Know-How. Within a reasonable time period following execution of this Agreement (but in all cases within thirty (30) days after the Effective Date), and promptly on an ongoing basis
during the Research Program Term, Ambrx shall disclose to Merck in English (and deliver in writing or in an electronic format) Ambrx Background Know-How related to the effects of the non-native amino acid format on process, protein folding,
stability, pharmacokinetics and safety not previously disclosed in writing to Merck. 

  

	 	2.5.2	 Technology Transfer of EuCODETM Technology or ReCODETM Technology during Research Program Term. For clarity, Ambrx shall be
solely responsible for all EuCODETM Modification activities and ReCODETM Modification activities involving the use or application of EuCODETM Technology or ReCODETM Technology under the applicable Research Plan during the applicable
Research Program Term. Notwithstanding the foregoing (and without limiting any other rights or remedies of Merck hereunder), if Ambrx is unable to perform such activity(ies) to a material degree and such inability continues for sixty (60) days

  
 - 17 - 

	 	
following receipt of written notice from Merck, Ambrx shall transfer to Merck the EuCODETM Technology and ReCODETM Technology (and any other relevant Ambrx Background Technology)
reasonably necessary for Merck to perform such activity(ies) and Ambrx shall reasonably assist Merck in performing such activity(ies). 

  

	 	2.6	Records and Reports 

  

	 	2.6.1	Records. Ambrx shall maintain complete and accurate records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all
work done and results achieved in the performance of the Research Program by Ambrx, as well as the number of FTEs utilized by Ambrx for the performance of the Research Program. Merck shall maintain complete and accurate records, in sufficient detail
and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work done and results achieved in the performance of the Research Program by Merck. Upon request during the Term, the other
Party shall provide copies of the records described in Section 2.6.1 above (provided, however, that Ambrx shall only have the right to receive copies of such records with respect to Reversion Compounds or other Collaboration Information and
Inventions over which Ambrx has prosecution control as set forth in Article 7). 

  

	 	2.6.2	Copies and Inspection of Records. During the Term, Merck shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all such records of Ambrx referred to in
Section 2.6.1 in order to verify the number of FTEs utilized by Ambrx in the performance of the Research Program. Merck shall have the right to arrange for its employees and/or consultants involved in the activities contemplated hereunder to
visit the offices and laboratories of Ambrx (and any of its Affiliates) and any of its Third Party contractors as permitted under Section 2.2 during normal business hours and upon reasonable notice, and to discuss the Research Program work and
its results in detail with the technical personnel and consultants of Ambrx. 

  

	 	2.6.3	Quarterly Reports. Within thirty (30) days following the end of each Calendar Quarter during the Research Program Term, each Party shall provide to other Party a written progress report in English
which shall describe the work performed during such Calendar Quarter on the Research Program, evaluate the work performed in relation to the goals of the Research Program for such Calendar Quarter and provide such other information as may be
required by the Research Program or reasonably requested by such other Party relating to the progress of the goals or performance of the Research Program. 

  

	 	2.6.4	 Data Integrity. Each Party acknowledges the importance of ensuring that the Research Program is undertaken in accordance with the
following good data management practices: (i) data is being generated using sound scientific techniques and processes; (ii) data is being accurately and reasonably 

  
 - 18 - 

	 	
contemporaneously recorded in accordance with good scientific practices by Persons conducting research hereunder; (iii) data is being analyzed appropriately without bias in accordance with
good scientific practices; and (iv) all data and results are being stored securely and can be easily retrieved. Each Party agrees that it shall carry out the Research Program so as to collect and record any data generated therefrom in a manner
consistent with the foregoing requirements. 

  

	 	2.7	Research Collaboration Information and Inventions 

  

	 	2.7.1	Ownership. Inventorship of Collaboration Information and Inventions shall be determined in accordance with United States patent laws (regardless of where the applicable activities occurred).
Notwithstanding the foregoing, all right, title and interest in and to any and all Collaboration Information and Inventions shall be determined in accordance with the following terms and conditions, such that the entire right, title and interest in:

  

	 	(a)	[***]; 

  

	 	(b)	[***]; and 

  

	 	(c)	[***]. 

  

	 	2.7.2	Disclosure. Ambrx shall promptly disclose to Merck in writing the development, making, conception or reduction to practice of Ambrx Collaboration Information and Inventions (including any Compounds within
such Ambrx Collaboration Information and Inventions) and/or Merck Collaboration Information and Inventions. Merck shall promptly disclose to Ambrx in writing the development, making, conception or reduction to practice of Ambrx Collaboration
Information and Inventions. Each Party shall promptly disclose to the other all Joint Collaboration Information and Inventions (including any Compounds within such Joint Collaboration Information and Inventions). 

 

	 	2.7.3	 Assignment of Interests to Effectuate Ownership. With respect to any Collaboration Information and Invention, each of Ambrx and Merck
shall, and hereby do, on behalf of themselves and each of their respective Affiliates, employees and contractors hereunder, assign to one another ownership of rights, title and interest in and to such Collaboration Information and Inventions to
effect the ownership of such Collaboration Information and Inventions as set forth in Section 2.7.1, subject to any licenses expressly granted under this Agreement. In furtherance of the foregoing, each Party shall, upon request by the other,
promptly undertake and perform (and/or cause its Affiliates and its and their respect employees and/or agents to promptly undertake and perform) such further actions as are reasonably necessary for Ambrx and Merck, as between the Parties, to each
perfect its title in any such Collaboration Information and Inventions as set forth 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
19 - 

	 	
in Section 2.7.1, as applicable, including by causing the execution of any assignments or other legal documentation, and/or providing the other Party or its patent counsel with reasonable
access to any employees or agents who may be inventors of such Collaboration Information and Inventions. 

  

	 	2.7.4	Joint Collaboration Information and Inventions. [***] 

  

	 	2.8	Research Program Term 

  

	 	2.8.1	Term. Except as otherwise provided herein, the term of each Research Program shall commence [***] 

  

	 	(a)	[***] 

  

	 	(b)	[***] 

  

	 	(c)	[***] 

 provided, however, that the Research Program Term for a given
Research Program (on a Research Program-by-Research Program basis) may be extended as set forth in Section 5.3. For clarity, to the extent a given Research Program is not otherwise terminated or discontinued pursuant to this Agreement, such
Research Program shall continue in accordance with the applicable Research Plan following the time that Merck exercises its Option with respect to such Research Program pursuant to Section 3.6.1. 

 

	 	2.8.2	Early Discontinuance of Research Program. Notwithstanding the provisions of Section 2.8.1, Merck shall have the right, in its discretion, to discontinue a given Research Program at any time (on a
Research Program-by-Research Program basis) prior to the scheduled end of the applicable Research Program Term by providing no less than ninety (90) days prior written notice of such discontinuance to Ambrx (which notice shall identify the
Research Program being discontinued and that the applicable Research Program is being discontinued pursuant to this Section 2.8.2). Upon delivery of such Research Program discontinuance notice by Merck to Ambrx (in accordance with
Section 10.4), the Research Program Term for the applicable Research Program shall automatically end on the date set forth in the discontinuance notice (but in any event no sooner than ninety (90) days following the delivery of such
discontinuance notice). For clarity, early discontinuance of a given Research Program under this Section 2.8.2 shall not be considered a termination of this Agreement with respect to such Research Program pursuant to Section 8.2.

  

	 	2.8.3	 Discontinuance of Research Program Activities. Upon expiration or early discontinuance of the Research Program Term for a given Research
Program, all 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
20 - 

	 	
further Research Program activities under such Research Program shall terminate (including all funding obligations of Merck with respect to such Research Program), but the other rights and
obligations under this Agreement shall not otherwise be affected and shall remain in full force and effect (including (i) any rights and obligations under any under any other Research Program, (ii) the rights of Merck to further research
and develop the Compounds and Products in accordance with this Agreement and (iii) the rights of Merck and Ambrx to further research and develop Reversion Compounds and Reversion Products in accordance with this Agreement). Immediately upon the
expiration or early discontinuance of a given Research Program, (a) each Party shall disclose to the other Party those Collaboration Information and Inventions as set forth in Section 2.7.2, and (b) Ambrx shall reimburse Merck for any
overpayments made by Merck under such Research Program, and/or Merck shall make any payments required under such Research Program (but solely to the extent such amounts were incurred and/or constitute an irrevocable obligation to pay prior to the
expiration or termination of such Research Program and are required to be paid by Merck in accordance with this Agreement), as the case may be. In addition, immediately following the applicable Option Outside Date, (x) with respect to any
Research Program for which Merck did not exercise its Option as set forth in Section 3.6, each Party shall return or cause to be returned to other Party all Confidential Information and all substances or compositions of the other Party
delivered or provided by such other Party, as well as any other material (including Materials) provided by such other Party in any medium under such Research Program (provided, however, that each Party may retain any such Confidential Information,
substances or compositions, as applicable, as are reasonably necessary for such Party’s continued practice under any licenses which survive the termination of the applicable Research Program Term and each Party may keep one copy of the
Confidential Information of the other Party in its confidential files for record purposes), and (y) with respect to any Research Program for which Merck did exercise its Option as set forth in Section 3.6, at Merck’s written request,
Ambrx shall return or cause to be returned to Merck all Confidential Information and all substances or compositions of Merck delivered or provided by Merck, as well as any other material (including Materials) provided by Merck in any medium under
such Research Program (provided, however, that Ambrx may retain one copy of the Confidential Information of Merck in its confidential files for record purposes). 

  

	 	2.9	Materials 

 Each Party shall provide the other with sufficient quantities of its
research materials to conduct the activities under the Research Program as set forth in the applicable Research Plan or as otherwise determined by the Committee (“Materials”, provided that for clarity, Compounds shall not be
considered “Materials”), which Materials shall be used solely for the purpose of enabling the Parties to perform their respective activities under the Research Program in accordance with the terms of this Agreement. The Materials are not
to be used in humans, nor shall any of the Materials, or any derivatives, analogs, modifications or components thereof, be transferred, delivered or disclosed to any Third Party (other than to permitted subcontractors hereunder in accordance with
Section 2.2.3) without the prior written approval of the delivering Party. Any unused Materials and any derivatives, analogs, 

  
 - 21 - 

 
modifications or components thereof shall be, at the delivering Party’s option, either returned or destroyed in accordance with instructions given by the delivering Party. All such
destruction shall be in accordance with Applicable Laws. THE MATERIALS ARE PROVIDED “AS IS” AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS
FOR ANY PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. 
  

	 	2.10	Research Program Costs 

 Except as otherwise set forth in Section 5.2, each
Party shall bear its own costs in connection with performing Research Program activities. 
  

	 	2.11	Exclusive Efforts 

  

	 	2.11.1	Ambrx. During the Term, Ambrx (and its Affiliates) shall work exclusively (even as to Ambrx itself and its Affiliates) with Merck (including, with respect to granting any rights under any Ambrx Know-How or Ambrx
Patent Rights) in efforts to discover, research, develop, identify and/or optimize polypeptide drug conjugates for each of the Selected Targets for use in the Field. [***]. Ambrx may work, itself, with an Affiliate or with a Third Party, in efforts
to discover, research, develop, identify and/or optimize polypeptide drug conjugates [***] for use in the Field. [***]. For clarity, the foregoing provisions of this Section 2.11.1 shall not prohibit or otherwise limit Ambrx from (a) discovering,
researching, developing, identifying, optimizing, commercializing or otherwise exploiting any compounds or products other than polypeptide drug conjugates for a Selected Target, or (b) discovering, researching, developing, identifying, optimizing,
commercializing or otherwise exploiting any compounds or products, including polypeptide drug conjugates other than Compounds and/or Products, for any target(s) other than a Selected Target. [***]. 

 

	 	    	[***]. Notwithstanding the foregoing, in the event that this Agreement expires or is terminated with respect to all Products for a particular Selected Target (or is terminated with respect to the Research Program for a
particular Selected Target) in accordance with Article 8, then the foregoing provisions of this paragraph of Section 2.11.1 shall not apply with respect to such Selected Target. 

 

	 	    	For clarity, the foregoing provisions of this Section 2.11.1 shall not prohibit a Third Party which becomes an Affiliate of Ambrx after the Effective Date due to a Change of Control involving Ambrx and such Third Party
from discovering, researching, developing, identifying or optimizing any polypeptide drug conjugate that was owned or otherwise controlled by such Third Party as of the time of such Change of Control; provided that (y) such Affiliate does not engage
in Research Program activities under this Agreement and (z) no Ambrx Know-How or Ambrx Patent Rights licensed to Merck hereunder are utilized in connection with such polypeptide drug conjugates. 

 

	 	2.11.2	 Merck. During the Research Program Term for a given Research Program, Merck (and its Affiliates) shall work exclusively (even as to Merck
itself and its Affiliates) with Ambrx in efforts to discover, research, develop, identify and/or optimize polypeptide drug conjugates for the Selected Target under such Research Program for use in the Field. Notwithstanding the foregoing, (i) in the
event that Merck does not exercise its Option with respect to a given Research Program in accordance with Section 3.6.1, then the foregoing provisions of this Section 2.11.2 shall not apply with respect to the Selected Target under such Research
Program, (ii) in the event that this Agreement expires or is terminated with respect to all Products for a particular Selected Target (or is terminated with respect to the Research Program for a particular Selected Target) in accordance with Article
8, then the foregoing provisions of this Section 2.11.2 shall not apply with respect to such Selected Target and (iii) the foregoing provisions of this Section 2.11.2 shall 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
22 - 

	 	
not apply with respect to any compounds or products (or programs for the discovery, research, development, identification and/or optimization of compounds or products), including polypeptide drug
conjugates, the rights to which are obtained after the Effective Date by Merck or any of its Affiliates from a Third Party whether through merger or acquisition or otherwise, including acquisition of substantially all of the assets of such Third
Party, but not by in-license of a particular polypeptide drug conjugate. For clarity, the foregoing provisions of this Section 2.11.2 shall not prohibit or otherwise limit Merck or any of its Affiliates (itself or with a Third Party) from (a)
exercising its rights and licenses, or carrying out activities, hereunder or (b) discovering, researching, developing, identifying, optimizing, commercializing or otherwise exploiting any compounds or products, other than polypeptide drug conjugates
for a Selected Target or (c) discovering, researching, developing, identifying, optimizing, commercializing or otherwise exploiting any compounds or products, including polypeptide drug conjugates, for any target(s) other than a Selected Target. For
further clarity, the foregoing provisions of this Section 2.11.2 shall not apply with respect to (a) Reversion Compounds and Reversion Products; or (b) the individual components of a given Product or Compound (e.g., a targeting polypeptide, linker
or payload), other than as part of a polypeptide drug conjugate for the Selected Target. 

  

	 	    	For clarity, the foregoing provisions of this Section 2.11.2 shall not prohibit a Third Party which becomes an Affiliate of Merck after the Effective Date due to a Change of Control involving Merck (or any of its
Affiliates) and such Third Party from discovering, researching, developing, identifying or optimizing any polypeptide drug conjugate that was owned or otherwise controlled by such Third Party as of the time of such Change of Control.

  

	 	2.12	Compliance with Law and Ethical Business Practices 

  

	 	2.12.1	Ambrx acknowledges that Merck’s corporate policy requires that Merck’s business must be conducted within the letter and spirit of the law. By signing this Agreement, Ambrx agrees to conduct the services
contemplated herein in a manner which is consistent with both law and good business ethics. 

  

	 	2.12.2	 Neither Party shall make any payment, either directly or indirectly, of money or other assets, including but not limited to the compensation
such Party derives from this Agreement (hereinafter collectively referred as a “Payment”), to government or political party officials, officials of international public organizations, candidates for public office, or representatives
of other businesses or persons acting on behalf of any of the foregoing (hereinafter collectively referred as “Officials”) where such Payment would constitute violation of any

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
23 - 

	 	
law. In addition regardless of legality, neither Party shall make any Payment either directly or indirectly to Officials if such Payment is for the purpose of influencing decisions or actions
with respect to the subject matter of this Agreement or any other aspect of such Party’s or the other Party’s business. 

  

	 	2.12.3	Each Party acknowledges that no employee of the other Party or its Affiliates shall have authority to give any direction, either written or oral, relating to the making of any commitment by such Party or its
agents to any Third Party in violation of terms of this Section 2.12. 

  

	 	2.12.4	Each Party certifies to the other Party that as of the date of this Agreement that such Party has screened itself, and its officers and directors against the Exclusions Lists and that it has informed the other
Party whether it, or any of its officers or directors, has been in Violation. After the execution of this Agreement, each Party shall notify the other Party in writing immediately if any such Violation occurs or comes to its attention.

  

	 	2.12.5	Each Party shall indemnify and hold the other Party and any of its Affiliates harmless from and against any and all liabilities (including all costs and reasonable attorneys’ fees associated with defending
against such claims) that may arise by reason of the acts or omissions of it or its agents or other Third Parties acting on its behalf which would constitute a violation of this Section 2.12. 

 

	 	2.13	Regulatory Matters. In the event that Merck determines that any regulatory filings for any Compounds or Products are required for any activities hereunder (including any activities under the Research
Program), including INDs, NDAs and other Marketing Authorizations (as applicable), then as between the Parties, Merck shall have the sole right, in its discretion, to obtain such regulatory filings (in its (or its Affiliate’s or Related
Party’s) name) and as between the Parties, Merck (or its Affiliate or Related Party) shall be the owner of all such regulatory filings. As between the Parties, Merck (or its Affiliate or Related Party) shall have the sole right to communicate
and otherwise interact with Regulatory Authorities with respect to the Compounds and/or Products (including during the Research Program Term). For clarity, Ambrx (and its Affiliates) shall have no right to, and shall not, make any regulatory filings
related to any Compounds or Products or otherwise interact with any Regulatory Authorities with respect to the Compounds or Products. 

  

	 	2.14	[***]. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
24 - 

 ARTICLE 3 

LICENSE; OPTION; DEVELOPMENT AND COMMERCIALIZATION 
  

	 	3.1	License Grant 

  

	 	3.1.1	By Ambrx. 

 Research Program Licenses 

 

	 	(a)	Subject to the rights retained by Ambrx in Section 3.1.1(c) and the terms and conditions of this Agreement, Ambrx hereby grants to Merck an exclusive license (even as to Ambrx and its Affiliates) to carry
out the activities in the Research Program during the Research Program Term in the Territory in the Field under Ambrx Patent Rights, with the right to sublicense as set forth in Section 3.7.1. 

 

	 	(b)	Subject to the rights retained by Ambrx in Section 3.1.1(c) and the terms and conditions of this Agreement, Ambrx hereby grants to Merck an exclusive license (even as to Ambrx and its Affiliates) to carry
out the activities in the Research Program during the Research Program Term in the Territory in the Field under Ambrx Know-How, with the right to sublicense as set forth in Section 3.7.1. 

 

	 	(c)	[***]. 

 Development, Manufacturing and Commercialization Licenses 

 

	 	(d)	Subject to the rights retained by Ambrx in Section 3.1.1(f) and the terms and conditions of this Agreement, Ambrx hereby grants to Merck an exclusive license (even as to Ambrx and its Affiliates) in the
Territory under the Ambrx Patent Rights, with the right to sublicense as set forth in Section 3.7.1, to research, develop, make, have made, use, offer to sell, sell, export and/or import Compounds and Products for use in the Field; provided,
however that Merck shall only have the right to exercise such license with respect to those Compounds (and the Products containing such Compounds) Discovered under a Research Program for which Merck has exercised its Option in accordance with
Section 3.6. For clarity, the license granted under this Section 3.1.1(d) shall terminate with respect to any Compounds (and Products containing such Compounds) Discovered under a given Research Program as to which the applicable Option
has not been exercised by Merck as of the applicable Option Outside Date. 

  

	 	(e)	 Subject to the rights retained by Ambrx in Section 3.1.1(f) and the terms and conditions of this Agreement, Ambrx hereby grants to Merck
an exclusive license (even as to Ambrx and its Affiliates) in the Territory under the Ambrx Know-How, with the right to sublicense as set forth in Section 3.7.1, to research, develop, make, have made, use, offer to sell, sell, export and/or
import Compounds and Products for use in the Field; provided, however that Merck shall only have the right to exercise such license with respect to those Compounds (and the Products containing such Compounds) Discovered under a Research Program

  
 - 25 - 

	 	
for which Merck has exercised its Option in accordance with Section 3.6. For clarity, the license granted under this Section 3.1.1(e) shall terminate with respect to any Compounds (and
Products containing such Compounds) Discovered under a given Research Program as to which the applicable Option has not been exercised by Merck as of the applicable Option Outside Date. 

 

	 	(f)	[***] 

 Additional Linker
Technology Licenses 
  

	 	(g)	Ambrx hereby grants to Merck [***]. 

  

	 	3.1.2	By Merck. 

 Research Program Licenses 

 

	 	(a)	If Merck requests Ambrx to perform activities under the Research Program that require a license under any Merck Patent Rights or Merck Know-How, Merck hereby grants a non-exclusive, non-transferable,
non-sublicensable, royalty free, license to Ambrx under such Merck Patent Rights or Merck Know-How, as applicable, solely as are necessary to perform such activities under the Research Program. 

Development, Manufacturing and Commercialization Licenses 
  

	 	(b)	With respect to a given Reversion Compound (and Reversion Product incorporating such Reversion Compound), Merck hereby grants to Ambrx a non-exclusive license, [***]. 

 

	 	(c)	[***]. 

  

	 	3.2	[***]  

  

	 	3.3	No Grant of Inconsistent Rights by Ambrx. 

  

	 	3.3.1	During the Term, Ambrx (and its Affiliates) shall not assign, transfer, convey or otherwise grant to any Person, or otherwise encumber (including through lien, charge, security interest, mortgage, encumbrance or
otherwise), any rights to any Ambrx Know-How or Ambrx Patent Rights (or any rights to any intellectual property that would otherwise be included in the Ambrx Know-How or Ambrx Patent Rights) in any manner that is inconsistent with or would interfere
with the exercise of the rights or licenses granted to Merck hereunder, including the exercise of the Options. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
26 - 

	 	3.3.2	In addition, following the Effective Date [***], as applicable, Ambrx (and its Affiliates) shall not assign, transfer, convey or otherwise grant to any Person,
or otherwise encumber (including through lien, charge, security interest, mortgage, encumbrance or otherwise) any rights to any Compounds or Products containing such Compounds (provided that Ambrx shall grant to Merck the rights to the Compounds and
Products as set forth herein). 

  

	 	3.3.3	Without limiting the foregoing, during the Term, Ambrx (and its Affiliates) shall not use (and shall not grant to any Third Party the right to use) any Compounds or Products containing such Compounds for any
purpose (including the research, development, manufacturing or commercialization thereof), except for Ambrx’s performance of the activities to be performed by Ambrx under the Research Program as set forth in the Research Plan in accordance with
this Agreement. 

  

	 	3.3.4	Notwithstanding the foregoing, (y) in the event that Merck does not exercise its Option with respect to a given Research Program in accordance with Section 3.6.1, then the foregoing provisions of this
Section 3.3 shall not apply with respect to Reversion Compounds or Reversion Products for the applicable Selected Target; and (z) in the event that this Agreement expires or is terminated with respect to all Compounds/Products for a
particular Selected Target in accordance with Article 8, then the foregoing provisions of this Section 3.3 shall not apply with respect to Reversion Compounds/Reversion Products for such Selected Target. 

 

	 	3.4	No Implied Licenses 

 Except as specifically and expressly set forth in this
Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, in any Confidential Information disclosed to it under this Agreement, know how or under any patents or patent applications owned
or controlled by the other Party or its Affiliates. 
  

	 	3.5	[***] 

 [***] 
  

	 	3.6	Merck Option 

  

	 	3.6.1	Grant of Option; Exercise of Option. On a Research Program-by-Research Program basis, Ambrx hereby grants to Merck the exclusive right and option, at Merck’s sole discretion, to obtain and
exercise the exclusive licenses under the Ambrx Patent Rights and Ambrx Know-How as set forth in Sections 3.1.1(d) and 3.1.1(e) with respect to the Compounds Discovered under such Research Program (and Products containing such Compounds) [***]:

  

	 	(a)	[***] 

  

	 	(b)	[***] 

  

	 	(c)	[***]. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
27 - 

 [***]. In the event that Merck does not
exercise a given Option by delivering written notice to Ambrx by the applicable Option Outside Date [***], then Merck’s Option to obtain the exclusive license set forth in Sections 3.1.1(d) and 3.1.1(e) with respect to the Compounds Discovered
under the applicable Research Program (and Products containing such Compounds) shall expire (provided, however, that for clarity, the expiration of a given Option shall not affect any other Option of Merck). Notwithstanding anything to the contrary
contained herein, in the event that Merck does not exercise a given Option with respect to a given Research Program [***], then (i) Merck (and its Affiliates), either alone or with a Third Party, shall have the right to research, develop and
commercialize any polypeptide drug conjugates against the Selected Target associated with such Research Program without any further obligations to Ambrx (financial or otherwise) [***] and (ii) Merck shall not owe any royalties, milestones or other
payments hereunder with respect to any Compounds (or Products containing such Compounds) Discovered under such Research Program [***]. 
  

	 	3.6.2	Technology Transfer Upon Option Exercise; Transfer of Activities. As soon as reasonably practicable after Merck exercises a given Option pursuant to Section 3.6.1, Ambrx shall disclose to Merck in
English (and deliver in writing or in an electronic format) all relevant Ambrx Collaboration Information and Inventions not previously disclosed in writing to Merck related to the Compounds under the Research Program for which such Option was
exercised. In addition, upon the request of Merck following Merck’s exercise of a given Option pursuant to Section 3.6.1, Ambrx shall transfer to Merck all relevant research cell lines, biologic materials and other materials (including the
Materials, and for clarity, Merck shall have the right to use such Materials solely in connection with the Compounds and Products hereunder, notwithstanding the provisions of Section 2.9) necessary or reasonably useful for the research,
development, manufacture or sale of the applicable Compounds and Products under the Research Program for which such Option was exercised, including for expressing or producing such Compounds and Products. Notwithstanding the foregoing, Ambrx shall
not be obligated to disclose or transfer to Merck any cell line that does not express the polypeptide component of a Compound or Product (other than, as covered under Section 2.5.2, those biologic materials and other materials that constitute
EuCODETM Technology or ReCODETM Technology or other Ambrx Background Know-How, which shall be provided to Merck as set forth therein). Ambrx shall assist Merck to effect an orderly transition and uninterrupted development and manufacturing
of the Compounds. Thereafter during the Term, Ambrx shall cooperate with Merck and promptly disclose to Merck in English (and deliver in writing or in an electronic format) any other intellectual property relating to such Compounds (or the research,
development, making, use or sale thereof) as may be developed or identified by Ambrx (or its Affiliates), to the extent that Merck has a license thereto under this Agreement. 

 

	 	3.6.3	Revisions to Research Plan Upon Exercise of Option. Within thirty (30) days after Merck has exercised its Option with respect to a given Research Program, to the extent that the Research Program Term
for such Research Program has not yet ended in accordance with this Agreement, the Committee shall review and, if determined by the Committee, amend, the Research Plan for such Research Program for the further research activities to be conducted
under such Research Program post Option exercise. 

  

	 	3.7	Sublicensing. 

  

	 	3.7.1	[***] 

 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
28 - 

	 	3.7.2	[***] 

  

	 	3.8	Development, Manufacture and Commercialization 

  

	 	3.8.1	Compounds and Products By Merck. Following the valid exercise of the applicable Option by Merck, Merck (and its Affiliates), either itself or together with Third Parties, shall have the sole right, at its
expense, to research, develop (including pre-clinical and clinical development), manufacture, register and commercialize Compounds Discovered under such Research Program (other than Reversion Compounds) and Products containing such Compounds (other
than Reversion Products) against any and all targets, and Ambrx (and its Affiliates) shall have no right to do so. In the event that Merck exercises its Option with respect to a given Research Program, then Merck shall use Commercially Reasonable
Efforts to develop and commercialize at least one Product (containing a Compound developed under such Research Program) in the Field in the Major Markets. All other development and commercialization efforts with respect to the Compounds and Products
shall be at the discretion of Merck. For clarity, in the event that Merck does not exercise its Option with respect to a given Research Program, then the licenses granted by Ambrx to Merck as set forth in Sections 3.1.1(d) and 3.1.1(e) hereunder for
the Compounds Discovered under such Research Program (and Products containing such Compounds) shall terminate. 

 Upon
expiration of the Research Program Term, and once per year thereafter until the First Commercial Sale of a Product, Merck shall, as soon as reasonably practicable after receipt of a written request by Ambrx, provide Ambrx with a written report that
summarizes the development progress and plans for such Product and the related Compound. 
  

	 	3.8.2	Reversion Compounds and Reversion Products By Ambrx and Merck. Following the completion (or earlier termination) of a given Research Program, Ambrx (and its Affiliates), either itself or together with
Third Parties, and Merck (and its Affiliates), either itself or together with Third Parties, shall each have the right, at its expense, to develop (including pre-clinical and clinical development), manufacture, register and commercialize any
Reversion Compounds (if any) and Reversion Products (if any). For clarity, except as expressly set forth in Section 3.1.2(b), Section 3.1.2(c) or Section 8.4(h) (if applicable), Merck is not granting any rights or licenses to any
Merck Know-How, Merck Patent Rights or any other intellectual property of Merck or any of its Affiliates in connection therewith. 

  

	 	3.9	Excused Performance 

 In addition to the provisions of Article 6 hereof, the
obligations of Merck with respect to any Product under Section 3.8.1 are expressly conditioned upon the continuing absence of any adverse condition or event relating to the safety or efficacy of the Product, and the

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
29 - 

 
obligation of Merck to develop or commercialize any such Product may be delayed or suspended so long as in Merck’s reasonable, good-faith opinion any such condition or event exists. 

ARTICLE 4 

CONFIDENTIALITY AND PUBLICATION 
  

	 	4.1	Nondisclosure Obligation 

 All Confidential Information disclosed by one Party to
the other Party hereunder shall be maintained in confidence by the receiving Party and shall not be disclosed to any Third Party or used for any purpose except as set forth herein without the prior written consent of the disclosing Party, except to
the extent that such Confidential Information: 
  

	 	(a)	is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; 

 

	 	(b)	is in the public domain by use and/or publication before its receipt from the disclosing Party, or thereafter enters the public domain through no fault of the receiving Party; 

 

	 	(c)	is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party; 

 

	 	(d)	is developed by the receiving Party independently of Confidential Information received from the disclosing Party, as documented by the receiving Party’s business records; 

 

	 	(e)	is disclosed to governmental or other regulatory agencies in order to obtain patents or to gain or maintain approval to conduct clinical trials or to market Product, but such disclosure may be only to the extent
reasonably necessary to obtain patents or authorizations; 

  

	 	(f)	is deemed necessary by Merck to be disclosed to Related Parties, agents, consultants, and/or other Third Parties for any and all purposes Merck and its Affiliates deem necessary or advisable in the ordinary
course of business in accordance with this Agreement (including the exercise of licenses granted to Merck hereunder) on the condition that such Third Parties agree to be bound by confidentiality and non-use obligations that substantially are no less
stringent than those confidentiality and nonuse provisions contained in this Agreement; provided, however, that the term of confidentiality for such Third Parties shall be no less than ten (10) years; or 

 

	 	(g)	 is deemed necessary by counsel to the receiving Party to be disclosed to such Party’s attorneys, independent accountants or financial
advisors for the sole 

  
 - 30 - 

	 	
purpose of enabling such attorneys, independent accountants or financial advisors to provide advice to the receiving Party, on the condition that such attorneys, independent accountants and
financial advisors agree to be bound by the confidentiality and non-use obligations no less protective than those set forth in this Agreement; provided, however, that the term of confidentiality for such attorneys, independent accountants and
financial advisors shall be no less than ten (10) years. 

  

	 	(h)	in connection with a financing, merger, or acquisition, each Party shall have the further right to disclose the material terms of this Agreement under a confidentiality obligation no less protective than those
set forth in this Agreement. 

  

	 	(i)	the Parties shall agree in advance with each other on the terms of this Agreement to be redacted in any Securities and Exchange Commission filings. 

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are
published or available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the
receiving Party. 
 If a Party is required by judicial or administrative process to disclose Confidential Information that is subject to the
non-disclosure provisions of this Section 4.1, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations.
Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 4.1, and the Party disclosing Confidential Information pursuant to
Applicable Law or court order shall take all steps reasonably necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information. 

 

	 	4.2	Publication 

 Merck and Ambrx each acknowledge the other Party’s interest in
publishing the results of its research in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in
protecting business interests and trade secret information. Consequently, except for disclosures permitted pursuant to Section 4.1, either Party, its employees or consultants wishing to make a publication with respect to the research under the
Research Program hereunder shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days prior to submission for publication or presentation. The reviewing Party shall
have the right (a) to propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication or presentation in order to protect patentable
information. If the reviewing Party requests a delay, the publishing Party shall delay submission or presentation for a period of ninety 

  
 - 31 - 

 
(90) days to enable patent applications protecting each Party’s rights in such information to be filed in accordance with Article 7 below. Upon expiration of such ninety (90) days,
the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party requests modifications to the publication or presentation, the publishing Party shall edit such publication to prevent disclosure of trade
secret or proprietary business information prior to submission of the publication or presentation. 
  

	 	4.3	Publicity/Use of Names 

 No disclosure of the existence, or the terms, of this
Agreement may be made by either Party, and neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employees in any publicity, promotion, news release or disclosure relating to this
Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by Applicable Law or as permitted pursuant to Section 4.1; provided that in the event disclosure is required by
Applicable Law, the disclosing Party shall use good-faith efforts to give the non-disclosing Party an opportunity, with reasonable advance notice, to review and comment on any proposed disclosure. Notwithstanding the foregoing, Ambrx shall have the
right to issue a press release regarding the execution of this Agreement, which press release shall be in a form agreed to by the Parties in writing in advance of the issuance of such press release. Disclosure of Confidential Information either for
which consent has previously been obtained or which has previously been disclosed publicly will not require advance approval. 
  

	 	4.4	Clinical Trial Register 

 Notwithstanding the foregoing, Merck shall have the
right to publish the results or summaries of results of any clinical trials conducted hereunder with respect to a Product on Merck’s clinical trial register. 
  

	 	4.5	Remedies 

 Each Party shall be entitled to seek, in addition to any other right or
remedy it may have, at law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the other Party from any violation or threatened violation of this Article 4. 

ARTICLE 5 
 PAYMENTS;
ROYALTIES AND REPORTS 
  

	 	5.1	Research Program Funding 

 In consideration for Ambrx’s performance of its
obligations under the Research Program and the licenses granted herein under the Ambrx Patent Rights and Ambrx Know-How, upon the terms and conditions contained herein, Merck shall pay to Ambrx, within ten (10) days following the Effective Date, an
upfront payment in the amount of Fifteen Million Dollars ($15,000,000), which shall be non-refundable and non-creditable. 

  
 - 32 - 

	 	5.2	FTE Funding under the Research Program 

  

	 	5.2.1	General. In consideration for Ambrx’s provision of FTEs for the performance of its obligations under the Research Program, upon the terms and conditions contained herein, Merck (i) shall pay
Ambrx the applicable FTE Rate per year during the Research Program Term for each FTE provided by Ambrx in accordance with this Section 5.2 and (ii) shall reimburse Ambrx for its direct, out-of-pocket research costs incurred by Ambrx and
paid to a Third Party contractor solely to perform research activities under the Research Program pursuant to the Research Plan (“Third Party Research Costs”) in accordance with this Section 5.2. The number of FTEs to be
provided by Ambrx for the performance of the Research Program per year shall be set forth in the applicable Research Plan; provided, however, that the Committee shall have the right to revise the number of FTEs in accordance with Section 2.4.
Such FTE funding shall be payable in advance in quarterly installments due on the first day of the applicable Calendar Quarter; provided, however, that the payments for the first Calendar Quarter and the last Calendar Quarter of a given Research
Program Term shall be made on a pro rata basis; and provided, further, that the payment for the second Calendar Quarter of 2012 (on a pro-rata basis) shall be payable within ten (10) days following the later of (i) the Effective Date; and
(ii) the first day of such Calendar Quarter. 

 The amount of any Third Party Research Costs which will be reimbursed by
Merck shall be expressly set forth in the applicable Research Plan (and the Research Plan shall also identify the Third Party contractor performing the applicable activities under the Research Plan and the activities to be performed by such Third
Party contractor). At the end of each Calendar Quarter during the Research Program Term, Ambrx shall invoice Merck for the Third Party Research Costs incurred during such Calendar Quarter to the extent that such Third Party Research Costs were
expressly set forth in the Research Plan. Merck shall pay such invoiced amounts within thirty (30) days of receipt of the invoice. Notwithstanding the foregoing, Merck shall only be obligated to reimburse Ambrx for those Third Party Research
Costs which are expressly agreed to by the Parties and set forth in the Research Plan (including with respect to the amount of such Third Party Research Costs and with respect to the activities to be performed by the applicable Third Party
contractor) and Ambrx shall be solely responsible for (and shall not be entitled to reimbursement for) any other costs, including any costs in excess of such agreed upon amount or any costs not directly related to the performance of activities under
the Research Plan or any costs not approved by the Committee. 
  

	 	5.2.2	 Reporting and Reconciliation. Ambrx shall, within [***] days following the end of
each Calendar Quarter during the Research Program Term, deliver to Merck a 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
33 - 

	 	
written report detailing the number of FTEs actually utilized in such Calendar Quarter for the performance of Research Program activities, including a description of the activities performed (and
Merck shall have the right to audit Ambrx’s records in connection therewith in accordance with Section 5.7, mutatis mutandis). In the event that the number of FTEs actually utilized in such Calendar Quarter is less than the number
of FTEs for which Merck made payment in advance pursuant to Section 5.2.1, then at Merck’s option, Ambrx shall either refund or credit Merck for the difference between the payment made by Merck and the actual payment due for such FTEs
(provided that if Merck opts for a refund, such refund shall be made by Ambrx within [***] days following notice by Merck thereof and if Merck opts for a credit, Merck shall be entitled to a credit against any future FTE amounts payable by Merck
pursuant to this Section 5.2). For clarity, in no event shall Ambrx be entitled to receive payment for (and Ambrx shall be solely responsible for) any and all FTEs in a given Calendar Quarter which are in excess of the number of FTEs authorized
to be utilized to conduct the Research Program activities in such Calendar Quarter as set forth in the applicable Research Plan or as otherwise expressly approved in writing by the Committee. 

 

	 	5.2.3	Elimination of FTEs. Notwithstanding anything to the contrary in this Section 5.2, in the event that the Parties or the Committee determines to reduce the number of FTEs for the conduct of Research
Program activities from those set forth in the applicable Research Plan (each, an “Eliminated FTE”), then Merck shall only be required to fund such reduced number of FTEs in accordance with the provisions of this Section 5.2
(and Merck shall not be required to fund any Eliminated FTEs); provided, however, that to the extent that Ambrx is unable to reassign (after using Commercially Reasonable Efforts) such Eliminated FTEs to other activities under the Research Program
hereunder or to other activities at Ambrx (or its Affiliates), then, for a period not to exceed [***] months, Merck shall continue to fund such Eliminated FTEs in accordance with this
Section 5.2 (provided that for clarity, after such [***] month period, Merck shall no longer be required to fund such Eliminated FTEs). 

  

	 	5.3	Extension of Research Program Term 

 Merck may, at its sole discretion and upon
written notice to Ambrx no later than ninety (90) days prior to the expiration of the applicable Research Program Term, extend Ambrx’s participation in any of the Research Programs for one (1) additional year each. In such event, the
applicable Research Program Term shall be extended to include such additional year. [***] 
  

	 	5.4	Milestone Payments 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
34 - 

	 	5.4.1	Research Milestones. In consideration for the licenses granted herein under the Ambrx Patent Rights and Ambrx Know-How, upon the terms and conditions contained herein, Merck shall pay to Ambrx the
following amounts, which shall be non-refundable and shall be non-creditable, with respect to each Selected Target for which Merck achieves the following milestone event during the Term (collectively, the “Research Milestones”):

  

					
	 Event
	  	Payment Amount	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

 For clarity, each of the foregoing Research Milestones in this Section 5.4.1 shall be payable [***] 

The maximum amount payable by Merck under this Section 5.4.1 is [***]. 

 

	 	5.4.2	Development and Commercialization Milestones. In consideration for the licenses granted herein under the Ambrx Patent Rights and Ambrx Know-How, upon the terms and conditions contained herein, Merck shall
pay to Ambrx the following amounts, which shall be non-refundable and shall be non-creditable, with respect to each Selected Target for which Merck achieves the following milestone event during the Term (provided, however that for clarity, the
following amounts shall only be triggered by Compounds (or Products containing such Compounds, as applicable) for which Merck exercised its Option pursuant to Section 3.6.1) (the “Development/Commercial Milestones”):

  

					
	 Event
	  	Payment Amount	 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 
	 [***]
	  	 	[***	] 

 For clarity, [***] 

[***]. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
35 - 

	 	5.4.3	Sales Milestones. In consideration for the licenses granted herein under the Ambrx Patent Rights and Ambrx Know-How, upon the terms and conditions contained herein, Merck shall pay to Ambrx the following
amounts, which shall be non-refundable and shall be non-creditable, with respect to each Selected Target for which Merck achieves the following milestone event during the Term (provided, however that for clarity, in determining whether the following
events were achieved, only Net Sales of the Products containing Compounds for which Merck exercised its Option pursuant to Section 3.6.1 shall be included): 

 

					
	 Event
	  	Payment Amount	 
	 First achievement of aggregate Net Sales in the Territory of all Products in the Territory for use against the applicable Selected
Target in a given Calendar Year exceeding [***] for such Calendar Year
	  	 	[***	] 
	 First achievement of aggregate Net Sales in the Territory of all Products for use against the applicable Selected Target in a given
Calendar Year exceeding [***] for such Calendar Year
	  	 	[***	] 

 [***] 

[***]. 
  

	 	5.4.4	Reporting and Payment. Merck shall notify Ambrx in writing within thirty (30) days following the achievement of each milestone as set forth in Section 5.4.1, 5.4.2 or 5.4.3, as applicable, and
shall make the appropriate milestone payment within thirty (30) days after the achievement of such milestone. 

  

	 	5.5	Royalties 

  

	 	5.5.1	Royalties Payable By Merck. Subject to the terms and conditions of this Agreement, Merck shall pay Ambrx royalties as set forth in this Section 5.5. 

 

	 	5.5.2	Patent Royalties. Subject to the provisions of Section 5.5.3, Merck shall pay Ambrx royalties in an amount equal to the following percentage of Net Sales of Royalty Products sold by Merck or its
Related Parties in the Territory for use in the Field, provided that the manufacture, use or sale of the applicable Royalty Product would infringe a Valid Patent Claim in the country of sale: 

 

	 	(a)	[***] of such Net Sales in the Territory in each Calendar Year up to and including Net Sales of [***]; 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
36 - 

	 	(b)	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding [***] up to and including [***]; and 

 

	 	(c)	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding [***]. 

[***] 
  

	 	5.5.3	[***]. 

  

	 	5.5.4	Royalty Period. Royalties on a given Royalty Product at the rates set forth above shall commence with the First Commercial Sale of the Royalty Product and continue on a country-by-country basis until the
expiration of the later of: (i) the last-to-expire Valid Patent Claim that would be infringed by the manufacture, use or sale of such Royalty Product in such country; or (ii) the period of ten (10) years following the First Commercial
Sale of such Royalty Product in such country (the “Royalty Period”). [***] 

  

	 	(i)	[***] 

  

	 	(ii)	[***] 

  

	 	(iii)	[***] 

  

	 	(iv)	[***] 

  

	 	(v)	[***] 

  

	 	(vi)	[***] 

  

	 	5.5.5	Royalties for Bulk Compound. In those cases in which Merck sells bulk Compound rather than Product in packaged form to an independent Third Party, the royalty obligations of this Section 5.5 shall be
applicable to the bulk Compound (but solely to the extent that a royalty would otherwise be payable on the Product incorporating such Compound). 

  

	 	5.5.6	Compulsory Licenses. If a compulsory license is granted to a Third Party with respect to Royalty Product in any country in the Territory with a royalty rate lower than the royalty rate provided by
Section 5.5.2 or 5.5.3, as applicable, then the royalty rate to be paid by Merck on Net Sales in that country under Section 5.5.2 or 5.5.3, as applicable, shall be reduced to the rate paid by the compulsory licensee. 

 

	 	5.5.7	[***] 

  
 - 37 - 

	 	5.6	Reports; Payment of Royalty 

 During the Term following the First Commercial Sale
of a Product, Merck shall furnish to Ambrx a quarterly written report for the Calendar Quarter showing the Net Sales of all Royalty Products subject to royalty payments sold by Merck and its Related Parties in the Territory for use in the Field
during the reporting period and the royalties payable under this Agreement. Reports shall be due on the [***] day following the close of each Calendar Quarter. Royalties shown to have accrued by
each royalty report shall be due and payable on the date such royalty report is due. Merck shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined. 

 

	 	5.7	Audits 

  

	 	(a)	Upon the written request of Ambrx and not more than once in each Calendar Year, Merck shall permit an independent certified public accounting firm of nationally recognized standing selected by Ambrx and
reasonably acceptable to Merck, at Ambrx’s expense, to have access during normal business hours to such of the records of Merck as may be reasonably necessary to verify the accuracy of the royalty reports hereunder for any Calendar Year ending
not more than twenty-four (24) months prior to the date of such request. The accounting firm shall disclose to Ambrx only whether the royalty reports are correct or incorrect and the amount of any discrepancy. No other information shall be
provided to Ambrx. 

  

	 	(b)	If such accounting firm identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy within thirty (30) days of the date Ambrx delivers to
Merck such accounting firm’s written report so concluding, or as otherwise agreed upon by the Parties. [***] 

  

	 	(c)	[***]. 

  

	 	(d)	Upon the expiration of twenty-four (24) months following the end of any Calendar Year, the calculation of royalties payable with respect to such Calendar Year shall be binding and conclusive upon Ambrx, and
Merck and its Related Parties shall be released from any liability or accountability with respect to royalties for such Calendar Year. 

  

	 	(e)	Ambrx shall treat all financial information subject to review under this Section 5.7 or under any sublicense agreement in accordance with the confidentiality and non-use provisions of this Agreement, and
shall cause its accounting firm to enter into an acceptable confidentiality agreement with Merck and/or its Related Parties obligating it to retain all such information in confidence pursuant to such confidentiality agreement. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
38 - 

	 	5.8	Payment Exchange Rate 

 All payments to be made by Merck to Ambrx under this
Agreement shall be made in United States dollars and may be paid by bank wire transfer in immediately available funds to such bank account in the United States as may be designated in writing by Ambrx from time to time. In the case of sales outside
the United States, the rate of exchange to be used in computing the monthly amount of currency equivalent in United States dollars due Ambrx shall be made at the monthly rate of exchange utilized by Merck in its worldwide accounting system [***]. 
  

	 	5.9	Income Tax Withholding 

 [***] 

 

	 	5.10	Reporting and Payments by Ambrx with Respect to Reversion Compounds and Reversion Products. 

Upon expiration of the Research Program Term, and once per year thereafter, Ambrx shall, upon request by Merck, provide Merck with a written
report that summarizes its development progress and plans for Reversion Compounds and Reversion Products. 
 With respect to any Reversion
Compound and Reversion Product, as applicable, Ambrx shall be required to pay to Merck the milestones set forth in Section 5.4 and the royalties set forth in Section 5.5 that Merck would have been required to pay to Ambrx pursuant to such
Sections if Merck had developed and commercialized such Reversion Compound and Reversion Product (as if Merck had exercised the Option for the Research Program under which such Reversion Compound was developed), mutatis mutandis; provided,
however, that Ambrx shall only be required to pay [***] of the amount of the milestone or royalty, as applicable, that would have been payable by Merck. [***] 

[***] 
 [***] 

 

	 	5.11	Ambrx Third Party Licenses 

 Notwithstanding the provisions of Section 5.5.7,
and except as otherwise agreed by the Parties in writing, Ambrx shall be solely responsible for satisfying all costs and payments of any kind (including all upfront fees, annual payments, milestone payments and royalty payments) (i) arising
under any license or other grant of rights from a Third Party to Ambrx (or any of its Affiliates), including under any of the Ambrx Third Party License Agreements, which payments arise as a result of any activities hereunder and/or
(ii) otherwise arising as a result of the use of Ambrx’s proprietary platform technology 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
39 - 

 
(including ReCODETM Technology and/or EuCODETM Technology) as contemplated hereunder. 

ARTICLE 6 

REPRESENTATIONS AND WARRANTIES; COVENANTS 
  

	 	6.1	Mutual Representations and Warranties 

 Each Party represents and warrants to the
other Party the following as of the Effective Date of this Agreement: 
  

	 	(a)	Corporate Power. Such Party is duly organized and validly existing under the laws of the state of its organization and has full corporate power and authority to enter into this Agreement and to perform its
obligations hereunder. 

  

	 	(b)	Due Authorization and Execution. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by the necessary corporate actions of
such Party. This Agreement has been duly executed by such Party. This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations of such Party enforceable against it in accordance with their respective
terms, except to the extent that enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors.

  

	 	(c)	Non-Contravention. The execution, delivery and performance by such Party of this Agreement and any other agreements and instruments contemplated hereunder will not (i) in any material respect violate
any statute, regulation, judgment, order, decree or other restriction of any governmental authority to which such Party is subject, (ii) violate any provision of the corporate charter, by-laws or other organizational documents of such Party, or
(iii) constitute a material violation or breach by such Party of any provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject although not a party (including, with respect
to Ambrx, the Ambrx Third Party License Agreements). 

  

	 	6.2	Ambrx Representations and Warranties 

  

	 	6.2.1	As of the Effective Date and Research Plan Approval Date. Ambrx represents and warrants to Merck that as of the Effective Date, solely with respect [***] is approved by the Committee, the following
representations and warranties as of such approval date solely with respect to [***], as applicable: 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
40 - 

	 	(a)	to the best of Ambrx’s knowledge, the Ambrx Patent Rights and Ambrx Know-How exist and are not invalid or unenforceable, in whole or in part; 

 

	 	(b)	it has the full right, power and authority, including the full right, power and authority under the Ambrx Third Party License Agreements, to enter into this Agreement, to perform the Research Program and to grant
the licenses granted under Article 3 hereof; 

  

	 	(c)	it (and its Affiliates) has not previously (i) assigned, transferred, conveyed or otherwise encumbered its right, title and/or interest in Ambrx Patent Rights or Ambrx Know-How, or (ii) granted any
rights to any Third Parties, in either case that would conflict with the rights granted to Merck hereunder; 

  

	 	(d)	to the best of Ambrx’s knowledge, it is the sole and exclusive owner or sole and exclusive licensee (pursuant to the Ambrx Third Party License Agreements, as applicable) of the Ambrx Patent Rights and Ambrx
Know-How, all of which are (and shall be) free and clear of any liens, charges and encumbrances, and no other person, corporate or other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership
whatsoever with respect to the Ambrx Patent Rights and/or Ambrx Know-How except pursuant to the Ambrx Third Party License Agreements; 

  

	 	(e)	to the best of Ambrx’s knowledge, the exercise of the license granted to Merck under the Ambrx Patent Rights and Ambrx Know-How, including the research, development, manufacture, use, sale, export and import
of Compounds and Products, do not interfere with or infringe any intellectual property rights owned or possessed by any Third Party; 

  

	 	(f)	there are no claims, judgments or settlements against or owed by Ambrx (or any of its Affiliates) and, to the best of Ambrx’s knowledge, no pending or threatened claims or litigation relating to the Ambrx
Patent Rights and/or Ambrx Know-How; 

  

	 	(g)	the Ambrx Third Party License Agreements are the only agreements (including any licenses), written or oral, granting any licenses or other rights to Ambrx (or any of its Affiliates) relating to the Ambrx Know-How
or Ambrx Patent Rights; 

  

	 	(h)	 with respect to each Ambrx Third Party License Agreement [***], (i) it is in full
force and effect; (ii) Ambrx is not in breach; (iii) Ambrx has not received any notice of breach or notice of threatened breach; and (iv) Ambrx has not received any notice from the counterparty to such Ambrx Third Party License
Agreement [***]) of intent to reduce the scope of the field or the licenses thereunder or render any of the licenses thereunder non-exclusive, and no event, act or omission has occurred which would reasonably be expected to give rise to the right of
the 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
41 - 

	 	
counterparty to such Ambrx Third Party License Agreement [***] to reduce the scope of the field or the licenses thereunder or render any of
the licenses thereunder non-exclusive; 

  

	 	(i)	Ambrx has disclosed to Merck all reasonably relevant information regarding (i) the Selected Target, and, to the best of Ambrx’s knowledge, relating to the Compounds or Products for use against such
Selected Target, and/or (ii) the Ambrx Patent Rights and Ambrx Know-How licensed under this Agreement; 

  

	 	(j)	Ambrx has disclosed to Merck the existence of any patent opinions related to the Ambrx Patent Rights and/or Ambrx Know-How licensed under this Agreement; 

 

	 	(k)	Ambrx has obtained all necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by it in connection with the execution, delivery and performance
of this Agreement; 

  

	 	(l)	Ambrx has not obtained, or filed for, any INDs, NDAs or Marketing Authorizations for any Compounds or Products (or other polypeptide drug conjugates) for use against the Selected Target; 

 

	 	(m)	Ambrx has disclosed all material information and data and all material correspondences to/from any Regulatory Authority controlled by Ambrx (or any of its Affiliates) or to which it (or any of its Affiliates) has
access, in each case related to (i) the Research Program regardless of whether such data and information would have a positive, negative or neutral impact on the potential commercial, scientific or strategic value or attractiveness of the
Research Program or (ii) the Selected Target (or to the best of Ambrx’s knowledge, Compounds or Products for use against the Selected Target) regardless of whether such data and information would have a positive, negative or neutral impact
on the potential commercial, scientific or strategic value or attractiveness of the Selected Target (or such Compounds or Products); 

  

	 	(n)	Ambrx has not employed or otherwise used in any capacity the services of any Person debarred under United States law, including to Section 21 USC 335a, with respect to the Compounds or Products for use
against the Selected Target; and 

  

	 	(o)	The Ambrx Patent Rights and the Ambrx Know-How constitutes all intellectual property owned or otherwise controlled (through license or otherwise) by Ambrx (or any of its Affiliates) that are related to any Linker
Technology or are otherwise reasonably necessary or useful to perform the Research Program. 

  

	 	6.2.2	As of An Option Exercise Date. Ambrx represents and warrants to Merck that as of an applicable Option Exercise Date, solely with respect to the applicable Selected Target (including the Compounds and
Products related thereto): 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
42 - 

	 	(a)	to the best of Ambrx’s knowledge, the Ambrx Patent Rights and Ambrx Know-How exist and are not invalid or unenforceable, in whole or in part; 

 

	 	(b)	it has the full right, power and authority, including the full right, power and authority under the Ambrx Third Party License Agreements, to grant the licenses granted under Article 3 hereof; 

 

	 	(c)	it (and its Affiliates) has not previously (i) assigned, transferred, conveyed or otherwise encumbered its right, title and/or interest in Ambrx Patent Rights or Ambrx Know-How, or (ii) granted any
rights to any Third Parties, in either case that would conflict with the rights granted to Merck hereunder; 

  

	 	(d)	to the best of Ambrx’s knowledge, it is the sole and exclusive owner or sole and exclusive licensee (pursuant to the Ambrx Third Party License Agreements, as applicable) of the Ambrx Patent Rights and Ambrx
Know-How, all of which are (and shall be) free and clear of any liens, charges and encumbrances, other than such liens, charges or encumbrances that would not conflict with the rights granted to Merck hereunder, and no other person, corporate or
other private entity, or governmental entity or subdivision thereof, has or shall have any claim of ownership whatsoever with respect to the Ambrx Patent Rights and/or Ambrx Know-How except pursuant to the Ambrx Third Party License Agreements;

  

	 	(e)	to the best of Ambrx’s knowledge, the exercise of the license granted to Merck under the Ambrx Patent Rights and Ambrx Know-How, including the research, development, manufacture, use, sale, export and import
of Compounds and Products, do not interfere with or infringe any intellectual property rights owned or possessed by any Third Party; 

  

	 	(f)	there are no claims, judgments or settlements against or owed by Ambrx (or any of its Affiliates) and, to the best of Ambrx’s knowledge, no pending or threatened claims or litigation relating to the Ambrx
Patent Rights and/or Ambrx Know-How or Compounds or Products; 

  

	 	(g)	the Ambrx Third Party License Agreements are the only agreements (including any licenses), written or oral, granting any licenses or other rights to Ambrx (or any of its Affiliates) relating to the Compounds or
Products; 

  

	 	(h)	with respect to each Ambrx Third Party License Agreement, (i) it is in full force and effect; (ii) Ambrx is not in breach; (iii) Ambrx has not received any notice of breach or notice of threatened
breach; and (iv) Ambrx has not received any notice from the counterparty to such Ambrx Third Party License Agreement of intent to reduce the scope of the field or the licenses thereunder or render any of the license thereunder non-exclusive,
and no event, act or omission has occurred which would reasonably be expected to give rise to the right of the counterparty to such Ambrx Third Party License Agreement to reduce the scope of the field or the licenses thereunder or render any of the
licenses thereunder non-exclusive; 

  
 - 43 - 

	 	(i)	Ambrx has disclosed to Merck all reasonably relevant information regarding Compounds or Products, including any safety or efficacy information related to such Compounds or Products; 

 

	 	(j)	Ambrx has not obtained, or filed for, any INDs, NDAs or Marketing Authorizations for any Compounds or Products (or other polypeptide drug conjugates) for use against the Selected Target; 

 

	 	(k)	Ambrx has disclosed all material information and data and all material correspondences to/from any Regulatory Authority, in each case, controlled by Ambrx (or any of its Affiliates) or to which it (or any of its
Affiliates) has access, related to Compounds or Products regardless of whether such data and information would have a positive, negative or neutral impact on the potential commercial, scientific or strategic value or attractiveness of such Compounds
or Products, as applicable; 

  

	 	(l)	Ambrx has not employed or otherwise used in any capacity the services of any Person debarred under United States law, including to Section 21 USC 335a, with respect to the Compounds Discovered under the
applicable Research Program or otherwise in performing any portion of the Research Program; and 

  

	 	(m)	The Ambrx Patent Rights and the Ambrx Know-How constitutes all intellectual property owned or otherwise controlled (through license or otherwise) by Ambrx (or any of its Affiliates) that are reasonably necessary
or useful to research, develop, manufacture, sell or use the Compounds and/or Products. 

  

	 	6.3	Ambrx Further Representations, Warranties and Covenants 

  

	 	6.3.1	 Ambrx Third Party License Agreements and [***]. Ambrx represents and warrants to Merck that it has provided to Merck in writing prior to
the Effective Date a true, correct and complete copy of each of the Ambrx Third Party License Agreements [***], and each such copy includes any and all amendments, restatements, side letters, or other modifications thereto, as each such Ambrx Third
Party License Agreement [***] is in effect as of the Effective Date. Ambrx further covenants and agrees that during the Term of this Agreement, (a) it will satisfy all of its material obligations (including all payment obligations) under, and take
all steps necessary to maintain in full force and effect, each of the Ambrx Third Party License Agreements [***], including taking all steps to ensure that all licenses granted thereunder remain in full force and effect (on an exclusive basis) and
that the scope of such licenses (including with respect to all licensed intellectual property (including all Patent Rights) and all fields) are not reduced or limited in any manner that would adversely affect Merck’s rights under this
Agreement; (b) it will not assign (except an assignment to a party to which this 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
44 - 

	 	
Agreement has been assigned as permitted under Section 10.2), amend, restate, amend and restate, terminate in whole or in part, or otherwise modify any of the Ambrx Third Party
License Agreements [***] in any manner that would adversely affect Merck’s rights or obligations hereunder without the prior written consent of Merck; and (c) it will provide Merck with prompt notice of any claim of a material breach under any
of the Ambrx Third Party License Agreements [***] or notice of termination of any of the Ambrx Third Party License Agreements [***], made by either Ambrx or the counterparty to such Ambrx Third Party License Agreement [***] (or any party acting on
behalf of such counterparty) which would reasonably be expected to have an adverse effect on Merck’s rights or obligations hereunder. For the purposes of clarity, Ambrx (and not Merck) shall be responsible for all of the financial and other
obligations of Ambrx (and/or any of its Affiliates) to the counterparty under any of the Ambrx Third Party License Agreements [***], including any and all financial obligations to such counterparty with respect to Net Sales of Merck and its Related
Parties. 

  

	 	6.4	Disclaimer 

 EACH PARTY HEREBY DISCLAIMS ANY AND ALL REPRESENTATIONS AND
WARRANTIES IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREIN NOT EXPRESSLY MADE IN THIS AGREEMENT TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAWS, INCLUDING WITH RESPECT TO THE COMPOUNDS, PRODUCTS, OR ANY TECHNOLOGY OR OTHER INTELLECTUAL
PROPERTY LICENSED OR GRANTED UNDER THIS AGREEMENT, INCLUDING ANY WARRANTY OF NON-INFRINGEMENT, QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE. FOR THE AVOIDANCE OF DOUBT, NOTHING CONTAINED IN THIS SECTION 6.4 SHALL
OPERATE TO LIMIT OR INVALIDATE ANY EXPRESS WARRANTY CONTAINED HEREIN OR ANY IMPLIED WARRANTY OF GOOD FAITH AND/OR FAIR DEALING. 
 ARTICLE
7 
 PATENT PROVISIONS 
  

	 	7.1	Filing, Prosecution and Maintenance of Patents for Collaboration Information and Inventions 

  

	 	7.1.1	Joint Collaboration Information and Inventions. Merck shall have the first right to file patent applications for Joint Collaboration Information and Inventions (in the name of both Merck and Ambrx) and
thereafter prosecute and maintain Patent Rights for such Joint Collaboration Information and Inventions. With respect to a given Joint Collaboration Information and Invention, Merck may elect not to file or may elect not to file in a particular
country and if so, Merck shall notify Ambrx and Ambrx shall have the right to file such patent applications for such Joint Collaboration Information and Invention (in the name of both Merck and Ambrx) and thereafter prosecute and maintain Patent
Rights for such Joint Collaboration Information and Invention. In such event, Merck shall execute such documents and perform such ministerial acts, at Ambrx’s expense, as may be reasonably necessary for Ambrx to continue such prosecution or
maintenance of Patent Rights claiming such Joint Collaboration Information and Invention. 

  

	 	7.1.2	Ambrx Collaboration Information and Inventions. Ambrx shall have the first right to file patent applications for Ambrx Collaboration Information and Inventions and thereafter prosecute and maintain Patent
Rights for such Ambrx Collaboration Information and Inventions with consultation with Merck. With respect to a given Ambrx Collaboration Information and Inventions, Ambrx may elect not to file or may elect not to file in a particular country and if
so, Ambrx shall notify Merck and Merck shall have the right to file such patent applications for such Ambrx Collaboration Information and Invention and thereafter prosecute and maintain Patent Rights for such Ambrx Collaboration Information and
Invention. In such event, Ambrx shall execute such documents and perform such ministerial acts, at Merck’s expense, as may be reasonably necessary for Merck to continue such prosecution or maintenance of Patent Rights claiming such Ambrx
Collaboration Information and Invention. [***]. 

  

	 	7.1.3	 Review and Consultation. In each case in connection with the foregoing with respect to Joint Collaboration Information and Inventions
and Ambrx Collaboration Information and Inventions, as applicable, the filing Party (a) shall keep the non-filing Party advised of the status of the actual and prospective patent filings; (b) upon the non-filing Party’s written request, shall
provide advance copies of any papers related to the filing, prosecution and maintenance of such patent filings; (c) shall give the non-filing Party an opportunity to review the text of the application before filing and shall consult with the
non-filing Party with 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
45 - 

	 	
respect thereto; (d) shall supply the non-filing Party with a copy of the application as filed, together with notice of its filing date and serial number; and (e) shall promptly give
notice to the non-filing Party of the grant, lapse, revocation, surrender, invalidation or abandonment of any Joint Patent Rights (or Patent Rights claiming Ambrx Collaboration Information and Inventions, as applicable) for which it is responsible
for the filing, prosecution or maintenance hereunder (provided that the filing Party shall give at least [***] days prior written notice to the non-filing Party of any desire to cease prosecution and/or maintenance of such Patent Rights on a country
by country basis in the Territory). 

  

	 	7.1.4	Costs. During the Term, with respect to applicable filings hereunder, (1) Ambrx shall be responsible for payment of all costs and expenses to the extent related to (x) patent applications claiming any
Improvement to Ambrx Background Technology, and (y) joint patent applications claiming Joint Collaboration Information and Inventions that Merck has elected not to pursue, and (2) Merck shall be responsible for payment of all costs and expenses to
the extent related to (x) Ambrx patent applications claiming Ambrx Collaboration Information and Inventions (other than patent applications claiming any Improvement to Ambrx Background Technology), but solely to the extent that Ambrx has notified
Merck in writing of the costs and expenses associated therewith and Merck has agreed in writing to the amount of such costs and expenses, and for clarity, Merck shall not be responsible for any costs or expenses in excess of such agreed amounts;
provided, however that Merck will not be responsible under this clause (x) for the costs and expenses of any particular patent application claiming Ambrx Collaboration Information and Inventions for which Merck has not exercised its Option to obtain
an exclusive license pursuant to Section 3.6 [***], and (y) joint patent applications claiming Joint Collaboration Information and Inventions that Merck has elected to pursue. 

 

	 	7.1.5	Merck Collaboration Information and Inventions. Notwithstanding the foregoing provisions of this Section 7.1, Merck shall have the sole right, in its discretion, to file, prosecute and maintain the Merck Patent
Rights claiming or covering any Merck Collaboration Information and Inventions, and Ambrx shall have no rights in connection therewith. 

  

	 	7.1.6	Interpretation of Article 7. The Parties hereby acknowledge and agree that any Patent Rights with respect to Joint Collaboration Information and Inventions filed by Merck in accordance with the foregoing
Section 7.1.1 shall be considered “Merck Patent Rights” for purposes of the remaining provisions of this Article 7 and any Patent Rights with respect to Joint Collaboration Information and Inventions filed by Ambrx in accordance with the
foregoing Section 7.1.1 shall be Normal;considered “Ambrx Patent Rights” for purposes of the remaining provisions of this Article 7, in each case, as applicable. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
46 - 

	 	7.2	Filing, Prosecution and Maintenance of Ambrx Patent Rights (other than Patent Rights for Collaboration Information and Inventions) and Merck Patent Rights (other than Patent Rights for Collaboration Information
and Inventions) 

  

	 	7.2.1	Ambrx Patent Rights (other than Patent Rights for Collaboration Information and Inventions). Ambrx agrees to, and shall, file, prosecute and maintain in the Territory, with consultation with Merck solely
with respect to Ambrx Patent Rights that claim Compounds or Products as composition of matter (“Ambrx Compound Patent Rights”), the Ambrx Patent Rights (other than Patent Rights for Collaboration Information and Inventions, which shall be
covered by Section 7.1), in each case, at Ambrx’s sole cost and expense. Ambrx shall give at least [***] days prior written notice to Merck of any desire to cease prosecution and/or maintenance of Ambrx Compound Patent Rights on a country by
country basis in the Territory and shall permit Merck, in its sole discretion, to continue prosecution or maintenance of such Ambrx Compound Patent Rights at its own expense. If Merck elects to continue prosecution or maintenance, Ambrx shall
execute such documents and perform such ministerial acts at Ambrx’s expense as may be reasonably necessary for Merck to perform such prosecution or maintenance or filing. [***] 

 

	 	7.2.2	Review and Consultation. In each case in connection with the foregoing with respect to Ambrx Compound Patent Rights (other than Patent Rights for Collaboration Information and Inventions, which shall be covered
by Section 7.1), the filing Party (a) shall keep the non-filing Party advised of the status of the actual and prospective patent filings; (b) upon the non-filing Party’s written request, shall provide advance copies of any papers related to the
filing, prosecution and maintenance of such patent filings; (c) shall give the non-filing Party an opportunity to review the text of the application before filing and shall consult with the non-filing Party with respect thereto; (d) shall supply the
non-filing Party with a copy of the application as filed, together with notice of its filing date and serial number; and (e) shall promptly give notice to the non-filing Party of the grant, lapse, revocation, surrender, invalidation or abandonment
of any such Ambrx Compound Patent Rights for which it is responsible for the filing, prosecution or maintenance hereunder [***]. 

  

	 	7.2.3	Merck Patent Rights. Notwithstanding the foregoing provisions of this Section 7.2, Merck shall have the sole right, in its discretion, to file, prosecute and maintain the Merck Patent Rights (other than Patent
Rights for Merck Collaboration Information and Inventions, which shall be covered by Section 7.1.5), and Ambrx shall have no rights in connection therewith. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
47 - 

	 	7.3	Interference, Opposition, Invalidation, Reexamination and Reissue 

  

	 	(a)	Ambrx shall, within [***] days of learning of such event, inform Merck of any request for, or filing or declaration of, any interference, opposition, invalidation, reissue or reexamination relating to (i) Ambrx
Compound Patent Rights or (ii) any other Ambrx Patent Rights claiming any Ambrx Collaboration Information and Invention (or any Joint Collaboration Information and Invention for which Ambrx is the filing party pursuant to Section 7.1). Merck and
Ambrx shall thereafter consult and cooperate fully to determine a course of action with respect to any such proceeding and Merck shall have the right to review and approve any submission to be made in connection with such proceeding.

  

	 	(b)	[***]. 

  

	 	(c)	In connection with any interference, opposition, invalidation, reissue, or reexamination proceeding relating to Ambrx Compound Patent Rights or other Ambrx Patent Rights referenced in the foregoing clause (a),
Merck and Ambrx will provide reasonable assistance that either may reasonably request. Ambrx shall keep Merck informed of developments in any such action or proceeding, including, to the extent permissible by law, consultation on and approval of any
settlement, the status of any settlement negotiations and the terms of any offer related thereto. 

  

	 	(d)	As between the Parties, Ambrx shall bear the expense of any interference, opposition, invalidation, reexamination, or reissue proceeding relating to Ambrx Compound Patent Rights or other Ambrx Patent Rights
referenced in the foregoing clause (a). 

  

	 	(e)	Notwithstanding the foregoing provisions of this Section 7.3, Merck shall have the sole right, in its discretion, to handle any interference, opposition, invalidation, reissue, or reexamination proceeding
relating to Merck Patent Rights (including any Patent Rights claiming any Merck Collaboration Information and Inventions or any Joint Collaboration Information and Invention for which Merck is the filing party pursuant to Section 7.1), [***]
provided, however, that at the request of Merck, Ambrx will provide Merck with reasonable assistance that Merck may reasonably request [***]. 

  

	 	7.4	Enforcement and Defense 

  

	 	(a)	 Ambrx shall give Merck, and Merck shall give Ambrx, notice of either (i) any infringement of (i) Ambrx Compound Patent Rights or (ii) any other
Ambrx Patent Rights claiming any Ambrx Collaboration Information and Invention (or any Joint Collaboration Information and Invention for which Ambrx is the filing 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
48 - 

	 	
party pursuant to Section 7.1), or (iii) any misappropriation or misuse of Ambrx Collaboration Information and Inventions, that may come to Ambrx’s or Merck’s attention. Merck
and Ambrx shall thereafter consult and cooperate fully to determine a course of action, including but not limited to, the commencement of legal action by either or both Merck and Ambrx, to terminate any infringement of such Ambrx Compound Patent
Rights, such Ambrx Patent Rights or any misappropriation or misuse of such Ambrx Collaboration Information and Invention, as applicable. [***]. Each Party shall have the right to be represented by counsel of its own choice. 

 

	 	(b)	[***]. 

  

	 	(c)	[***]. Each Party shall keep the other informed of developments in any action or proceeding, including, to the extent permissible by Applicable Law, consultation on and approval of any settlement, the status of any
settlement negotiations and the terms of any offer related thereto. 

  

	 	(d)	Any recovery obtained by either or both Merck and Ambrx in connection with or as a result of any action contemplated by the foregoing provisions of this Section 7.4 with respect to Ambrx Compound Patent Rights or
other Ambrx Patent Rights referenced in the foregoing clause (a) or Ambrx Collaboration Information and Inventions, whether by settlement or otherwise, shall be shared [***]. 

 

	 	(i)	[***] 

  

	 	(ii)	[***] 

  

	 	(iii)	[***] 

  

	 	(e)	 Ambrx shall inform Merck of any certification regarding any Ambrx Compound Patent Rights or other Ambrx Patent Rights referenced in the
foregoing clause (a) it has received pursuant to either 21 U.S.C. §§355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or its successor provisions, or any similar provisions in a country in the Territory, and shall provide Merck with a copy of such
certification [***]. Ambrx’s and Merck’s rights with respect to the initiation and prosecution of any legal action as a result of such certification or any recovery obtained as a result of such legal action shall be as defined in
paragraphs 7.4(a)-(d) hereof; provided, however, that Ambrx shall exercise its first right to initiate and prosecute any action and shall inform Merck of such decision within [***] of receipt of the certification, after which time Merck shall have
the right to initiate and prosecute such action. Regardless of which Party has the right to initiate and prosecute such action, both Parties shall, as 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
49 - 

	 	
soon as practicable after receiving notice of such certification, convene and consult with each other regarding the appropriate course of conduct for such action. The non-initiating Party shall
have the right to be kept fully informed and participate in decisions regarding the appropriate course of conduct for such action, and the right to join and participate in such action. 

 

	 	(f)	[***] Merck shall have the sole right, in its discretion, to handle any action with respect to any infringement of Merck Patent Rights (including any Patent Rights claiming any Merck Collaboration Information and
Inventions) or any misappropriation or misuse of any Merck Background Know-How (or any Merck Collaboration Information and Inventions or any Joint Collaboration Information and Inventions), and Ambrx shall have no rights in connection therewith.
[***] As between the Parties, any recovery obtained in connection with or as a result of any action contemplated by this Section 7.4(f), whether by settlement or otherwise, shall be shall be retained solely by Merck. Merck shall also have the sole
right, in its discretion, to handle any certification matter regarding any Merck Patent Rights pursuant to either 21 U.S.C. §§355(b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) or its successor provisions, or any similar provisions in a country in the
Territory, and Ambrx shall have no rights in connection therewith. 

  

	 	7.5	Cooperation; Patent Term Restoration 

 The Parties agree to cooperate and to take
reasonable actions to maximize the protections available under the safe harbor provisions of 35 U.S.C. 103(c) for U.S. patents/patent applications with respect to any patents/patent applications claiming any Collaboration Information and Invention.
The Parties hereto shall provide reasonable assistance that either may reasonably request in obtaining patent term restoration or supplemental protection certificates or their equivalents in any country in the Territory where applicable to (i) Ambrx
Compound Patent Rights or (ii) other Ambrx Patent Rights claiming Collaboration Information and Inventions. In the event that elections with respect to obtaining such patent term restoration are to be made, Merck shall have the right to make the
election and Ambrx agrees to abide by such election. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
50 - 

 ARTICLE 8 

TERM AND TERMINATION 
  

	 	8.1	Term and Expiration 

 This Agreement shall be effective as of the Effective Date
and unless terminated earlier pursuant to Sections 8.2 or 8.3 below, this Agreement shall continue in full force and effect on a Product-by-Product and country-by-country basis until expiration of all Merck royalty obligations hereunder with respect
to such Product in such country. The period from the Effective Date until the date of expiration or earlier termination of this Agreement in its entirety, or as the case may be, until the date of the expiration or earlier termination of this
Agreement in part with respect to a given Product on a country-by-country basis, shall be referred to herein as the “Term”. 

 

	 	8.2	Termination by Merck 

 Merck shall have the right to terminate this Agreement at
any time and from time to time in its sole discretion [***]. Any termination under this Section 8.2 shall be accomplished by Merck giving ninety (90) days’ advance written notice to Ambrx (provided, however that Merck shall have the
right to terminate this Agreement with respect to a given Product immediately upon written notice to Ambrx in the event that Merck has a safety or efficacy concern with respect to such Product (a “Safety/Efficacy Termination”)).
In the event that this Agreement is terminated only with respect to a given Product and/or a given country and/or a given Research Program pursuant to this Section 8.2, then the effects of termination as set forth in Section 8.4 shall only
apply with respect to such Product and/or such country and/or such Research Program, as applicable. For clarity, early discontinuance of a given Research Program under Section 2.8.2 shall not be considered a termination of this Agreement with
respect to such Research Program pursuant to this Section 8.2. 
  

	 	8.3	Termination for Cause 

  

	 	8.3.1	Cause for Termination. This Agreement may be terminated at any time during the Term: 

  

	 	(a)	 upon written notice by either Party if the other Party is in breach of its material obligations hereunder, and has not cured such breach within
[***] days after notice requesting cure of the breach; provided, however, that in the event of a good faith dispute with respect to the existence of a material breach, the [***] day cure period shall be tolled until such time as the dispute is
resolved pursuant to Section 10.6 hereof; provided further, however, that notwithstanding the foregoing, it is agreed that termination pursuant to this Section 8.3.1(a) shall be on a Product-by-Product and country-by-country basis to which the material breach relates, as applicable, and that the non-breaching Party cannot terminate this Agreement
under this Section 8.3.1(a) with respect to non-affected Products and non-affected countries (and the effects of termination as set forth in Section 8.4 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
51 - 

	 	
shall only apply with respect to such terminated Product and such terminated country, as applicable); or 

  

	 	(b)	upon written notice by Merck if Ambrx materially fails to conduct a given Research Program in accordance with the terms of this Agreement (including with respect to a failure to comply with its diligence
obligations under Section 2.2) or otherwise materially breaches any of its obligations with respect to a given Research Program, and Ambrx has not cured such breach within [***] days after
notice requesting cure of the breach; provided, however, that notwithstanding the foregoing, it is agreed that termination pursuant to this Section 8.3.1(b) shall be on a Research Program-by-Research Program basis to which the breach relates,
as applicable, and Merck cannot terminate this agreement under this Section 8.3.1(b) with respect to the non-affected Research Programs (and the effects of termination as set forth in Section 8.4 shall only apply with respect to such
terminated Research Program) (provided that for clarity, the provisions of this Section 8.3.1(b) shall be without limitation to any rights of Merck under Section 8.3.1(a)); or 

 

	 	(c)	by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by
the other Party; provided, however, that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy or such proceeding is not dismissed within [***]
days after the filing thereof; or 

  

	 	(d)	immediately upon written notice by either Party if the Research Program has terminated in its entirety and Merck has not exercised any of its Options within the time periods set forth in Section 3.6.

  

	 	8.4	Effect of Termination 

  
  

	 	(a)	If Merck terminates this Agreement under Section 8.2: (i) Ambrx’s license pursuant to Section 3.1.2(b) shall survive such termination with respect to any Reversion Compounds (if any, as of the date of such
termination) and Reversion Products (if any, as of the date of such termination) (subject to the payment obligations of Ambrx as set forth in Section 5.10 and subject to the provisions of Section 3.1.2(b)) (provided, however that this license shall
not survive in the event of a Safety/Efficacy Termination with respect to such Reversion Compound or Reversion Product, and for clarity, in the event of such a Safety/Efficacy Termination, Ambrx’s licenses pursuant to Section 3.1.2(b) shall
automatically terminate); and (ii) no later than [***] days after the effective date of any such termination, each Party shall return or cause to be returned to the other Party all Confidential Information received from the other Party and all
copies thereof; provided, however, that each Party may retain any Confidential Information, substances, compositions and/or material provided by the other Party, as applicable, as are reasonably necessary for such Party’s continued practice
under any licenses which survive such termination and may keep one copy of Confidential Information received from the other Party in its confidential files for record purposes. 

 

	 	(b)	If Merck terminates this Agreement under Section 8.3.1(a): (i) Merck’s licenses [***] for which an Option was exercised shall become perpetual, irrevocable licenses (provided, however, that Merck shall
continue to be obligated to pay the milestone and royalty amounts under Sections 5.4 and 5.5 that would otherwise have been payable under the terms of this Agreement during its Term; provided further, however, that such amounts shall be reduced
[***] Ambrx’s license pursuant to Section 3.1.2(b) shall survive such termination with respect to any Reversion Compounds (if any, as of the date of such termination) and Reversion Products (if any, as of the date of such termination) (subject
to the payment obligations of Ambrx as set forth in Section 5.10 and subject to the provisions of Section 3.1.2(b)), and (iv) Ambrx shall, within [***] days after the effective date of such termination, return or cause to be returned to Merck all
Confidential Information and all Merck substances or Merck compositions delivered or provided by Merck, as well as any other Merck material provided by Merck in any medium (provided, however, that Ambrx may retain any such Confidential Information,
substances, compositions and/or material, as applicable, as are reasonably necessary for Ambrx’s continued practice under any licenses which survive such termination and Ambrx may keep one copy of Confidential Information received from
Merck in its confidential files for record purposes). 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
52 - 

	 	(c)	If Ambrx terminates this Agreement under Section 8.3.1(a), (i) Merck’s licenses pursuant to Sections 3.1.1(d) and 3.1.1(e) shall terminate, (ii) Ambrx’s license pursuant to Section 3.1.2(b) shall
survive such termination with respect to any Reversion Compounds (if any, as of the date of such termination) and Reversion Products [***] and (iii) each Party shall, within [***] days after the effective date of such termination, return or cause to
be returned to the other Party all Confidential Information of the other Party and all substances or compositions owned by the other Party delivered or provided by such other Party, as well as any other material owned by such other Party provided by
such other Party in any medium [***] 

  

	 	(d)	If Merck terminates this Agreement with respect to a given Research Program under Section 8.3.1(b): (i) if Merck elects in writing (in its discretion) to Ambrx, then for purposes of this Agreement, it shall be
treated as if [***] (ii) [***] provided, however, [***] provided further, however, [***] (iii) except with respect to [***] (iv) the provisions of [***] shall apply, and (v) Ambrx shall [***] 

 

	 	(e)	If this Agreement is terminated by either Party under Section 8.3.1(d), (i) Merck’s licenses pursuant to Sections 3.1.1(d) and 3.1.1(e) shall terminate, (ii) Ambrx’s license pursuant to Section 3.1.2(b)
shall survive such termination with respect to any Reversion Compounds (if any, as of the date of such termination) and Reversion Products (if any, as of the date of such termination) (subject to the payment obligations of Ambrx as set forth in
Section 5.10 and subject to the provisions of Section 3.1.2(b)), and each Party shall, within thirty (30) days after the effective date of such termination, return or cause to be returned to the other Party all Confidential Information of the other
Party and all substances or compositions owned by the other Party delivered or provided by such other Party, as well as any other material owned by such other Party provided by such other Party in any medium (provided, however, that the receiving
Party may retain any such Confidential Information, substances, compositions and/or material, as applicable, as are reasonably necessary for such Party’s continued practice under any licenses(s) which survive such termination and the receiving
Party may keep one copy of Confidential Information received from the other Party in its confidential files for record purposes). 

  

	 	(f)	 Notwithstanding the foregoing, upon termination of this Agreement by Merck pursuant to Section 8.2, or by Ambrx pursuant to Section 8.3.1(a),
or by either Party pursuant to Section 8.3.1(d), if an Option has been exercised, the 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
53 - 

	 	
applicable licenses set forth in Sections 3.1.1(d) and 3.1.1(e) shall survive for a period of [***] in order for Merck and its Affiliates, sublicensees and distributors, at their
discretion, during such [***] period immediately following the effective date of termination, to finish any Product related manufacturing work-in-progress and to sell any Products or Compound remaining in inventory, in accordance with the terms of
this Agreement, in each case, utilizing such licenses (subject to the payment obligations of Merck as set forth in Section 5). 

  

	 	(g)	If this Agreement is terminated by Merck pursuant to Section 8.3.1(c), then the provisions of Section 8.4(b) shall apply, and in addition, if such termination is due to the rejection of this Agreement by or on
behalf of Ambrx under Section 365 of the United States Bankruptcy Code (the “Code”), all licenses and rights to licenses granted under or pursuant to this Agreement by Ambrx to Merck are, and shall otherwise be deemed to be, for
purposes of Section 365(n) of the Code, licenses of rights to “intellectual property” as defined under Section 101(35A) of the Code. The Parties agree that Merck, as a licensee of such rights under this Agreement, shall retain and may
fully exercise all of its rights and elections under the Code. The foregoing provisions of Section 8.4(g) are without prejudice to any rights Merck may have arising under the Code or other Applicable Law. 

 

	 	(h)	If this Agreement is terminated by Ambrx under Sections 8.3.1(a) or 8.3.1(c) with respect to a given Compound and/or Product, upon Ambrx’s written request: 

(i) If this Agreement is so terminated by Ambrx under Sections 8.3.1(a) or 8.3.1(c) with respect to a given Compound and/or Product
[***] then to the extent that Merck has [***] then Ambrx shall have [***]. In such event, Ambrx and Merck shall [***] as well as (x) [***] and (y) [***] provided, however, that Merck shall [***] and Ambrx shall [***]. 

(ii) For purposes of this subsection (h), [***] shall mean [***]; and [***] shall mean [***]. 

 

	 	(i)	For clarity, if this Agreement is terminated only with respect to a given Product(s) and/or a given country(ies) and/or a given Research Program, as applicable, then the foregoing provisions of this Section 8.4 shall
only apply with respect to such Product and/or such country and/or such Research Program, as applicable. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
54 - 

	 	8.5	Effect of Expiration or Termination; Survival 

  

	 	(a)	Upon expiration of the Term, (i) Merck’s licenses pursuant to Sections 3.1.1(d) and 3.1.1(e) with respect to any Compounds and Products as to which the applicable Option has been exercised (if any)
shall become fully paid-up, perpetual, irrevocable licenses and (ii) Ambrx’s license pursuant to Section 3.1.2(b) shall survive such expiration with respect to any Reversion Compounds (if any,
as of the date of such expiration) and Reversion Products (if any, as of the date of such expiration) (subject to the payment obligations of Ambrx as set forth in Section 5.10 and subject to the provisions of Section 3.1.2(b)).

  

	 	(b)	Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Each Party shall pay all amounts then due and owing as of the
expiration or termination date (and Ambrx shall reimburse Merck for any uncredited fees paid by Merck pursuant to the Research Program). Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against
the other accrued or accruing under this Agreement prior to expiration or termination, including the obligation to pay royalties for Product(s) or Compound sold prior to such expiration or termination. 

 

	 	(c)	The provisions of Article 4 shall survive the expiration or termination of this Agreement and shall continue in effect for [***]. In addition, the provisions
of Articles 1 (as necessary for the interpretation of other surviving provisions), 7 and 10, and Sections 2.6.1, 2.6.4, 2.7, 2.9 (other than the first sentence thereof), 2.12.5, 3.1.1(g), 3.1.2(b), 3.1.2(c), 3.7.2, 5.2.2, 5.7, 5.10, 6.4, 8.4, 9.1
through 9.4, and this 8.5 shall survive any expiration or termination of this Agreement. 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
55 - 

 ARTICLE 9 

INDEMNIFICATION; LIMITATION ON LIABILITY 
  

	 	9.1	Indemnification by Merck 

 Merck hereby agrees to indemnify, hold harmless and
defend Ambrx, its Affiliates and their respective officers, directors, agents, employees, successors and assigns (collectively, the “Ambrx Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising
out of or relating to claims, allegations, suits, actions or proceedings asserted by any Third Party, whether governmental or private, arising out of or relating to (i) the research, development, manufacture, use, sale or other disposition of
Compounds and Products by Merck or its Affiliates or sublicensees under this Agreement, (ii) the breach of any of Merck’s covenants, representations or warranties under this Agreement, or (iii) the negligence or willful misconduct by
Merck, its Affiliates or their respective officers, directors, agents or employees, in performing any obligations under this Agreement; provided, however, that Merck shall not be required to indemnify, hold harmless or defend any Ambrx Indemnified
Party against any claim to the extent that Ambrx has an obligation to indemnify the Merck Indemnified Parties under clauses (iii) or (iv) of Section 9.2. 
  

	 	9.2	Indemnification by Ambrx 

 Ambrx agrees to indemnify, hold harmless and defend
Merck, its Affiliates and their respective officers, directors, agents, employees, successors and assigns (collectively, the “Merck Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or
relating to claims, allegations, suits, actions or proceedings asserted by any Third Party, whether governmental or private, arising out of or relating to (i) the research, development, manufacture, use, sale or other disposition of Reversion
Compounds and/or Reversion Products by Ambrx or its Affiliates or sublicensees, (ii) the research, development, manufacture or use of Compounds and/or Products by Ambrx or its Affiliates or sublicensees under this Agreement, (iii) the
breach of any of Ambrx’s covenants, representations or warranties under this Agreement, or (iv) the negligence or willful misconduct by Ambrx, its Affiliates or their respective officers, directors, agents or employees, in performing any
obligations under this Agreement; provided, however, that Ambrx shall not be required to indemnify, hold harmless or defend any Merck Indemnified Party against any claim to the extent that Merck has an obligation to indemnify the Ambrx Indemnified
Parties under clauses (ii) or (iii) of Section 9.1. 
  

	 	9.3	Procedure 

 If either Party is seeking indemnification under Section 9.1 or
9.2 (the “Indemnified Party”), it shall inform the other Party (the “Indemnifying Party”) of the claim giving rise to the obligation to indemnify pursuant to such Section as soon as reasonably practicable after
receiving notice of the claim (provided, however, any delay or failure to provide such notice shall not constitute a waiver or release of, or otherwise limit, the Indemnified Party’s rights to indemnification under, as applicable,
Section 9.1 or 9.2, except to the extent that such delay or failure materially prejudices the Indemnifying 

  
 - 56 - 

 
Party’s ability to defend against the relevant claims). The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the
Indemnified Party. The Indemnified Party shall cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified
Party shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. The Indemnifying Party shall not settle any claim without the prior
written consent of the Indemnified Party, not to be unreasonably withheld. The Indemnified Party shall not settle or compromise any such claim without the prior written consent of the Indemnifying Party, which it may provide in its sole discretion.
If the Parties cannot agree as to the application of Section 9.1 or 9.2 to any claim, pending resolution of the dispute pursuant to Section 10.6, the Parties may conduct separate defenses of such claims, with each Party retaining the right
to claim indemnification from the other Party in accordance with Section 9.1 or 9.2 upon resolution of the underlying claim. 
  

	 	9.4	Limitation of Liability 

 NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL,
CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES (INCLUDING LOST PROFITS) ARISING FROM OR RELATING TO THIS AGREEMENT (INCLUDING BREACH OF THIS AGREEMENT) OR THE EXERCISE OF ITS RIGHTS HEREUNDER, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF
SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 9.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT (1) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 9.1 OR 9.2, OR (2) DAMAGES AVAILABLE FOR A
PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER Article 4. 
  

	 	9.5	Insurance 

 Each Party shall procure and maintain insurance, including product
liability insurance (or self-insure), adequate to cover its obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Product or Reversion Product, as
applicable, is being clinically tested with human subjects or commercially distributed or sold by such Party. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its
indemnification obligations under this Article 9 or otherwise. Each Party shall provide the other Party with written evidence of such insurance upon request. Each Party shall provide the other Party with written notice at least thirty (30) days
prior to the cancellation, non renewal or material change in such insurance or self insurance which materially adversely affects the rights of the other Party hereunder. 

  
 - 57 - 

 ARTICLE 10 

MISCELLANEOUS 
  

	 	10.1	Force Majeure 

 Neither Party shall be held liable to the other Party nor be
deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the
affected Party, potentially including, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or
acts, omissions or delays in acting by any governmental authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable
efforts necessary to cure such force majeure circumstances. 
  

	 	10.2	Assignment/Change of Control 

 Except as provided in this Section 10.2, this
Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party. [***]. 

 

	 	10.3	Severability 

 If any one or more of the provisions contained in this Agreement is
held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s)
adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their good faith efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar
as practical, implement the purposes of this Agreement. 
  

	 	10.4	Notices 

 All notices which are required or permitted hereunder shall be in
writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified
mail, postage prepaid, return receipt requested, addressed as follows: 
  

			
	If to Ambrx, to:	 	Ambrx, Inc.
		 	10975 North Torrey Pines Road
		 	La Jolla, CA 92037
		 	Attn: Office of General Counsel

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
58 - 

			
		 	Facsimile No.: (858) 453-9511
		
	With a copy to:	 	Latham & Watkins, LLP
		 	12636 High Bluff Drive, Suite 400
		 	San Diego, CA 92130
		 	Attention: Faye H. Russell, Esq.
		 	Facsimile No.: (858) 523-5450
		
	If to Merck, to:	 	[***]
		 	[***]
		 	[***]
		 	[***]
		 	[***]
		 	[***]
		
		 	[***]
		 	[***]
		 	[***]
		 	[***]
		 	[***]
		 	[***]
		 	[***]

 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party
in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business
day); (b) on the business day after dispatch, if sent by nationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail. 

 

	 	10.5	Applicable Law 

 This Agreement shall be governed by and construed in accordance
with the laws of the [***] and the patent laws of the United States, without reference to any rules of conflict of laws or renvoi. 
  

	 	10.6	Dispute Resolution 

  

	 	10.6.1	 The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to
this Agreement or the 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
59 - 

	 	
breach thereof. If the Parties do not fully settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim that is not an “Excluded Claim” shall be finally
resolved by binding arbitration in accordance with the Commercial Arbitration Rules and Supplementary Procedures for Large Complex Disputes of the American Arbitration Association (“AAA”), and judgment on the arbitration award may
be entered in any court having jurisdiction thereof. 

  

	 	10.6.2	The arbitration shall be conducted by a panel of three persons experienced in the pharmaceutical business: within thirty (30) days after initiation of arbitration, each Party shall select one person to act
as arbitrator; and the two Party-selected arbitrators shall select a third arbitrator within thirty (30) days of their appointment. If the arbitrators selected by the Parties are unable or fail to agree upon the third arbitrator, the third
arbitrator shall be appointed by the AAA. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. 

  

	 	10.6.3	Either Party may apply to the arbitrators for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under
this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any
other type of damages not measured by a Party’s compensatory damages. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration.

  

	 	10.6.4	Except to the extent necessary to confirm an award or as may be required by Applicable Law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior
written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of
limitations. 

  

	 	10.6.5	The Parties agree that, in the event of a good faith dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute
through arbitration or other judicial determination. The Parties further agree that any payments made pursuant to this Agreement pending resolution of the dispute shall be refunded if an arbitrator or court determines that such payments are not due.

  

	 	10.6.6	As used in this Section, the term “Excluded Claim” shall mean a dispute, controversy or claim that concerns (a) the validity or infringement of a patent, trademark or copyright; or
(b) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory. 

  

	 	10.7	Entire Agreement; Amendments 

  
 - 60 - 

 This Agreement together with the Schedules hereto contains the entire understanding of the
Parties with respect to the subject matter hereof, including the Research Program and the licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with
regard to the subject matter hereof, including the Research Program and/or the licenses granted hereunder, are superseded by the terms of this Agreement. The Schedules to this Agreement are incorporated herein by reference and shall be deemed a part
of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. 
  

	 	10.8	Headings and Interpretation 

 The captions to the several Articles and Sections
and subsections hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. Any reference in this Agreement to an Article, Section, subsection, paragraph,
clause, or Schedule or Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this
Agreement otherwise requires, (a) words of any gender include each other gender, (b) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular
provision in which such words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any provision of this Agreement uses the term “including” (or “includes” or words of similar
import), such term shall not be limiting and such term shall be deemed to mean “including without limitation” (or “includes without limitation”), (e) the word “or” shall not be construed as exclusive, and
(f) references to any Articles or Sections include Sections and subsections that are part of the reference Article or section (e.g., a section numbered “Section 2.2.1” would be part of “Section 2.2.”, and references to
“Article 2” or “Section 2.2.” would refer to material contained in the subsection described as “Section 2.2.2”). 
  

	 	10.9	Independent Contractors 

 It is expressly agreed that Ambrx and Merck shall be
independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Ambrx nor Merck shall have the authority to make any statements, representations or commitments of any kind,
or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party. 

  
 - 61 - 

	 	10.10	Waiver 

 The waiver by either Party hereto of any right hereunder, or of any
failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise. 

 

	 	10.11	Cumulative Remedies 

 No remedy referred to in this Agreement is intended to be
exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 
  

	 	10.12	Waiver of Rule of Construction 

 Each Party has had the opportunity to consult
with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

 

	 	10.13	Business Day Requirements 

 In the event that any notice or other action or
omission is required to be taken by a Party under this Agreement on a day that is not a business day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day. 

 

	 	10.14	Counterparts 

 This Agreement may be executed in two or more counterparts, each of
which shall be deemed an original, but all of which together shall constitute one and the same instrument. For purposes hereof, a scanned copy of this Agreement, including the signature pages hereto, will be deemed to be an original. 

 

	 	10.15	Further Actions 

 Each Party will execute, acknowledge and deliver such further
instruments, and to do all such other ministerial, administrative or similar acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

 

	 	10.16	No Third Party Rights 

 The provisions of this Agreement are for the exclusive
benefit of the Parties, and no other person or entity shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. 

  
 - 62 - 

	 	10.17	Expenses 

 Except as otherwise specifically provided in this Agreement, each Party
(and its Affiliates) shall bear its own costs and expenses in connection with entering into this Agreement and the consummation of the transactions and performance of its obligations contemplated hereby. 

 

	 	10.18	Extension to Affiliates 

 Merck shall have the right to extend the rights,
licenses, immunities and obligations granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as
such terms and provisions apply to Merck. Merck shall remain fully liable for any acts or omissions of such Affiliates. 
 [Remainder of
this page is left intentionally blank] 

  
 - 63 - 

 

 
  

 IN WITNESS WHEREOF, the Parties have executed this Research Collaboration, Option and
Exclusive License Agreement as of the date first set forth above. 
  

					
		 	MERCK SHARP & DOHME CORP.
			
		 	By:	 	 /s/ Barbara Yanni

		 	Name:	 	Barbara Yanni
		 	Title:	 	Vice President and Chief Licensing Officer
		
		 	AMBRX, INC.
			
		 	By:	 	 /s/ John D. Diekman

		 	Name:	 	John D. Diekman
		 	Title:	 	Chairman of the Board

 SIGNATURE PAGE TO RESEARCH COLLABORATION, 

OPTION AND EXCLUSIVE LICENSE AGREEMENT 

 

 
  

 SCHEDULE 1.72 

RESEARCH PLAN 1 
 [See
Attached] 
  

 RESEARCH PLAN 1 

[***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 2
- 

 SCHEDULE 1.90 

TARGET 1 
 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 3
- 

 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 -
4- 

 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 5
- 

 SCHEDULE 2.1.1 

EXCLUDED TARGETS 
 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 - 6
-EX-10.21

 Exhibit 10.21 

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED
MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 CO-DEVELOPMENT AND LICENSE AGREEMENT 

Between 
 Zhejiang Medical
Corporation 
 and 

AMBRX, INC. 
 Dated as of
June 14, 2013 

 CO-DEVELOPMENT AND LICENSE AGREEMENT 

This CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of June 14, 2013 (the “Effective Date”),
is between AMBRX, Inc., a Delaware Corporation having the principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”),
and , Zhejiang Medicine Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having the principal business address at 268 Dengyun Road, Gongshu District, Hangzhou, Zhejiang, P.R. China, for and
on behalf of itself and its Affiliates (together with its Affiliates, “ZMC”). AMBRX and ZMC may each be referred to herein individually as a “Party” or, collectively, as the “Parties.” 

RECITALS 
 WHEREAS,
Ambrx owns and/or controls Ambrx Background Technology (as hereinafter defined) and has rights to Licensed Intellectual Property Rights as hereinafter defined) with respect to aHer2-ADC Program (as
hereinafter defined); 
 WHEREAS, ZMC is a pharmaceutical company engaged in research, development, and commercialization of
pharmaceutical products, including the human therapeutic products in the Territory (as hereinafter defined); 
 WHEREAS, ZMC desires
to obtain an exclusive license under the Ambrx Existing Patent Rights in the Territory upon the terms and conditions set forth herein, and Ambrx desires to grant such a license, in order for ZMC to develop, make, use, sell, offer for sale the
Licensed Products (as hereinafter defined) for the prevention or treatment of human diseases and human conditions in the Territory; 

WHEREAS, ZMC desires to obtain assistance from AMBRX and AMBRX desires to offer such assistance to ZMC to develop aHer2-ADC Program to the Licensed Products in the Territory under the world-class standards and complete phase I human clinical trials outside the Territory and build a cGMP manufacturing facility to produce
the Licensed Product for commercialization in the Territory and/or aHer2-ADC API or aHer2-ADC Product (as hereinafter defined) outside the Territory. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of
which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 As used in
this Agreement, the following terms shall have those meanings set forth in this Article 1 unless the context dictates otherwise. 

  
 2 

	1.1	“Affiliate” shall mean, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control with such Person. A Person shall be deemed
to control another Person if such Person possesses the power to direct or cause the direction of the management, business and policies of such Person, , whether through the ownership of fifty percent (50%) or more of the voting securities of
such Person by voting agreement, by contract or otherwise. 

  

	1.2	“Her2” shall mean v-erb-b2 erythroblastic leukemia viral oncogene homolog having a Genbank ID number of 2064 and a protein sequence as shown in Exhibit 1. 

 

	1.3	“aHer2-Antibody” shall mean an Antibody that primarily binds to Her2. 

 

	1.4	“aHer2-ADC” shall mean an Antibody Drug Conjugate (ADC) which is capable of binding primarily to Her2 and being conjugated to one cytotoxic
payload. For clarity, aHer2-ADC includes ADC that has been conjugated to one cytotoxic payload. 

  

	1.5	“aHer2-ADC API” shall mean aHer2-ADC in compliance with regulatory requirements by CFDA in the
Territory, the FDA in the United States and other such appropriate Regulatory Authority and suitable as an active pharmaceutical ingredient for pharmaceutical or biological preparation. 

 

	1.6	“aHer2-ADC Candidate(s)” shall mean aHer2-ADC controlled and provided by AMBRX to ZMC for further
evaluation under the aHer2-ADC Program to determine suitability for continued development for regulatory approval and commercialization. 

 

	1.7	“aHer2-ADC Program” shall mean development, preclincal and clinical activities directed by the joint Steering Committee and undertaken
by ZMC to develop an aHer2-ADC API and/or aHer2-ADC Product from aHer2-ADC Candidate(s). 

 

	1.8	“aHer2-ADC Product” shall mean any pharmaceutical or biological preparation in final form containing
aHer2-ADC API. For clarity, different formulations or dosage strengths of a given aHer2-ADC API shall be considered the same
aHer2-ADC Product for purposes of this Agreement. 

  

	1.9	“AMBRX Background Technology” shall mean Know How and AMBRX Patent Rights, including inventions, discoveries, improvements, processes, methods, protocols, formulas,
compositions, data, inventions, know-how and/or trade secrets, patentable or otherwise, which are owned and/or Controlled by AMBRX or any of its Affiliates as of the Effective Date or during the Term of this Agreement. 

 

	1.10	 “AMBRX Existing Patent Rights” shall mean all Patent Rights owned or 

  
 3 

	 	
Controlled by or licensed to Ambrx as of the Effective Date which is related to aHer2-ADC as shown in Exhibit X. 

 

	1.11	“AMBRX Improvements” shall mean all Patent Rights and Know-How first (i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have utility by one or more
employees or Third Parties working on behalf of AMBRX, in connection with the development of Licensed Products or in the course of engaging in aHer2-ADC Program during the Term of this Agreement without
involvement of any employees from ZMC. 

  

	1.12	“AMBRX Know-How” shall mean all Confidential Information & Materials, technical knowledge, materials, cells or cell lines, software, trade secrets, Know How, process technology
and other knowledge, information, or technology in possession of AMBRX and its Affiliate, as of the Effective Date and during the Royalty Term, concerning subject matter relating to Licensed Products, or which otherwise are useful for the
development, manufacture, use or sale of Licensed Products. 

  

	1.13	“AMBRX Patent Rights” shall mean any Patent Rights Controlled or owned by AMBRX as of the Effective Date or during the Term of this Agreement. For clarity, AMBRX Patent Rights excludes AMBRX
Existing Patent Rights. 

  

	1.14	“Antibody(ies)” shall mean a full length antibody which is a “Y”-shaped protein consisting of four polypeptide chains: two identical heavy chains and two identical light chains
connected by disulfide bonds, capable of binding to an antigen, whether polyclonal, monoclonal, human, humanized, chimeric, murine, synthetic or from any other source. 

 

	1.15	“Antibody Drug Conjugate” or “ADC” shall mean an Antibody which 1) has undergone modification through the incorporation, substitution or addition of one or more non-naturally
encoded amino acids (i.e., amino acids other than the 20 naturally-encoded amino acids), 2) provides one or more specific site(s) in the amino acid sequence of the Antibody suitable for conjugation, and 3) is suitable and capable of being
conjugated, linked or attached to one or more cytotoxic payload(s) via one or more specific site(s). For clarity, ADC includes an Antibody that has been conjugated, linked or attached to one or more cytotoxic payload(s) via one or more specific
site(s). 

  

	1.16	“Applicable Laws” shall mean the applicable laws of any jurisdiction which are applicable to any of the Parties or their respective Affiliates in carrying out activities hereunder or to which any
of the Parties or their respective Affiliates in carrying out the activities hereunder is subject by law or by agreement, and shall include all statutes, enactments, acts of legislature, laws, ordinances, rules, regulations, notifications,
guidelines, policies, directions, directives and orders of any statutory authority, tribunal, board, or court or any central or state government or local authority or other governmental entity in such jurisdictions. 

  
 4 

	1.17	“Calendar Quarter” shall mean the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.

  

	1.18	“Calendar Year” shall mean each successive period of twelve (12) months commencing on January 1 and ending on December 31. 

 

	1.19	“CFDA” shall mean China Food and Drug Administration in the People’s Republic of China, or any successor thereto. 

 

	1.20	“cGMP” or “Current Good Manufacturing Practice” shall mean the applicable then-current standards for manufacturing of pharmaceuticals or biologicals, as set forth in the
United States Federal Food, Drug and Cosmetic Act, 21 U.S.C §§ 301, as amended from time to time, together with any similar standards of good manufacturing practice as required by CDA and other relevant Regulatory Authority.

  

	1.21	“Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a Party with respect to any objective, reasonable, diligent, good faith efforts to accomplish such
objective as such Party would normally use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the research, discovery, development or commercialization of any Licensed Product (or aHer2-ADC, aHer2-ADC Candidate, aHer2-ADC API, aHer2-ADC Product, as
applicable) by either Party, such efforts shall be substantially equivalent to those efforts and resources commonly used by such Party for a product owned by it or to which it has rights, which product is at a similar stage in its development or
product life and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of
regulatory approval, the profitability and commercial potential of the product to the applicable Party (including the amounts payable to licensors of patent or other intellectual property rights), alternative products and other relevant factors.

  

	1.22	“Confidential Information & Material” shall mean any and all proprietary and/or confidential information, materials, and data, including all scientific, pre-clinical, clinical,
regulatory, process, formulation, manufacturing, marketing, financial and commercial information or data, compounds, cells, cell lines, whether communicated in writing or orally or by any other method, which are provided by one Party to the other
Party prior to or during the Term of this Agreement. 

  

	1.23	 “Control”, “Controls” or “Controlled by” shall mean with respect to any Existing Patent
Rights, Patent Rights, Know-How, Confidential Information & Materials, or other intellectual property assets or other items or rights, as applicable, the possession of (whether by ownership or license or other right, other than pursuant to
a license under this Agreement), or the ability of a Party to grant access to, or a license or sublicense of, such item or right as provided for 

  
 5 

	 	
herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or
license or sublicense. 

  

	1.24	“Covered By” shall mean, with respect to Patent Rights: materials, products and services developed, manufactured, used, sold or provided by ZMC, which but for the License, would infringe a Valid
Claim of such Patent Rights in the Territory in which such products or services are developed, used, manufactured, sold or provided by ZMC, respectively. 

  

	1.25	“Effective Date” shall mean the date first set forth above. 

  

	1.26	“FDA” shall mean the United States Food and Drug Administration, or any successor thereto. 

  

	1.27	“Field” shall mean the field of aHer2-ADC including all human indications and uses, such as diagnosis, prevention, and treatment of human diseases and
conditions associated with aHer2. For clarity, Field is for human use only and excludes all non-human indications and uses. 

 

	1.28	“First Commercial Sale” shall mean, with respect to Licensed Product, the first sale to the general public of such Licensed Product in the Territory after all required marketing and pricing
approvals have been granted, or otherwise permitted, by the governing health authority of Territory such as CFDA. “First Commercial Sale” shall not include the provision of any Licensed Product for use in clinical trials or for
compassionate use prior to the receipt of necessary Marketing Authorization. 

  

	1.29	“Full Time Equivalent” or “FTE” shall mean a dedicated full-time employee or contractor of Ambrx, as the case may be, or in the case of less than a full-time dedicated person, a
full-time, equivalent person year, each based upon the total of one thousand six hundred eighty (1680) hours per year of work on activities hereunder.  

  

	1.30	“FTE Rate” means the yearly rate at which ZMC will fund Ambrx FTEs. 

  

	1.31	“China GAAP” shall mean Generally Accepted Accounting Principles for the People’s Republic of China. 

  

	1.32	“Generic Competition” shall mean the sale of products containing aHer2-ADC in the Territory by a Third Party. 

 

	1.33	“Joint Development Committee” shall mean the entity organized and acting pursuant to Section 3. 

 

	1.34	 “Joint Development Technology” or “Joint Improvements” shall mean all Inventions and Know-How first
(i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have utility by, on one hand, one or more employees or 

  
 6 

	 	
Third Parties working on behalf of ZMC, on the one hand, with one or more employees or Third Parties working on behalf of AMBRX, on the other hand, in connection with the development of Licensed
Products or in the course of engaging in aHer2-ADC Program, as well as any and all Patents covering the same. 

  

	1.35	“Know-How” shall mean unpatented technical and other information or materials which are not in the public domain including information comprising or relating to discoveries, inventions, data,
designs, formulae, methods, models, assays, research plans, procedures, designs for experiments and tests and results of experimentation and testing (including results of research or development or
aHer2-ADC Program), cells or cell lines (including cells or cell lines producing aHer2 Antibody or aHer2 ADC),
processes (including manufacturing processes, specifications and techniques), laboratory records, chemical, pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports or
summaries and information contained in submissions to and information from ethical committees and regulatory authorities. Know-How includes rights protecting Know-How. The fact that an item is known to the public shall not be taken to exclude the
possibility that a compilation including the item, and/or a development relating to the item, is (and remains) not known to the public. 

  

	1.36	“License” shall mean all of the rights granted by Ambrx to ZMC by this Agreement under the Licensed Intellectual Property Rights pursuant to Sections 2.1.1 and 2.1.2. 

 

	1.37	“Licensed Intellectual Property Rights” shall mean (a) AMBRX Know How; and (b) AMBRX Existing Patent Rights. 

 

	1.38	“Licensed Products” shall mean any aHER2-ADC product related to aHer2-ADC products, that meets any of the following criteria: (i) the
development, use, manufacture or sale of any such aHER2-ADC product is or will be Covered By a Valid Claim of any Existing Patents and/or AMBRX Patent Rights; or (ii) such product (a) is not described in clause (i) above and
(b) is developed, manufactured, sold or provided using AMBRX Know-How. For the avoidance of doubt, Licensed Products include aHer2-ADC, aHer2-ADC
Candidate, aHer2-ADC API, and aHer2-ADC Product. 

  

	1.39	“Marketing Authorization” shall mean all approvals from CFDA necessary to market and sell a Licensed Product in the Territory or a Regulatory Authority in a corresponding jurisdiction outside
Territory. 

  

	1.40	 “Net Sales” shall mean (I) to AMBRX, the revenue AMBRX received from a Third Party by transferring, assigning or
licensing Phase I Clinical Data to such Third Party, or from the commercialization of an aHer2-ADC Product outside Territory whereas the Market Authorization of such
aHer2-ADC Product is 

  
 7 

	 	
based on Phase I Clinical Data, excluding FTEs, reimbursements and deductions as defined in 1.40(II)(a)-(i); and 

(II) to ZMC, the gross invoice price (not including value added taxes, sales taxes, or similar taxes) of Licensed Product sold
by ZMC or its Affiliate to the first Third Party in which ZMC has no equity interest after deducting, if not previously deducted, from the amount invoiced or received: 
  

	 	(a)	trade and quantity discounts actually given other than early payment cash discounts; 

  

	 	(b)	returns, rebates, charge backs and other similar fees and allowances actually taken; 

  

	 	(c)	retroactive price reductions that are actually allowed or granted; 

  

	 	(d)	deductions to gross invoice price of Licensed Product imposed by Regulatory Authorities or other governmental entities; 

  

	 	(e)	sales commissions, distribution fees and other similar fees paid to Third Party distributors and/or selling agents actually paid; 

 

	 	(f)	early payment cash discounts, transportation and insurance, and custom duties actually taken; and 

(g) the standard inventory cost of devices or delivery systems used for dispensing or administering or delivering Product; 

 

	 	(h)	interest charge, late payment penalty and other similar fees; and 

  

	 	(i)	uncollectable unpaid invoices. 

 Any individual items that are estimated and deducted in
calculating Net Sales shall be periodically (but at least on a calendar quarter basis) trued up and adjusted by ZMC consistent with its customary practices and in accordance with China GAAP. Any deductions subsequently reversed shall be included in
Net Sales for the royalty period in which such deductions are reversed. The calculation of Net Sales hereunder shall be in accordance with China GAAP and ZMC’ and/or its Affiliates’ customary accounting policies, applied consistently
across periods, and 
 (a) Transfer or sale of a Licensed Product within ZMC, between ZMC and an Affiliate, or between ZMC and a
non-Affiliate Third Party in which ZMC has equity interest shall not be considered a sale, commercial use or disposition for the purpose of the foregoing paragraphs; 

(b) in the event that ZMC has to transfer or sell any Licensed Product to a non-Affiliate Third Party in which ZMC has equity interest, ZMC and
AMBRX shall 

  
 8 

 
jointly discuss and determine the value of Net Sales; and 
 (c) in the event that ZMC
receives consideration for any Licensed Products in the case of transactions not at arm’s length with a non-Affiliate of ZMC, Net Sales will be calculated based on the fair market value of such consideration or transaction, assuming an
arm’s length transaction made in the ordinary course of business. 
  

	1.41	“Party” shall mean AMBRX or ZMC and, when used in the plural, shall mean AMBRX and ZMC. 

  

	1.42	“Patent Rights” shall mean any and all rights under any of the following, whether existing now or in the future, and whether or not filed: (i) a United States, international or foreign
patent, utility model, design registration, certificate of invention, patent of addition or substitution, or other governmental grant for the protection of inventions or industrial designs anywhere in the world, including any reissue, renewal,
re-examination or extension thereof; and (ii) any application for any of the foregoing, including any international, provisional, divisional, continuation, continuation-in-part, or continued prosecution application. 

 

	1.43	“Person” shall mean any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or any agency
or political subdivision thereof. 

  

	1.44	“Phase I Clinical Data” shall mean data, information, or regulatory filings related to Phase I Clinical Trial in a country that would satisfy the requirements of 21 CFR 312.21(a), as may be
amended, or the foreign equivalent thereof. 

  

	1.45	“Phase I Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(a), as may be amended, or the foreign equivalent thereof.

  

	1.46	“Phase II Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(b), as may be amended, or the foreign equivalent thereof.

  

	1.47	“Phase III Clinical Trial” shall mean a human clinical trial in any country that would satisfy the requirements of 21 CFR 312.21(c), as may be amended, or the foreign equivalent thereof.

  

	1.48	“Regulatory Authority” shall mean any applicable government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of an aHer2-ADC API or aHer2-ADC Product in the Territory or outside Territory, including, in the Territory, CFDA, and in the United States, the United States Food and
Drug Administration and any successor governmental authority having substantially the same function 

  

	1.49	 “Royalty Term” shall mean the period commencing with the First Commercial

  
 9 

	 	
Sale of the Licensed Product and continue until the expiration of the later of: (i) the last-to-expire Valid Patent Claim that would be infringed by the manufacture, use or sale of Licensed
Product in the Territory; or (ii) the period of twenty (20) years following the First Commercial Sale of such Licensed Product in Territory. 

  

	1.50	“Territory” shall mean all cities, zones, provinces, territories and other divisions or regions in and throughout the People’s Republic of China. 

 

	1.51	“Third Party” shall mean a person or entity other than Ambrx, ZMC or their Affiliates. 

  

	1.52	“Valid Claim” means: (a) a claim of an issued and unexpired patent within the Patent Rights that has not been (i) held permanently revoked, unenforceable, unpatentable or invalid by a
decision of a court or governmental body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, (ii) rendered unenforceable through disclaimer or otherwise, (iii) abandoned or (iv) permanently lost
through an interference or opposition proceeding without any right of appeal or review; or (b) a pending claim of a pending patent application within the Patent Rights that (i) has been asserted and continues to be prosecuted in good faith
and (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling. 

  

	1.53	“ZMC Improvements” shall mean all Patent Rights and Know-How first (i) conceived, (ii) developed, (iii) reduced to practice or (iv) shown to have utility by one or more
employees or Third Parties working on behalf of ZMC, in connection with the development of Licensed Products or in the course of engaging in aHer2-ADC Program without any involvement with employee(s) of
AMBRX. 

  

	1.54	“ZMC Manufacturing Facility” shall mean a manufacturing facility to be built or acquired and operated by ZMC or on behalf of ZCM, which 1) meets the regulatory requirement under CFDA for
Marketing Authorization of the Licensed Product in the Territory, and 2) meets the cGMP requirements under United State FDA to manufacture aHer2-ADC API or
aHer2-ADC Product and passes the inspection from FDA. 

 ARTICLE 2 

LICENSE; DEVELOPMENT AND COMMERCIALIZATION 
  

	2.1	EXCLUSIVE LICENSE GRANT BY AMBRX. 

  

	 	2.1.1	Subject to the rights retained by AMBRX in Sections 2.1.3 & 2.1.4, AMBRX hereby grants to ZMC an exclusive right and license in the Field throughout the Territory, with the right to grant sublicenses
subject to Section 2.7.1, under AMBRX Existing Patents to develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products. 

 

	 	2.1.2	 Subject to the rights retained by AMBRX in Sections 2.1.3 & 2.1.4,

  
 10 

	 	
AMBRX hereby grants to ZMC an exclusive right and license in the Field throughout the Territory, with the right to grant sublicenses subject to Section 2.7.1, under AMBRX Know-How to
develop, have developed, use, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products. 

  

	 	2.1.3	AMBRX shall retain non-exclusive and sublicensable rights under the foregoing Licenses in Section 2.1.1 and 2.1.2 solely as are necessary to perform documented research activities in the Territory and AMBRX
shall notify ZMC of such activities. 

  

	 	2.1.4	AMBRX shall retain all rights under Licensed Intellectual Property Rights unless otherwise specifically and expressly set forth in this Agreement. 

 

	2.2	NON-EXCLUSIVE LICENSE GRANT BY AMBRX. AMBRX hereby grants to ZMC a non-exclusive right and license in the Field in a mutually approved jurisdiction outside the Territory, under Licensed Intellectual Property
Rights, for the sole purpose of conducting regulatory activities for Phase I Clinical Data in said jurisdiction for the Licensed Products; provided that Australia is deemed as a mutually approved jurisdiction as of the Effective Date of this
Agreement for the purpose of this section and the Joint Steering Committee may amend such jurisdiction from time to time. 

  

	2.3	NON-EXCLUSIVE SUBLICENSE GRANT BY AMBRX. In the event that, during the term of this Agreement and after the Effective Date, AMBRX licenses from any Third Party rights in the Field to any Valid Claim of any issued
patent or patent application issued to a Third Party that shall be necessary for ZMC’s exercise of its rights pursuant to Section 2.1 herein (a “AMBRX Third Party License”) in the Territory, AMBRX shall promptly so notify ZMC of
the terms of such AMBRX Third Party License and the rights covered by such license. Upon request by ZMC, and to the extent not prohibited by such AMBRX Third Party License, AMBRX shall grant to ZMC, and does hereby grant to ZMC, a non-exclusive
right and sublicense in the Field throughout the Territory, with the right to grant further sublicenses subject to Section 2.7.1, under the rights granted to AMBRX in the AMBRX Third Party License. AMBRX shall use reasonable efforts to secure
the right to grant the sublicense under this Section in any AMBRX Third Party License. If ZMC is required to pay certain royalty payment to such a Third Party under AMBRX Third Party License, ZMC is entitled to offset such royalty payment pursuant
to the terms in Section 6.6. 

  

	2.4	 NO ASSERTION BY AMBRX. So long as ZMC is in compliance with the terms and conditions of this Agreement, AMBRX shall not assert against any
claims for infringement of any AMBRX Background Technology owned or Controlled by AMBRX covering ZMC’s permitted exercise of its rights hereunder solely for the purpose of developing, making, having made, using, selling, offering for sale,
having sold any Licensed Product in the Territory or solely for the purpose of engaging permitted regulatory activities for Phase I Clinical Data in Australia or a 

  
 11 

	 	
mutually approved jurisdiction outside the Territory pursuant to Section 2.2. 

  

	2.5	NON-EXCLUSIVE LICENSE GRANT BY AMBRX. AMBRX hereby grants to ZMC a non-exclusive, sub-licensable, royalty-free right and license in the Territory, under AMBRX’s interest in the AMBRX Improvements, to use,
develop and exploit AMBRX Improvements only for Licensed Products. 

  

	2.6	EXCLUSIVE LICENSE GRANT BY ZMC. As the consideration to the rights granted by AMBRX under Section 2.3, ZMC hereby grants to AMBRX an exclusive (even as to ZMC), sub-licensable, royalty-free right and license
in the world outside the Territory, under ZMC’s interest in the ZMC Improvements and Joint Improvements, to use, develop and exploit ZMC Improvements and Joint Improvements. 

 

	2.7	NON-EXCLUSIVE LICENSE GRANT BY ZMC. As the consideration to the rights granted by AMBRX under Section 2.5, ZMC hereby grants to AMBRX a non-exclusive, sub-licensable, royalty-free right and license in the
Territory, under ZMC’s interest in the ZMC Improvements, to use, develop and exploit ZMC Improvements. 

  

	2.8	TRANSFER OR EXCLUSIVE LICENSE GRANT BY ZMC REGARDING PHASE I CLINICAL DATA. To the extent permissible by Applicable Law, ZMC shall transfer and assign to AMBRX ownership of all preclinical, clinical, regulatory
filings, and Phase I Clinical Data in Australia or a mutually approved jurisdiction outside the Territory, provided however, if such transfer and assignment is not legally permitted, ZMC hereby grants to AMBRX an exclusive (even as to ZMC),
sub-licensable, transferable, perpetual, irrevocable, non-terminable, royalty-bearing right and license in the world outside the Territory, under ZMC’s interest in information including regulatory filings and Phase I Clinical Data, to use,
develop and exploit such information by AMBRX, its Affiliate or a Third Party authorized by AMBRX. ZMC shall make reasonable effort to perfect such transfer, assignment or exclusive license under this section. 

 

	2.9	SUBLICENSES. 

  

	 	2.9.1	 Any sublicense by ZMC of the rights granted to ZMC under Sections 2.1 and 2.2 shall obtain written approval from the Joint Steering Committee
first, and then AMBRX prior written consent not unreasonably withhold or delayed, be consistent with the terms of this Agreement, include an obligation for the sublicensee to comply with the applicable obligations of the sublicensing Party set forth
in this Agreement. ZMC shall not grant any sublicense hereunder that would impose obligations on AMBRX greater than those obligations of AMBRX contained in this Agreement. ZMC shall provide to AMBRX a copy of each sublicense hereunder, which shall
permit verification by AMBRX of compliance with the provisions of this Agreement. Parties expressly agree that AMBRX 1) shall reasonably withhold the written consent if ZMC sublicenses its

  
 12 

	 	
substantially entire rights and interests granted herein to a Third Party unless Parties negotiate in good faith to reach an agreement prior to such sublicense, and 2) shall not unreasonably
withhold such consent if ZMC enters such sublicense for the purpose of distributing or supplying Licensed Products in the Territory or otherwise expressed approved herein or by the Joint Steering Committee. 

 

	 	2.9.2	With respect to any sublicense by one Party of the rights granted to said Party under Sections 2.5, 2.6 and 2.7, said Party shall not grant any sublicense hereunder that would impose obligations on the other
Party greater than those obligations of the other Party contained in this Agreement. 

  

	 	2.9.3	Both Parties expressly acknowledges and agrees that WUXI AppTec Co. Ltd shall be deemed as an approved sublicensee under Section 2.8.1 solely for the purpose of conducting preclinical and clinical trials and
manufacturing the Licensed Product in Territory prior to the completion and operation of ZMC’s Manufacturing Facility. Parties expressly acknowledges that ZMC shall enter a service agreement with WUXI AppTec within one month from the Effective
Date (“ZMC–WUXI Service Agreement as shown in Exhibit 3) for the purpose of developing, conducting preclinical and clinical trials and manufacturing the Licensed Product in Territory. 

 

	2.10	NO OTHER GRANT OF RIGHTS. Except as expressly provided herein, nothing in this Agreement will be construed to confer any ownership interest, license or other rights upon Licensee by implication, estoppel or otherwise as
to any technology, intellectual property rights, products or biological materials of AMBRX, or any other entity, regardless of whether such technology, intellectual property rights, products or biological materials are dominant, subordinate or
otherwise related to any AMBRX Background Technology or Licensed Intellectual Property Rights. 

 ARTICLE 3 

JOINT STEERING COMMITTEE 
  

	3.1	 MEMBERS. The Parties shall establish a Joint Steering Committee (the “Joint Steering Committee”), which shall comprise six
(6) members, three (3) designated by ZMC and three (3) by AMBRX (or such other number as the Parties may agree in writing). The initial members of the Joint Steering Committee are set forth on Exhibit 5. Any member of the Joint
Steering Committee may be represented at any meeting by a designee who is appointed by the Party designating such member for such meeting and who has authority to act on behalf of such member, as evidenced by written notice from the Party
designating such member to the chairperson of the Joint Steering Committee. The chairperson of the Joint Steering Committee shall be one of the members designated by Ambrx during the first three-year period following the Effective Date and one of
the members 

  
 13 

	 	
designated by ZMC thereafter. The initial chairperson is designated on Exhibit 5. Each Party shall be free to replace its representative members with new appointees who have authority to act on
behalf of such Party on the Joint Steering Committee, on written notice to the other Party. 

  

	3.2	RESPONSIBILITIES. The Joint Steering Committee shall be responsible for (a) approving and providing implementation plans to ZMC that are suitable for WUXI AppTec to perform the work plans defined in the
ZMC-WUXI Service Agreement or sub-agreement thereof and (b) planning, overseeing and directing evaluation and review of aHer2-ADC Candidates, selection of
aHer2-ADC API or aHer2-ADC Product from aHer2-ADC Candidates based on the performance of aHer2-ADC Program, the development and commercialization of, and regulatory filings relating to, Licensed Products (including aHer2-ADC API or aHer2-ADC Product) in Territory or Phrase I Clinical Trials of Licensed Products outside the Territory, including, without limitation, overseeing all research, development, pre-clinical, and clinical trial
activities, coordination of activities in building a manufacture facility in compliance with cGMP requirements and overseeing early stage manufacture, preclinical, and clinical development activities to be conducted by a Third Party regarding the
Licensed Products pursuant to Section 2.8. 

  

	3.3	MEETINGS. The Joint Steering Committee shall meet as frequently as the Parties deem appropriate during the first three-year period following the Effective Date but no less frequently than once a Calendar Quarter
(or more frequently, as agreed upon by the Parties) thereafter, on such dates and at such times as the Parties shall agree, on ten (10) days’ written notice to the other Party unless such notice is waived by the other Party. The Joint
Steering Committee may convene or be polled or consulted from time to time by means of telecommunications, video conferences or correspondence, as deemed necessary or appropriate by the Parties. To the extent that meetings are held in person, they
shall alternate between the offices of the Parties unless the Parties otherwise agree. The chairperson shall be responsible for sending notices of meetings to all members. 

 

	3.4	DECISIONS. 

  

	 	3.4.1	A quorum for a meeting of the Joint Steering Committee shall require the presence of at least two AMBRX members (or designees) and at least two ZMC members (or designees) in person or by telephone. All decisions
made or actions taken by the Joint Steering Committee shall be made unanimously by its members, with the AMBRX members present at a meeting cumulatively having one vote and the ZMC members present at a meeting cumulatively having one vote.

  

	 	3.4.2	 In the event that unanimity cannot be reached by the Joint Steering Committee with respect to a matter that is a subject of its decision-making
authority within thirty (30) days after the matter is first brought before the Joint Steering Committee, then the matter shall be decided unanimously 

  
 14 

	 	
by the Chairman of ZMC and the CEO of AMBRX or by their designated representative. If no such decision is made then the chairperson of the Joint Steering Committee shall make a final decision in
good faith, provided however, in the event such decision is relevant to activities outside Territory or cGMP compliance, such decision shall be made by a member designated by AMBRX. 

 

	3.5	MINUTES. Within fifteen (15) days after each Joint Steering Committee meeting, the chairperson of the Joint Steering Committee shall prepare and distribute minutes of the meeting, which shall provide a
description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or determinations approved by the Joint Steering Committee at such meeting. The chairperson of the Joint Steering Committee shall be
responsible for circulation of all draft and final minutes. Draft minutes shall be circulated to all members of the Joint Steering Committee sufficiently in advance of the next meeting to allow review and comment prior to the meeting. Minutes shall
be approved or disapproved, and revised as necessary, at the next meeting. Final minutes shall be distributed to the members of the Joint Steering Committee. 

  

	3.6	TERM. The Joint Steering Committee shall exist until the expiration of the Royalty Term for all Licensed Products. 

ARTICLE 4 
 DEVELOPMENT
AND COMMERCIALIZATION 
  

	4.1	DEVELOPMENT EFFORT BY ZMC. ZMC shall, either itself or through its Affiliates or Third Parties mutually approved by the Join Steering Committee, at ZMC’s sole expense, use Commercially Reasonable Efforts to conduct
the development and commercialization of Licensed Products within the Territory. ZMC shall exercise in the performance of such development commercially reasonable effort, technical skill and competence. Such diligent efforts shall include, without
limitation, the funding and expenditure by ZMC to perform the work plans as defined in the ZMC-WUXI Service Agreement (“WORK PLAN” as shown in Exhibit 4, which is incorporated herein in its entirety as a part of the this Agreement and the aHer2-ADC Program and can be revised by the Joint Steering Committee from time to time) and the development and commercialization of Licensed Products. In addition, without limiting the foregoing, ZMC shall use
Commercially Reasonable Efforts to achieve the following objectives (“ZMC MILESTONES”): 

  

	 	4.1.1	 ZMC either on its own, on behalf or through WUXI AppTec pursuant to Section 2.8) or any other Third Party approved by the Joint Steering
Committee from time to time, shall use Commercially Reasonable Efforts to engage in the performance of the WORK PLAN and/or the aHer2-ADC

  
 15 

	 	
Program, under the guidance and supervision of the Joint Steering Committee, to evaluate aHer2-ADC Candidate(s) provided by AMBRX and select aHer2-ADC API or aHer2-ADC Product therefrom for development and commercialization. 

 

	 	4.1.2	ZMC either on its own, on behalf or through WUXI AppTec (pursuant to Section 2.8) or any other Third Party approved by the Joint Steering Committee from time to time, shall use Commercially Reasonable
Efforts to pursue preclinical and initiate clinical trial evaluations for Licensed Products (including aHer2-ADC API or aHer2-ADC Product) under CFDA or the
equivalent regulatory agency required for Marketing Authorization and thereafter commercialize the Licensed Product in Territory; provided however, should ZMC decide to build or acquire a ZMC Manufacturing Facility in Territory suitable to
manufacture Licensed Product, such ZMC Manufacturing Facility shall be to a world class standard meeting cGMP requirements with the capacity to supply aHer2-ADC API on a world-wide scale, provided further
that cGMP standard is determined by a Third Party mutually approved and selected by both Parties, and thereafter, ZMC shall use Commercially Reasonable Efforts to transfer any information and materials related to the performance of the WORK PLAN
and/or the aHer2-ADC Program and/or manufacturing of Licensed Products from WUXI AppTech or a Third Party herein to such ZMC Manufacturing Facility. 

 

	 	4.1.3	ZMC either on its own, on behalf or through any Third Parties mutually approved by the Joint Steering Committee, shall use Commercially Reasonable Efforts to pursue preclinical and Phase I Clinical Trial for
Licensed Products under a Regulatory Authority in Australia as mutually agreed upon by Parties or a mutually approved country outside Territory from time to time by the Join Steering Committee; thereafter, ZMC shall promptly provide to the Joint
Steering Committee and AMBRX copies of all correspondence related the Licensed Product delivered to or received from the Regulatory Authority and diligently assist AMBRX to further transfer Phase I Clinical Data to AMBRX or transferees to whom AMBRX
transfers in countries outside Territory; provided that regulatory filings outside the Territory shall be owned by AMBRX, to the extent permitted by Applicable Law or otherwise exclusively licensed to AMBRX pursuant to Section 2.8 of this
Agreement. Upon obtaining Phase I Clinical Data, ZMC has the first right, but not obligation, to negotiate with AMBRX on terms and financial obligations for ZMC to engage in Phase II Clinical Trials or Phase III Clinical Trials outside Territory.

 provided, however, that, upon request by ZMC, ZMC shall present to the Joint Steering Committee and AMBRX, revisions to the
milestones described in clauses 4.1.1 through 4.1.3 above, or in the designated time periods, with supporting evidence of technical difficulties or delays in financing, clinical 

  
 16 

 
studies, or regulatory processes that AMBRX shall deem appropriate at its sole discretion. 

ARTICLE 5 
 SUPPORT AND
ASSISTANCE 
  

	5.1	EFFORTS BY AMBRX . AMBRX shall, either itself or through its Affiliates, use commercially reasonable efforts to provide technical and consulting assistance or other services as requested by ZMC, at ZMC’s expense,
which are necessary for ZMC to exercise its rights under this Agreement to achieve ZMC Milestones under Sections 4.1.1 to 4.1.3. In addition, without limiting the foregoing, AMBRX shall use commercially reasonable efforts to undertake the following
responsibilities (“AMBRX RESPONSIBILITIES”): 

  

	 	5.1.1	AMBRX shall assist ZMC to secure arrangement(s) with Third Party contract research organization(s) and/or consultant(s) under Section 4.1, approved by the Joint Steering Committee, to conduct development,
preclinical and clinical development activities for the Licensed Products in the Territory and produce the Licensed Products on behalf of ZMC before the transferring of clinical and/or manufacturing programs and protocols from said Third Party under
Section 4.1 to ZMC Manufacturing Facility. 

  

	 	5.1.2	AMBRX shall assist ZMC to select a Third Party under Section 4.1.3, approved by the Joint Steering Committee, to conduct preclinical and Phase I Clinical Trials and evaluation of Phase I Clinical Data for
Licensed Product outside the Territory. 

  

	 	5.1.3	Should ZMC decide to build or acquire a ZMC Manufacturing Facility in Territory under Section 4.1.2, AMBRX shall assist ZMC, during the construction of or acquiring ZMC Manufacturing Facility, to communicate
with United States FDA and recommend Third Party consultant(s) having experience in FDA inspections on cGMP requirements (or having worked at FDA) at the expenses of ZMC, as necessary for ZMC to prepare for FDA inspection of ZMC Manufacturing
Facility and achieve ZMC Milestones under Section 4.1. 

  

	5.2	TECHNICAL ASSISTANCE: Parties agree that AMBRX will dispatch two FTEs during the first three years period following the Effective Date, provided however, the Joint Steering Committee may request from time to time and
ZMC may at its sole discretion approve additional FTEs from AMBRX to provide technical and consulting assistance or other services to ZMC, as necessary for ZMC to achieve ZMC Milestones under Section 4.1. 

ARTICLE 6 
 MONETARY
OBLIGATIONS, REPORTS AND AUDITS 
  

	6.1	PAYABLE BY ZMC. Subject to the terms and conditions of this Agreement, ZMC shall pay AMBRX royalties as set forth in Section 6.2. 

  
 17 

	6.2	PATENT ROYALTIES. ZMC shall pay Ambrx royalties in an amount equal to the following percentage of Net Sales of Licensed Products sold by ZMC or its Affiliates: 

 

	 	6.2.1	[***] of such Net Sales in the Territory in each Calendar Year up to and including Net Sales of [***]; 

  

	 	6.2.2	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding of [***] up to and including of [***]; and 

 

	 	6.2.3	[***] of such Net Sales in the Territory in each Calendar Year for the portion of such Net Sales exceeding [***]. 

  

	6.3	KNOW-HOW ROYALTY. Notwithstanding the provisions of Section 6.2 above, in the event that and after the manufacture, use or sale of Licensed Products by ZMC or its Affiliates would not infringe a Valid
Patent Claim, or Existing Patents covering the Licensed Products are deemed invalid or have expired, the Net Sales of such Licensed Products in the Territory shall remain the same during the Royalty Term in determining the applicable royalty rate
according to Section 6.2, provided however, the Net Sales of such Licensed Products shall be [***] if Generic Competition exists. 

 

	6.4	ROYALTY TERM. Royalties on Licensed Product at the rates set forth above shall be paid during the Royalty Term, which shall commence with the First Commercial Sale of the Licensed Product and continue until the
expiration of the later of: (i) the last-to-expire Valid Patent Claim of AMBRX Existing Patent Rights that would be infringed by the manufacture, use or sale of Licensed Product in the Territory; or (ii) the period of twenty
(20) years following the First Commercial Sale of such Licensed Product in Territory. 

  

	6.5	PAYABLE BY AMBRX. AMBRX shall pay ZMC royalties in an amount equal to the following percentage of Net Sales of Phase I Clinical Data transferred or licensed by AMBRX to a Third Party: 

 

	 	6.5.1	[***] of such Net Sales if AMBRX or its Affiliate(s) transfers or licenses Phase I Clinical Data without making additional efforts as defined in Sections 6.5.2 to 6.5.4; 

 

	 	6.5.2	[***] of such Net Sales if AMBRX or its Affiliate(s) transfers or licenses Phase I Clinical Data after AMRBX initiates Phase II Clinical Trial outside Territory; 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

18 

	 	6.5.3	[***] of such Net Sales if AMBRX or its Affiliate(s) transfers or licenses Phase I Clinical Data after AMRBX initiates Phase III Clinical Trial outside Territory; and 

 

	 	6.5.4	[***] of such Net Sales if AMBRX or its Affiliate(s) commercializes and sales a Licensed Product outside Territory, the Market Authorization of such Licensed Product is based on Phase I Clinical Data.

  

	6.6	THIRD PARTY ROYALTY SET-OFF. If ZMC under AMBRX Third Party License is required to pay royalty as necessary for ZMC’s exercise of its rights hereunder in Territory pursuant to Section 2.3 or obtain a
license from a Third Party due to infringement action under Section 7.4, it may offset any royalty payments actually paid by ZMC to such Third Party due thereunder with respect to sales of Licensed Products against the royalty payments that are
due to AMBRX; provided that in no event shall the royalty payments to AMBRX with respect to such Licensed Products be reduced by more than [***] of the amount otherwise due. 

 

	6.7	FUNDING FOR DEVELOPMENT. ZMC shall be responsible and pay the full amounts related to the development efforts made by ZMC as described under Section 4.1, ZMC Milestone as described under Sections, and assistance
provided by AMBRX as described under Section 5.1. 

  

	6.8	THIRD PARTY PAYMENTS. ZMC shall be responsible for and at its sole expense shall pay all amounts owing to WUXI APPTEC and any Third Party under Sections 4.1.1 to 4.1.3 and 5.1.1 to 5.1.3 as necessary for ZMC to achieve
ZMC Milestones. The invoice from WUXI APPTEC OR OTHER Third Party approved within the WORK PLAN or incurred by AMBRX for a given Calendar Quarter will be sent to ZMC within forty-five (45) days following the end of such Calendar Quarter. Such
invoice reimbursable by ZMC shall be payable within thirty (30) days after ZMC receives such invoice. 

  

	6.9	FTE PAYMENTS TO AMBRX. In consideration of technical assistance provided by AMBRX pursuant to Sections 5.2 and 5.3, ZMC shall fund a minimal of two AMBRX FTEs during the first three years period following the
Effective Date at the FTE Rate of [***] per FTE per Calendar Year. ZMC shall pay AMBRX in an amount of [***] for the two AMBRX FTEs at the beginning of each Calendar Quarter during the three years period following the Effective Date and any
additional amount quarterly if more FTEs from AMBRX are requested and approved pursuant to Section 5.2. 

  

	6.10	REPORTS. During the Term following the First Commercial Sale of Licensed Product, ZMC shall furnish to Ambrx a quarterly written report for the Calendar 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

19 

	 	
Quarter showing the gross and Net Sales of all Licensed Products subject to royalty payments sold by ZMC and its Affiliates in the Territory during the reporting period and the royalties payable
under this Agreement. Reports shall be due on the forty-fifth (45th) day following the close of each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. ZMC
and its Affiliates shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined. 

  

	6.11	Audits 

  

	 	6.11.1	ACCOUNTING FIRM. Upon the written request of Ambrx and not more than once in each Calendar Year, ZMC shall permit a qualified and reputable independent certified public accounting firm selected by AMBRX and
approved by ZMC not unreasonably withhold, at AMBRX’s expense, to have access during normal business hours to such of the records of ZMC related to the production and sales of Licensed Products as may be reasonably necessary to verify the
accuracy of the royalty reports pursuant to Section 6.10 for any Calendar Year ending not more than thirty six (36) months prior to the date of such request. The accounting firm shall disclose to AMBRX and ZMC whether the royalty reports
are correct or incorrect and the amount of any discrepancy. 

  

	 	6.11.2	ACCESS. In order to fulfill the auditing, the accounting firm so selected shall have the right to access, examine, review and copy all books or accounts of ZMC, relevant procurement/distribution agreements and
other purchase/sales contracts, purchase/sales orders, operation records, tax paid to local government, and itemized tax for the Licensed Products, and to discuss the business, operations and conditions of ZMC with its respective directors,
officers, employees, accounts, auditors, financial advisors, legal counsel and investment bankers, to the extent reasonably deemed by AMBRX as necessary for determining the accuracy of the royalty reports. ZMC shall not unreasonably restrict the
accounting firm’s access to premises of ZMC during normal business hours. 

  

	 	6.11.3	PAYMENT AND FEES. If such accounting firm identifies a discrepancy made during such period, the appropriate Party shall pay the other Party the amount of the discrepancy within thirty (30) days of the date
AMBRX delivers to ZMC such accounting firm’s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by AMBRX, provided however, that if such audit uncovers an
underpayment of royalties by ZMC that exceeds [***] of the total royalties owed for the period in question, the fees of such 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

20 

	 	
accounting firm shall be equally shared by AMBRX and ZMC. 

  

	 	6.11.4	SUBLICENSEE. ZMC shall include in each sublicensee granted by it pursuant to this Agreement a provision requiring the sublicensee to make reports to ZMC, to keep and maintain records of sales made pursuant to
such sublicense and to grant access to such records by AMBRX’s independent accountant to the same extent required of ZMC under this Agreement. 

  

	 	6.11.5	CONFIDENTIALITY. AMBRX shall treat all financial information subject to review under this Section 6.11 or under any sublicense agreement in accordance with the terms of Article 8 of this Agreement, and shall
cause its accounting firm to enter into an acceptable confidentiality agreement with AMBRX, or with ZMC and/or its Affiliates or sublicensee, obligating it to retain all such information in confidence pursuant to such confidentiality agreement.

  

	6.12	PAYMENT EXCHANGE RATE. All royalty payments due hereunder shall be paid in United States dollars by wire transfer to a bank account designated by AMBRX. Any payments or portions thereof due hereunder which are
not paid on the date such payments are due under this Agreement shall bear interest at a rate equal to the lesser of prime rate as reported by Citibank, New York, New York (or its successor in interest) or the maximum rate permitted by law,
calculated on the number of days such payment is delinquent. If the royalty payments are paid in United States Dollar, the Parties shall apply the middle exchange rate between RenMinBi and United States Dollar announced by the People’s Bank of
China on the date of occurrence of payment of the royalty during the calendar quarter giving rise to the payment of royalty in United States Dollar. 

  

	6.13	TAX WITHHOLDING. AMBRX shall be liable for all income and/or other taxes (including interest) imposed upon any royalty payments made by ZMC to AMBRX under this Agreement (“Taxes”). In the event
Applicable Laws require withholding of Taxes, ZMC shall notify Ambrx in writing number of tax payable in advance, before it makes such withholding payments and subtracts the amount thereof from the payments. ZMC shall submit appropriate proof of
payment of the withheld Taxes to Ambrx and shall provide Ambrx with the official receipts within a reasonable period of time. Notwithstanding the foregoing, to the extent permitted by Applicable Laws and upon request of Ambrx, ZMC shall Commercially
Reasonable Efforts to apply for approvals from competent PRC tax authorities, on behalf of Ambrx, for reduction or exemption of applicable PRC taxes over the payments made by ZMC to AMBRX, before it makes the withholding payments and subtracts the
amount thereof from the payments due to Ambrx. 

  

	6.14	 PAYMENT PROCEDURES. ZMC shall be responsible for obtaining any and all governmental approval/registration procedures (if legally required) and
foreign exchange related procedures/formalities in connection with repatriation of any 

  
 21 

	 	
payments made by ZMC to AMBRX under the Agreement to the bank accounts designated by AMBRX outside China, and AMBRX will provide reasonable assistance if necessary. 

ARTICLE 7 
 INTELLECTUAL
PROPERTY 
  

	7.1	OWNERSHIP. ZMC is the sole owner of ZMC Improvement. AMBRX is the sole owner of AMBRX Improvement. Joint Development Technology is co-owned by ZMC and AMBRX. Other than provided herein, each Party is responsible
for filing and prosecuting of patents stemming from its own improvements. 

  

	7.2	FILING, PROSECUTION AND MAINTENANCE OF PATENTS FOR JOINT DEVELOPMENT TECHNOLOGY 

  

	 	7.2.1	JOINT DEVELOPMENT TECHNOLOGY. AMBRX shall have the first right to file patent applications for Joint Development Technology (in the name of both ZMC and AMBRX) and thereafter prosecute and maintain Patent Rights for
such Joint Development Technology. In the event that AMBRX files such patent applications and thereafter prosecutes and maintains Patent Rights for such Joint Development Technology, ZMC shall execute such documents and perform such ministerial
acts, at ZMC’ expense, as may be reasonably necessary for AMBRX to continue such prosecution or maintenance of Patent Rights claiming such Joint Development Technology. AMBRX shall, in its sole discretion, have a right to choose external
counsel to assist in the procurement and maintenance of such Joint Development Technology; provided that AMBRX’ choice of counsel will not present a conflict of interest for ZMC. With respect to a given Joint Development Technology, AMBRX may
elect not to file or may elect not to file in a particular country and if so, AMBRX shall notify ZMC and ZMC shall have the right to file such patent applications for such Joint Development Technology (in the name of both ZMC and AMBRX) and
thereafter prosecute and maintain Patent Rights for such Joint Development Technology. In the event that ZMC files such patent applications and thereafter prosecutes and maintains Patent Rights for such Joint Development Technology, AMBRX shall
execute such documents and perform such ministerial acts, at AMBRX’s expense, as may be reasonably necessary for ZMC to continue such prosecution or maintenance of Patent Rights claiming such Joint Development Technology. ZMC shall, in its sole
discretion, have a right to choose external counsel to assist in the procurement and maintenance of such Joint Development Technology; provided that ZMC’s choice of counsel will not present a conflict of interest for AMBRX. 

  
 22 

	 	7.2.2	ZMC IMPROVEMENTS. ZMC shall have the first right, at its sole cost and expense, to file patent applications for ZMC Improvement and thereafter prosecute and maintain Patent Rights for such ZMC Improvements. With
respect to a given ZMC Improvement, ZMC may elect not to file or may elect not to file in a particular country outside the Territory and if so, ZMC shall notify AMBRX and AMBRX shall have the right but not the obligation to file such patent
applications for such ZMC Improvement and thereafter prosecute and maintain Patent Rights for such ZMC Improvement. In such event, ZMC shall execute such documents and perform such ministerial acts, at AMBRX’ expense, as may be reasonably
necessary for AMBRX to continue such prosecution or maintenance of Patent Rights claiming such ZMC Improvements outside the Territory. 

  

	 	7.2.3	REVIEW AND CONSULTATION. In each case in connection with the foregoing with respect to Joint Development Technology and ZMC Improvement, as applicable, the filing Party (a) shall keep the non-filing Party
advised of the status of the actual and prospective patent filings; (b) upon the non-filing Party’s written request, shall provide advance copies of any papers related to the filing, prosecution and maintenance of such patent filings;
(c) shall give the non-filing Party an opportunity to review the text of the application before filing and shall consult with the non-filing Party with respect thereto; (d) shall give the non-filing Party an opportunity to review and
comment on any documents relating to such patent filings that will be filed in any patent office at least twenty (20) days before such filing and give due consideration to such substantive, non-cumulative comments; (e) shall supply the
non-filing Party with a copy of the application as-filed, together with notice of its filing date and serial number; and (f) shall promptly give notice to the non-filing Party of the grant, lapse, revocation, surrender, invalidation or
abandonment of any Patent Rights claiming Joint Development Technology and ZMC Improvement, as applicable) for which it is responsible for the filing, prosecution or maintenance hereunder (provided that the filing Party shall give at least thirty
(30) days prior written notice to the non-filing Party of any desire to cease prosecution and/or maintenance of such Patent Rights). 

  

	 	7.2.4	 COSTS. The Parties shall equally split the costs of filing patent applications and procuring and maintaining Patent Rights in the United
States, Japan, China, Brazil, and with the European Patent Office (including but not limited to all National Phase filing costs and fees) for such Joint Development Technology; AMBRX shall be responsible for the costs of filing patent applications
and procuring and maintaining Patent Rights for such Joint Development Technology in all other jurisdictions outside the Territory, provided however, if, pursuant to Section 7.2.1, AMBRX elects not to file in a particular country in such other
jurisdictions and ZMC elects to file in such particular country for such Joint Development Technology, then ZMC shall pay 100% of the costs to 

  
 23 

	 	
file and maintain said Patent Rights in said elected country. Further, if, pursuant to Section 7.2.2, ZMC elects not to file in a particular country outside Territory and Ambrx elects to
file and maintain Patent Rights on such ZMC Improvements, then AMBRX shall pay 100% of the costs to file and maintain said Patent Rights in the elected country(ies). For clarity, AMBRX shall be responsible for prosecuting and maintaining AMBRX
Existing Patent Rights and AMBRX Patent Rights in and outside the Territory at its own expense. 

  

	7.3	ENFORCEMENT OF PATENT RIGHTS 

  

	 	7.3.1	NOTICE. Each Party shall promptly notify the other Party of any infringement or possible infringement by a third party of any rights licensed to ZMC under this Agreement. Further, Ambrx shall give ZMC, and ZMC
shall give Ambrx, notice of any infringement of (i) any AMBRX Existing Patent Rights in the Territory, or any misappropriation or misuse of Ambrx Know-How, that may come to AMBRX’s or ZMC’ attention. ZMC and Ambrx shall thereafter
consult and cooperate fully to determine a course of action, including but not limited to, the commencement of legal action by ZMC and/or Ambrx, to terminate any infringement of such Ambrx Existing Patent Rights or any misappropriation or misuse of
such Ambrx Know-How, as applicable. 

  

	 	7.3.2	 SUIT BY ZMC. ZMC shall have the first right, but not obligation, to initiate and prosecute such legal action at its own expense and in the name
of ZMC to terminate any infringement relating to such AMBRX Existing Patent Rights or such Ambrx Know-How in the Territory, as applicable. Should ZMC elect to bring suit against an infringer, ZMC shall keep AMBRX reasonably informed of the progress
of the action and shall give AMBRX a reasonable opportunity in advance to consult with ZMC and offer its views about major decisions affecting the litigation. ZMC shall give careful consideration to Ambrx views, but shall have the right to control
the action; provided, however, that if the validity and/or enforceability of the Existing Patent Rights is raised by the infringer in the action or, or if ZMC’s license to a Valid Claim in the suit terminates, AMBRX may elect to take control of
the action pursuant to Section 7.3.5. Should ZMC elect to bring suit against an infringer and AMBRX is joined as party plaintiff in any such suit, AMBRX shall have the right to approve the counsel selected by ZMC to represent ZMC and AMBRX,
such approval not to be unreasonably withheld. The expenses of such suit or suits that ZMC elects to bring, including any expenses of AMBRX incurred in conjunction with the prosecution of such suits or the settlement thereof, shall be paid for
entirely by ZMC and ZMC shall hold AMBRX free, clear and harmless from and against any and all costs of such litigation, including reasonable attorneys’ fees. ZMC shall not compromise or settle such litigation without the prior written consent
of AMBRX, which consent shall not be unreasonably withheld or delayed. 

  
 24 

	 	
In the event ZMC exercises its right to sue pursuant to this Section 7.3.2, it shall first reimburse itself out of any sums recovered in such suit or in settlement thereof for all costs and
expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such reimbursement, any funds shall remain from said recovery, then AMBRX shall receive an amount
equal to [***] of such funds and the remaining [***] of such funds shall be retained by ZMC. 

  

	 	7.3.3	SUIT BY AMBRX. If ZMC does not take action in the prosecution, prevention, or termination of any Infringement pursuant to Section 7.3.2 above, and has not commenced negotiations with the infringer for
the discontinuance of said infringement, within ninety (90) days after receipt of notice to ZMC by AMBRX of the existence of an Infringement, AMBRX may elect to do so. Should AMBRX elect to bring suit against an infringer and ZMC is joined as
party plaintiff in any such suit, AMBRX shall have the right to select the counsel to represent AMBRX and ZMC unless otherwise conflicted out. The expenses of such suit or suits that AMBRX elects to bring, including any expenses of ZMC incurred in
conjunction with the prosecution of such suits or the settlement thereof, shall be paid for entirely by AMBRX. In the event AMBRX exercises its right to sue pursuant to this Section 7.3.3, it shall first reimburse itself out of any sums
recovered in such suit or in settlement thereof for all costs and expenses of every kind and character, including reasonable attorneys’ fees, necessarily incurred in the prosecution of any such suit. If, after such reimbursement, any funds
shall remain from said recovery, then ZMC shall receive an amount equal to [***] of such funds and the remaining [***] of such funds shall be retained by AMBRX. Notwithstanding the foregoing,
AMBRX shall have the right to initiate and prosecute any legal action(s) relating to Licensed Intellectual Property Rights or AMBRX Background Technology outside Territory at its own expense. 

 

	 	7.3.4	COOPERATION. Each party agrees to cooperate fully in any action under this Article 7 that is controlled by the other party, provided that the controlling party reimburses the cooperating party promptly for any
costs and expenses incurred by the cooperating party in connection with providing such assistance. 

  

	 	7.3.5	DECLARATORY JUDGMENT & INVALIDITY CHALLENGE. If a declaratory judgment action is brought naming ZMC and/or any of its Affiliates as a defendant, or a claim alleging invalidity or unenforceability of any
Valid Claims within the Existing Patent Rights, ZMC shall 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

25 

	 	
promptly notify AMBRX in writing and AMBRX may elect, upon written notice to ZMC within thirty (30) days after AMBRX receives notice of the commencement of such action, to take over the
defense of the invalidity and/or unenforceability aspect of the action solely. 

  

	7.4	INFRINGEMENT ACTIONS BY THIRD PARTIES. 

  

	 	7.4.1	NOTICE. Each Party shall notify the other Party promptly in writing of any claim of, or action for, infringement of any Patents owned or licensed by Third Parties which is threatened, made or brought against
either Party by reason of either Party’s performance of its obligations under this Agreement or development, manufacture, use or sale of any Licensed Products in the Territory. 

 

	 	7.4.2	DEFENSE. In the event that such an action for infringement is commenced by a Third Party solely against a Party or both Parties jointly and/or any of their respective Affiliates, as the case may be, with respect
to a Licensed Product developed and commercialized by ZMC and/or its Affiliate, AMBRX shall defend such action at its own expense, and ZMC hereby agrees to assist and cooperate with AMBRX to the extent necessary in the defense of such suit. AMBRX
shall have the right to settle any such action or consent to an adverse judgment thereto, and ZMC’s consent shall not be required unless such settlement or consent: (i) imposes any material obligation on ZMC or limits AMBRX’s
obligations to ZMC under this Agreement or (ii) materially impairs ZMC’s rights herein. For clarity, any payment including royalty payments to such Third Party as a result of such settlement shall not require ZMC’s consent.

  

	 	7.4.3	PAYMENT OBLIGATION. During the pendency of any such action, ZMC shall continue to pay all royalties and other payments due hereunder. AMBRX shall retain any award or compensation (including the fair market value
of non-monetary compensation) received by AMBRX as a result of any such action (i.e., as a result of a counterclaim). 

ARTICLE 8 

CONFIDENTIALITY & PUBLICATIONS 
  

	8.1	 NONDISCLOSURE OBLIGATION. EXCEPTIONS. Except to the extent expressly authorized by this Agreement the Parties agree that, during the Term of
this Agreement and for ten (10) years thereafter, each Party and its Affiliates, if any (collectively, a “receiving Party”), shall use their best efforts to keep Confidential Information & Materials completely confidential,
shall not publish or otherwise disclose to any Third Party and shall not use for any purpose other than the performance of this Agreement both the financial terms of this Agreement and any information furnished to it by the other Party or its
Affiliates, if any (collectively, a “disclosing Party”) (and shall ensure that its and its Affiliates’ respective directors, officers, employees or agents do likewise), except to the

  
 26 

	 	
extent that it can be established by the receiving Party by competent proof that such information: (i) is, or hereafter becomes, generally available to the public other than by reason of any
default by the receiving Party with respect to its confidentiality obligations hereunder; (ii) was already known to the receiving Party at the time of disclosure by the disclosing Party; (iii) was lawfully disclosed to the receiving Party
by a Third Party not in default of any confidentiality obligation to the disclosing Party; or (iv) is independently developed by or for the receiving Party without reference to or reliance upon the information furnished by the disclosing Party.

  

	8.2	EXCLUSIONS TO CONFIDENTIALITY. The restrictions contained in Section 8.1 shall not apply to any Confidential Information & Materials in the hands of a receiving Party that (i) is submitted by the
receiving Party to governmental authorities to facilitate the issuance of Marketing Authorization for Licensed Products in the Territory, provided that reasonable measures shall be taken to assure confidential treatment of such information, if
practicable, or (ii) is otherwise required to be disclosed in compliance with Applicable Laws (including, without limitation, to comply with any governmental or stock exchange disclosure requirements) or an order by a court or other regulatory
body having competent jurisdiction; provided, however, that if a receiving Party is required to make any such disclosure of the disclosing Party’s Confidential Information & Materials such receiving Party shall, except where
impracticable for necessary disclosures (for example to physicians conducting studies or to health authorities), give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of
patent applications or otherwise, will use its best efforts to secure confidential treatment of such Confidential Information & Materials required to be disclosed. In addition, any press release or other public announcement permitted by the
terms of Section 8.4 hereof shall be excluded from the provisions of Section 8.1. 

  

	8.3	 PUBLICATION. ZMC and AMBRX each acknowledge the other Party’s interest in publishing the results of its research in order to obtain
recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent protection and in protecting business interests and trade secret information.
Consequently, except for disclosures permitted pursuant to Section 8.2, either Party, its employees or consultants wishing to make a publication with respect to the development or clinical results regarding the Licensed Products hereunder shall
deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least sixty (60) days prior to submission for publication or presentation. The reviewing Party shall have the right (a) to propose
modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication or presentation in order to protect patentable information. If the reviewing Party
requests a delay, the publishing Party shall delay submission or presentation for a period of one hundred and twenty (120) days to enable patent applications protecting each Party’s rights in such information to be filed in accordance with

  
 27 

	 	
Article 7 above. Upon expiration of such one hundred and twenty (120) days, the publishing Party shall be free to proceed with the publication or presentation. If the reviewing Party
requests modifications to the publication or presentation, the publishing Party shall edit such publication to prevent disclosure of trade secret or proprietary business information prior to submission of the publication or presentation.

  

	8.4	PUBLICITY/USE OF NAMES. No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates
or their respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be required by Applicable Law or
as permitted pursuant to Section 8.2; provided that in the event disclosure is required by Applicable Law, the disclosing Party shall use good-faith efforts to give the non-disclosing Party an opportunity, with reasonable advance notice, to
review and comment on any proposed disclosure. Notwithstanding Section 8.4 herein, ZMC and AMBRX shall make reasonable effort to issue a mutually agreed joint press releases as shown in Exhibit 6 regarding the execution of this Agreement and
the cooperation between both Parties, provided further, any further press release to be issued by one Party mentioning the execution of this Agreement or naming the other Party shall be approved in advance by the other Party. 

 

	8.5	INJUNCTIVE RELIEF. The Parties acknowledge that monetary damages alone may not adequately compensate the disclosing Party in the event of a material breach by the receiving Party of this Article 8, and that, in
addition to all other remedies available to the disclosing Party under this Agreement, at law or in equity, to the extent permitted by Applicable Laws, it shall be entitled to seek injunctive relief for the enforcement of its rights under this
Section 8. 

 ARTICLE 9 

REPRESENTATIONS AND WARRANTIES 
  

	9.1	MUTUAL REPRESENTATIONS AND WARRANTIES 

 Each Party represents and warrants to the other Party
the following as of the Effective Date: 
  

	 	(a)	CORPORATE POWER. Such Party is duly organized and validly existing under the laws of the country/state of its organization, and has full legal and corporate power and authority to enter into this Agreement and to
perform its obligations hereunder. 

  

	 	(b)	 DUE AUTHORIZATION AND EXECUTION. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have
been duly authorized by the necessary 

  
 28 

	 	
corporate actions of such Party. This Agreement has been duly executed by such Party. This Agreement and any other documents contemplated hereby constitute valid and legally binding obligations
of such Party enforceable against it in accordance with their respective terms, except to the extent that enforcement of the rights and remedies created thereby is subject to bankruptcy, insolvency, reorganization, moratorium and other similar laws
of general application affecting the rights and remedies of creditors. 

  

	 	(c)	NON-CONTRAVENTION. The execution, delivery and performance by such Party of this Agreement and any other agreements and instruments contemplated hereunder will not (i) in any material respect violate any
statute, regulation, judgment, order, decree or other restriction of any governmental authority to which such Party is subject, (ii) violate any provision of the corporate charter, by-laws or other organizational documents of such Party, or
(iii) constitute a material violation or breach by such Party of any provision of any material contract, agreement or instrument to which such Party is a party or to which such Party may be subject although not a party. 

 

	9.2	REPRESENTATIONS BY AMBRX 

 AMBRX represents and warrants to ZMC the following as of the
Effective Date: 
  

	 	(a)	to AMBRX’s knowledge, the Licensed Intellectual Property Rights exist and are not invalid or unenforceable, in whole or in part; 

 

	 	(b)	it has not previously (i) assigned, transferred, conveyed or otherwise encumbered its right, title and/or interest in Licensed Intellectual Property Rights related to
aHer2-ADC in the Territory, or (ii) granted any rights to any Third Parties, in either case that would conflict with the rights granted to ZMC hereunder; 

 

	 	(c)	to AMBRX’s knowledge, it is the sole and exclusive owner or sole and exclusive licensee of Licensed Intellectual Property Rights related to aHer2-ADC in the Territory,

  

	 	(d)	to AMBRX’s knowledge, there are no claims, judgments or settlements against or owed by Ambrx and, no pending or threatened claims or litigation relating to Licensed Intellectual Property Rights in the Territory.

 9.3 REPRESENTATIONS BY ZMC. ZMC represents, warrants and covenants to AMBRX that: 

 

	 	9.3.1	 All necessary consents, approvals and authorizations of all regulatory authorities and other governmental authorities and other persons or entities
required to be obtained by ZMC in order to enter into this Agreement have been obtained or, with respect to such consents, approvals and 

  
 29 

	 	
authorizations of regulatory authorities or other governmental authorities that cannot be obtained before the Effective Date, will be obtained within sixty (60) days after the Effective
Date. 

  

	 	9.3.2	ZMC, its Affiliates, and its and their respective principals, owners, officers, directors, employees, agents, consultants, and joint venture partners, and any other party acting on behalf of ZMC (collectively as
“ZMC Representatives”), have not and shall not offer, promise, provide, or accept any item of value (broadly meaning any monetary payment, such as fees or commissions, or nonmonetary benefit, such as employment opportunities, gifts,
travel or entertainment), directly or indirectly, to or from any person in exchange for a business advantage; 

  

	 	9.3.3	All ZMC Representatives shall abide by all applicable anti-bribery and corruption laws, including the United States Foreign Corrupt Practices Act of 1977 and any other international or local laws of a similar nature or
having similar effect now existing or to be enacted in the future; 

  

	 	9.3.4	No principal, owner, officer, director, employee or agent of ZMC or its Affiliates is currently a “Government Official,” defined as: (a) an officer, agent or employee of a government; or (b) a
candidate for government or political office. 

  

	 	9.3.5	No Government Official who is closely related to a ZMC Representative has been or will be, directly or indirectly, involved in influencing, obtaining, or retaining business on behalf of ZMC or fulfilling ZMC’s
obligations to AMBRX under this Agreement; 

  

	 	9.3.6	No ZMC Representative (i) is listed on the Office of Foreign Assets Control’s (“OFAC”) “Specially Designated National and Blocked Person List” (“SDN List”) or otherwise subject to
any sanction administered by OFAC (“U.S. Economic Sanctions”); (ii) is owned, controlled by or acting on behalf of, directly or indirectly, any person, entity, or government listed on the SDN List or otherwise subject to any U.S.
Economic Sanction; (iii) has made sales to, contracted with, or otherwise engaged in any dealing or transaction with or for the benefit of any person, entity, or government listed on the SDN List or otherwise subject to any U.S. Economic
Sanction during the previous five years; or (iv) has used, directly or indirectly, any corporate funds to contribute to or finance the activities of any person, entity, or government listed on the SDN List or otherwise subject to any U.S.
Economic Sanction. 

  

	 	9.3.7	ZMC and its Affiliates (i) are in compliance in all material respects with all Applicable Laws relating to anti-money laundering, and (ii) are not and have not been part of any proceedings (nor is any such
proceeding pending or threatened) with respect to any such laws. 

  
 30 

	 	9.3.8	Both the AMBRX Existing Patent Rights and the AMBRX Know-How are permitted to be imported into China under PRC law, and none of it falls within the PRC categories for technologies that are restricted or prohibited from
being imported. 

  

	 	9.3.9	ZMC and its Affiliates will use the AMBRX Existing Patent Rights and AMBRX Know-How solely for the purpose of the development, use, manufacture or sale of the Licensed Products in Territory strictly in accordance with
the terms of this Agreement and not for any other purpose. 

  

	 	9.3.10	ZMC and its Affiliates shall invest sufficient resources and funds and use Commercially Reasonable Efforts to achieve ZMC Milestones so as to develop and commercialize Licensed Product in the Territory and obtain Phase
I Clinical Data outside the Territory. 

  
 31 

 ARTICLE 10 

INDEMNIFICATION & INSURANCE 
  

	10.1	INDEMNIFICATION BY ZMC. ZMC hereby agrees to indemnify, hold harmless and defend AMBRX, its Affiliates and their respective officers, directors, agents, employees, successors and assigns (collectively, the “AMBRX
Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to claims, allegations, suits, actions or proceedings asserted by any Third Party, whether governmental or private, arising out
of or relating to the development, manufacture, use, sale or other disposition of Licensed Products by ZMC or its Affiliates or sublicensees under this Agreement, (ii) ZMC’s failure to perform its obligations under this Agreement by ZMC,
its Affiliates or their respective officers, directors, agents or employees, (iii) the breach of any of ZMC’ covenants, representations or warranties under this Agreement, or (iv) the negligence or willful misconduct by ZMC, its
Affiliates or their respective officers, directors, agents or employees, in performing any obligations under this Agreement. 

  

	10.2	INDEMNIFICATION BY AMBRX. AMBRX hereby agrees to indemnify, hold harmless and defend ZMC, its Affiliates and their respective officers, directors, agents, employees, successors and assigns (collectively, the
“ZMC Indemnified Parties”) against any and all losses, costs, expenses, fees or damages arising out of or relating to claims, allegations, suits, actions or proceedings asserted by any Third Party, whether governmental or private,
arising out of or relating to (i) AMBRX’s failure to perform its obligations under this Agreement by AMBRX, its Affiliates or their respective officers, directors, agents or employees,, (ii) the breach of any of AMBRX’ covenants,
representations or warranties under this Agreement, or (iii) the negligence or willful misconduct by AMBRX, its Affiliates or their respective officers, directors, agents or employees, in performing any obligations under this Agreement.

  

	10.3	 PROCEDURE. If a Party is seeking indemnification under Article 10 (the “Indemnified Party”), it shall inform the other Party (the
“Indemnifying Party”) of the claim giving rise to the obligation to indemnify pursuant to Article 10 as soon as reasonably practicable after receiving notice of the claim (provided, however, any delay or failure to provide such
notice shall not constitute a waiver or release of, or otherwise limit, the Indemnified Party’s rights to indemnification under, as applicable, Article 10 except to the extent that such delay or failure materially prejudices the Indemnifying
Party’s ability to defend against the relevant claims). The Indemnifying Party shall have the right to assume the defense of any such claim for which it is obligated to indemnify the Indemnified Party. The Indemnified Party shall
cooperate with the Indemnifying Party and the Indemnifying Party’s insurer as the Indemnifying Party may reasonably request, and at the Indemnifying Party’s cost and expense. The Indemnified Party shall have the right to participate, at
its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by the Indemnifying Party. The Indemnifying Party shall not settle any claim without the prior written

  
 32 

	 	
consent of the Indemnified Party, which the Indemnifying Party may provide in its sole discretion. The Indemnified Party shall not settle or compromise any such claim without the prior written
consent of the Indemnifying Party, not to be unreasonably withheld. 

  

	10.4	INSURANCE. 

  

	 	10.4.1	AMOUNT. Beginning the First Commercial Sale of Licensed Product by ZMC or by an Affiliate, ZMC shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than
$1,000,000 per incident and $5,000,000 annual aggregate and naming AMBRX as additional insured. During clinical trials of Licensed Product, ZMC shall, at its sole cost and expense, procure and maintain commercial general liability insurance in such
equal or lesser amount as AMBRX shall require, naming AMBRX as additional insured. Such commercial general liability insurance shall provide: (a) product liability coverage and (b) broad form contractual liability coverage for ZMC’s
indemnification obligations under this Agreement. 

  

	 	10.4.2	EVIDENCE. ZMC shall provide AMBRX with written evidence of such insurance upon request of AMBRX. ZMC shall provide ZMBRX with written notice at least fifteen (15) days prior to the cancellation, non-renewal or
material change in such insurance. 

  

	 	10.4.3	MAITENENCE. ZMC shall maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during: (a) the period that any Licensed Product is being commercially distributed
or sold by ZMC or its Affiliate and (b) a reasonable period after the period referred to in (a) above which in no event shall be less than ten (10) years 

ARTICLE 11 

TERM & TERMINATION 
  

	11.1	TERM. The term of this Agreement shall commence on the Effective Date and, unless earlier terminated as provided in this Article 11, shall continue in full force and effect until the expiration of the Royalty
Term with respect to Licensed Products in Territory (the “Expiration”). 

  

	11.2	Effect of Expiration. Following the expiration of this Agreement with respect to Licensed Product in the Territory pursuant to Section 11.1, ZMC shall have the royalty-free, perpetual right to continue to
make, have made, use, sell, offer for sale, have sold and export such Licensed Product In the Territory. 

  

	11.3	TERMINATION BY ZMC. ZMC may terminate this Agreement upon six (6) months prior written notice to AMBRX. 

  
 33 

	11.4	TERMINATION FOR DEFAULT. Each Party shall have the right to terminate this Agreement, upon notice to the other Party, in the event that: 

 

	 	11.4.1	Such other Party materially defaults with respect to any of its material obligations under this Agreement or the terms in ZMC-WUXI Service Agreement and does not cure such default within sixty (60) days after the
receipt of a notice from the non-breaching Party specifying the nature of, and requiring the remedy of, such default (or, if such default cannot be cured within such sixty (60)-day period, if the breaching Party does not commence and diligently
continue actions to cure same during such sixty (60)-day period); 

  

	 	11.4.2	The other Party shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief under the bankruptcy, insolvency or other similar laws of any jurisdiction, (ii) applied for, or
consented to, the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its property, (iii) filed an answer admitting the material allegations of a
petition filed against or in respect of it in any such proceeding, (iv) made a general assignment for the benefit of creditors of all or substantially all of its assets, (v) admitted in writing its inability to pay all or substantially all
of its debts as they become due, or (vi) taken corporate action for the purpose of effecting any of the foregoing; or 

  

	 	11.4.3	An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a court of competent jurisdiction seeking: (i) relief in respect of the other Party, or of its property,
under the bankruptcy, insolvency or similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for such other Party or for all or substantially all of
its property, or (iii) the winding-up or liquidation of such other Party; and, in each case, such proceeding or petition shall have continued undismissed for sixty (60) days, or an order or decree approving or ordering any of the foregoing
shall have continued unstayed, unappealed and in effect for thirty (30) days. 

  

	11.5	EFFECT OF TERMINATION. 

  

	 	11.5.1	TERMINATION OF RIGHTS. 

  

	 	(a)	 Upon termination of this Agreement by AMRBX pursuant to Section 11.4 or by ZMC pursuant to Section 11.3, (i) the rights and licenses
granted to ZMC under Sections 2.1, 2.2, 2.3, 2.5, shall terminate, all rights therein or under will revert to AMBRX and neither ZMC nor its Affiliates may make, develop, manufacture, have manufactured, sell, offer for sale and have sold Licensed
Products in the Territory; (ii) the rights and licensed granted to AMBRX under Sections 2.6 and 2.7 will revert back to ZMC, 

  
 34 

	 	
provided however, ZMC shall not assert against AMBRX, its Affiliates or sublicensees any claims for infringement of the reverted rights in the event AMRBX and/or its Affiliate and/or sublicensees
continue to make, develop, manufacture, have manufactured, sell, offer for sale and have sold Licensed Products; and (iii) any existing agreements that contain a Sublicense shall terminate to the extent of such Sublicense; provided, however,
that, for each sublicensee, upon termination of the Sublicense agreement with such sublicensee, if the sublicensee is not then in breach of its Sublicense agreement with ZMC such that ZMC would have the right to terminate such Sublicense, such
sublicensee shall have the right to seek a license from AMBRX at AMBRX’s sole discretion. 

  

	 	(b)	Upon termination of this Agreement by ZMC pursuant to Section 11.4, (i) the rights and licenses granted to ZMC under Sections 2.1, 2.2, 2.3 and 2.5 shall terminate, all rights therein or under will revert to
AMBRX and neither ZMC nor its Affiliates may make any further develop, manufacture, have manufactured, sell, offer for sake and have sold Licensed Products in the Territory; and (ii) rights and licensed granted to AMBRX under Section 2.6
and 2.7 will revert to ZMC. 

  

	 	11.5.2	NO RELEASE. Termination of this Agreement for any reason shall not release any Party hereto from any liability which, at the time of such termination, has already accrued to the other Party or which is
attributable to a period prior to such termination, nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or in equity which accrued or are based upon any event occurring prior to such termination.

  

	 	11.5.3	RIGHTS TO SELL STOCK ON HAND. After the date of termination, ZMC and its Affiliates (a) may sell Licensed Products then in stock and may perform Licensed Services then in process (b) may complete the
production of Licensed Products then in the process of production and sell the same; provided that, in the case of both (a) and (b), Licensee shall pay the applicable royalties and payments to AMBRX in accordance with Article 6.

  

	 	11.5.4	 TRANSFER OF INFORMATION, MATERIALS AND REGULATORY FILINGS AND. Notwithstanding the foregoing, upon termination of this Agreement by either party
pursuant to Section 11.4 or by ZMC pursuant to Section 11.3, ZMC shall promptly transfer and assign to AMBRX ownership of all preclinical data, clinical data, regulatory filings and any other information and materials as necessary for
AMBRX, its Affiliate or successor to continue to develop and commercialize aHer2 ADC API or aHer2 ADC Product in Territory, Phase I Clinical Data in a
jurisdiction outside Territory to the extent permissible by Applicable Law; if such transfer and assignment is not legally permitted, ZMC shall provide AMBRX with the right to reference, cross-reference, review, have access

  
 35 

	 	
to, incorporate and use all documents and other materials filed by or on behalf of ZMC and its Affiliates with any Regulatory Authority in furtherance of applications for Marketing Authorization
in the Territory or outside Territory with respect to Licensed Product. AMBRX shall be entitled to freely and exclusively use and to grant others the right to use all such materials and documents delivered pursuant to this Section 11.5.4

  

	 	11.5.5	RETURN CONFIDENTIAL INFORMATION & MATERIALS. Upon any termination of this Agreement, each Party shall promptly return to the other Party all Confidential Information & Materials or Know How received
from the other Party, except as reasonably required to exercise any surviving rights or licenses hereunder. 

  

	11.6	SURVIVAL. 

  

	 	11.6.1	Termination or expiration of this Agreement for any reason shall be without prejudice to any rights which shall have accrued to the benefit of either Party prior to such termination or expiration. Such termination or
expiration shall not relieve either Party from obligations which are expressly indicated to survive termination or expiration of this Agreement. The rights of the Parties upon termination described in this Agreement shall not be exclusive of any
other rights or claims at law or in equity that either Party may have against the other arising out of this Agreement. 

  

	 	11.6.2	Termination, relinquishment or expiration of this Agreement shall not terminate each Party’s obligation to pay all royalties, milestone payments and other monetary obligations that may have accrued hereunder prior
to such termination. All of the Parties’ rights and obligations under Sections 2.8, 7.1, 7.2, 7.3, 7.4, 11.5, and 14.4, Article 1, Article 8, Article 10, Article 12, and Article 13 shall survive termination, relinquishment or expiration
hereof. 

 ARTICLE 12 

LIMITATIONS OF LIABILITY 
  

	12.1	 EXCLUSION OF DAMAGE. EXCEPT WITH RESPECT TO ARTICLES VIII (CONFIDENTIALITY), IX (REPRESENTATIONS AND WARRANTIES) AND X (INDEMNIFICATION), IN NO EVENT
WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, OR PUNITIVE DAMAGES INCURRED BY SUCH PARTY ARISING UNDER OR AS A RESULT OF THIS AGREEMENT (OR THE TERMINATION HEREOF) INCLUDING, BUT NOT LIMITED TO, THE LOSS OF
PROSPECTIVE PROFITS OR ANTICIPATED SALES, OR ON ACCOUNT OF EXPENSES, INVESTMENTS, OR COMMITMENTS IN CONNECTION WITH THE BUSINESS OR GOODWILL OR OTHERWISE, 

  
 36 

	 	
EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 

  

	12.2	MAXIMUM LIABILITY. EXCEPT FOR ZMC’S PAYMENT OBLIGATIONS HEREUNDER AND EXCEPT WITH RESPECT TO ARTICLES VIII (CONFIDENTIALITY), IX (REPRESENTATIONS AND WARRANTIES) AND X (INDEMNIFICATION), EACH PARTY’S
MAXIMUM LIABILITY TO THE OTHER PARTY FOR ANY KIND OF LOSS, DAMAGE OR LIABILITY ARISING UNDER OR IN CONNECTION WITH ITS PERFORMANCE OR BREACH HEREOF, UNDER ANY THEORY OF LIABILITY, SHALL NOT EXCEED ONE MILLION UNITED STATES DOLLARS (U.S. $1,000,000).

  

	12.3	FAILURE OF ESSENTIAL PURPOSE. The limitations specified in this Article XII shall survive and apply even if any limited remedy specified in this Agreement is found to have failed of its essential purpose.

 ARTICLE 13 

DISPUTE RESOUTION 
  

	13.1	JURISDICTION. The Parties shall negotiate in good faith and use reasonable efforts to settle any dispute, controversy or claim arising from or related to this Agreement or the breach thereof. If the Parties do not fully
settle, and a Party wishes to pursue the matter, each such dispute, controversy or claim shall be submitted to the exclusive jurisdiction of the court at the place of the execution of this Agreement for final resolution. 

 

	13.2	EFFECT. The Parties agree that, in the event of a good faith dispute over the nature or quality of performance under this Agreement, neither Party may terminate this Agreement until final resolution of the dispute by a
court decision. 

 ARTICLE 14 

MISCELLANEOUS 
  

	14.1	FORCE MAJEURE 

 Neither Party shall be held liable to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent that such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party,
potentially including, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or
delays in acting by any governmental authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as 

  
 37 

 
reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. 

 

	14.2	ASSIGNMENT 

 Except as provided in this Section 14.2, this Agreement may not be assigned or
otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s consent, assign this
Agreement and its rights and obligations hereunder in whole or in part to an Affiliate; provided, however, that the assigning party must notify the other party at least twenty (20) days prior to completion of any such assignment. Further, each
party may assign this Agreement to any assignee of all or substantially all of such Party’s business or in the event of such Party’s merger, consolidation or similar transaction. Any permitted assignee shall assume all obligations of its
assignor under this Agreement. This Agreement is binding upon the permitted successors and assigns of the Parties. Any attempted assignment not in accordance with this Section 14.2 shall be void 

 

	14.3	SEVERABILITY 

 If any one or more of the provisions contained in this Agreement is held invalid,
illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely
affects the substantive rights of the Parties. The Parties shall in such an instance use their good faith efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as
practical, implement the purposes of this Agreement. 
  

	14.4	NOTICES 

 All notices which are required or permitted hereunder shall be in writing and
sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally-recognized overnight courier or sent by registered or certified mail,
postage prepaid, return receipt requested, addressed as follows: 
  

					
	If to Ambrx, to:	 		  	Ambrx, Inc.
		 		  	10975 North Torrey Pines Road
		 		  	La Jolla, CA 92037
		 		  	Attn: Office of General Counsel
		 		  	Facsimile No.: (858) 453-9511
	
	With a copy to:

  
 38 

					
			
		 		  	If to ZMC, to:
	
	With a copy to:

 or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party
in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered, if personally delivered or sent by facsimile on a business day (or if delivered or sent on a non-business day, then on the next business
day); (b) on the business day after dispatch, if sent by internationally-recognized overnight courier; or (c) on the fifth (5th) business day following the date of mailing, if sent by mail. 

 

	14.5	APPLICABLE LAW 

 This Agreement shall be governed by and construed in accordance with the
laws of the People’s Republic of China, without reference to any rules of conflict of laws or renvoi. The United Nations Convention on the Sale of Goods shall not apply to this Agreement. 

 

	14.6	ENTIRE AGREEMENT; AMENDMENTS 

 This Agreement together with the Schedules hereto contains
the entire understanding of the Parties with respect to the subject matter hereof, including the research program and the licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments,
either oral or written, with regard to the subject matter hereof, including the research program and/or the licenses granted hereunder, are superseded by the terms of this Agreement. The Schedules to this Agreement are incorporated herein by
reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. 

 

	14.7	HEADINGS AND INTERPRETATION 

 The captions to the several Articles and Sections and subsections
hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, or Schedule or
Exhibit shall be deemed to be a reference to an Article, Section, subsection, paragraph, clause, or Schedule or Exhibit, of or to, as the case may be, this Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise
requires, (a) words of any gender include each other gender, (b) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to the particular provision in which such
words appear, (c) words using the singular shall include the plural, and vice versa, (d) whenever any provision of this 

  
 39 

 
Agreement uses the term “including” (or “includes” or words of similar import), such term shall not be limiting and such term shall be deemed to mean “including without
limitation” (or “includes without limitation”), (e) the word “or” shall not be construed as exclusive, and (f) references to any Articles or Sections include Sections and subsections that are part of the reference
Article or section (e.g., a section numbered “Section 2.2.1” would be part of “Section 2.2.”, and references to “Article 2” or “Section 2.2.” would refer to material contained in the subsection described as
“Section 2.2.2”). 
  

	14.8	INDEPENDENT CONTRACTORS 

 It is expressly agreed that Ambrx and ZMC shall be independent
contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Ambrx nor ZMC shall have the authority to make any statements, representations or commitments of any kind, or to take any
action, which shall be binding on the other Party, without the prior written consent of the other Party. 
  

	14.9	WAIVER 

 The waiver by either Party hereto of any right hereunder, or of any failure of the
other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party, whether of a similar nature or otherwise. 

 

	14.10	CUMULATIVE REMEDIES 

 No remedy referred to in this Agreement is intended to be
exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 
  

	14.11	WAIVER OF RULE OF CONSTRUCTION 

 Each Party has had the opportunity to consult with
counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

 

	14.12	BUSINESS DAY REQUIREMENTS 

 In the event that any notice or other action or omission is required
to be taken by a Party under this Agreement on a day that is not a business day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring business day. 

 

	14.13	COUNTERPARTS 

  

  
 40 

 This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. For purposes hereof, a scanned copy of this Agreement, including the signature pages hereto, will be deemed to be an original. 

 

	14.14	PRC REGULATORY MATTERS 

 ZMC shall be responsible for any and all PRC related regulatory
approvals, registrations and/or filings in connection with performance of this Agreement, including without limitation registering this Agreement with competent commission of commerce and providing registration certificate to Ambrx within sixty
(60) days after execution of this Agreement. Before ZMC’s filing or submission of any reports or other documents with any PRC governmental authority or securities exchange, it shall provide copies of any such reports or documents to be
filed or submitted to Ambrx for its prior consents; after regulatory approvals, registrations and/or filings are completed, ZMC shall provide a copy of relevant certificates to Ambrx immediately. 

 

	14.15	EXPORT LAWS 

 Notwithstanding anything to the contrary contained herein, all obligations of
Ambrx and ZMC are subject to prior compliance with the export regulations of the United States and any other relevant country and such other laws and regulations in effect in the United States and/or any other relevant country as may be applicable,
and to obtaining all necessary approvals required by the applicable agencies of the governments of the United States and any other relevant countries. Ambrx and ZMC shall cooperate with each other and shall provide assistance to the other as
reasonably necessary to obtain any required approvals. 
  

	14.16	FURTHER ACTIONS 

 Each Party will execute, acknowledge and deliver such further instruments, and
to do all such other ministerial, administrative or similar acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  

	14.17	NO THIRD PARTY RIGHTS 

 The provisions of this Agreement are for the exclusive benefit of
the Parties, and no other person or entity shall have any right or claim against any Party by reason of these provisions or be entitled to enforce any of these provisions against any Party. 

 

	14.18	EXPENSES 

 Except as otherwise specifically provided in this Agreement, each Party (and its
Affiliates) shall bear its own costs and expenses in connection with entering into this Agreement and the consummation of the transactions and performance of its obligations contemplated hereby. 

  
 41 

	14.19	EXTENSION TO AFFILIATES 

 ZMC shall have the right to extend the rights, licenses, immunities
and obligations granted in this Agreement to one or more of its Affiliates. All applicable terms and provisions of this Agreement shall apply to any such Affiliate to which this Agreement has been extended to the same extent as such terms and
provisions apply to ZMC. ZMC shall remain fully liable for any acts or omissions of such Affiliates. 
  

	14.20	LANGUAGE 

 The official text of this Agreement is in the English language as written and spoken
in the United States of America. Any text or version of this Agreement in another language, even if such text or version is made by translation or prepared by or executed by one or both of the Parties for a Party’s convenience shall not be
binding and shall have no force or effect. Without limiting the foregoing, in the event of any conflict or inconsistency between the English text of this Agreement and any text or version of this Agreement in another language, the English text of
this Agreement will prevail. 
 [Remainder of this page is left intentionally blank] 

  
 42 

 IN WITNESS WHEREOF, the Parties have executed this Co-development and License Agreement as
of the Effective Date in HuangPu District, Shanghai, People’s Republic of China. 
  

					
	Zhejiang Medicine Co., Ltd.
		
	By:	 	 /s/ Chunbo Li

	Name:	 	Chunbo Li
	Title:	 	Board Chairman
	
	AMBRX, INC.
		
	By:	 	 /s/ Lawson Macartney

	Name:	 	Lawson Macartney
	Title:	 	CEO

  
 43 

 Exhibit 1 

Protein Sequence of HER2 
 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 2 

AMBRX Existing Patent Rights 
 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  

 Exhibit 3 

ZMC-WUXI Service Agreement 

DEVELOPMENT, MANUFACTURING, AND TESTING TERMS AND CONDITIONS 

This Development, Manufacturing and Testing Terms and Conditions together with any Technology Development Contracts attached hereto is made
and entered into as of Jun 14_, 2013 (Effective Date) by and between WuXi AppTec Biopharmaceuticals Co., Ltd., a company organized under the laws of PR.China, having a principal place of business at 88 West Meiliang Rd, Wuxi City, Jiangsu, PR China
and its affiliates. (collectively, “WuXi”) and Zhejiang Medicine Co Ltd, a company organized under the laws of PR China having a principle place of business at 268 Dengyun Rd Gongshu District, Hangzhou, PR China (“Customer”).
Customer and WuXi are referred to herein individually as a “Party” and collectively as the “Parties”. 
 The Parties agree as follows:

 1. Definitions 
 1.1
Defined Terms. The following terms (whether or not underscored) when used in this Agreement, shall, except where the context otherwise requires, have the following meanings: 

1.1.1 “Affiliate” means any company, partnership or other entity which directly or indirectly controls, is controlled by or
is under common control with the relevant Party to this Agreement. “Control” means the ownership of at least fifty per cent (50%) of the equity of the entity or the legal power to direct the general management and policies of the
entity. 
 1.1.2 “Agreement” means these Terms and Conditions together with an applicable Technology Development Contract.

 1.1.3 “Batch” means the total Product obtained from one bioreactor run and associated purification using the Process
and carried out in accordance with cGMP or non cGMP if so identified in the Technology Development Contract. 
 1.1.4 “Cell
Line” means the cell line used to produce Product, particulars of which are set out in Technology Development Contracts. 
 1.1.5
“Certificate of Analysis” means a certificate of analysis as to testing of Specifications of any Product in form and substance agreed to by WuXi and Customer. 

1.1.6 “cGMP” means current Good Manufacturing Practices and General Biologics Products Standards as promulgated under the US
Federal Food Drug and Cosmetic Act at 21 CFR (Chapters 210, 211, 600 and 610), the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC and ICH Guidance Q7A (Good Manufacturing Practice
Guidance for Active Pharmaceutical Ingredients. WuXi’s operational quality standards are defined in internal GMP policy documents. 

1.1.7 “cGMP Product” means Product which may be required under Technology Development Contracts to be manufactured in
accordance with cGMP. 
 1.1.8 “Customer” means Zhejiang Medicine Co Ltd and its successors and assigns. 

  
 1 

 

 
  

 1.1.9 “Customer Information” means all technical and other information from
time to time supplied by Customer to WuXi, which at the time of supply by Customer is not (i) already in the public domain or (ii) already known by WuXi at the time of disclosure as established by written records. 

1.1.10 “Customer Know-How” means all technical and other information relating to the Product or the Process known to
Customer from time to time other than WuXi Know-How and information in the public domain. 
 1.1.11 “Customer Materials”
means the materials supplied by Customer to WuXi and identified as such in Technology Development Contracts hereto. 
 1.1.12
“Customer Patent Rights” means all patents and patent applications of any kind throughout the world that are necessary or useful in performance of the Services, or related to the Products or the Process, which from time to time
Customer is the owner of or is entitled to use. 
 1.1.13 “Deliver”, “Delivered” or
“Delivery” has the meaning ascribed to it by Section 5.1. 
 1.1.14. “Price” means the price
specified in Technology Development Contracts for the Services. 
 1.1.15 “Process” means the process for the production
of the Product from the Cell Line, including any improvements or modifications thereto from time to time. 
 1.1.16
“Product” means all or any part of the product manufactured (including any sample thereof), particulars of which are set out in Technology Development Contracts and includes all derivatives thereof. 

1.1.17 “Quality Agreement” means the quality agreement between the Parties. The Quality Agreement is attached as Appendix X and
hereby incorporated into this Agreement and all related Technology Development Contracts by reference. 
 1.1.18
“Services” means all or any part of the services that are the subject of the Agreement, particulars including but not limited to specifications, cost, quantity, and delivery dates of which are set out in Technology Development
Contracts. 
 1.1.19 “Specification” means the specification for Product or Services, as applicable, particulars of which
are set out in Technology Development Contracts. 
 1.1.20 “Terms of Payment” means the terms of payment specified in
Technology Development Contracts. 
 1.1.21 “Testing Laboratories” means any third party instructed to carry out tests on
the Cell Line or the Product. All proposed third party laboratories (or for that matter, any other Parties to which WuXi subcontracts work on Customer Cell Line or Product) shall be subject to prior review and approval by Customer. 

1.1.22 “Technology Development Contract” means any such appendix to this Agreement specifying Services, as agreed to in writing by
the Parties from time to time during the Term of this Agreement. Approved Technology Development Contract(s) shall be attached to this Agreement and shall, when approved in writing signed by both Parties, be deemed an integral part hereof.
Technology Development Contract(s) may be updated from time to time by mutual written agreement of the Parties. 

  
 2 

 

 
  

 1.1.23 “WuXi” means WuXi AppTec Biopharmaceutical Co Ltd, and its
successors and assigns. 
 1.1.24 “WuXi Know-How” means all technical and other information and materials, ideas,
concepts, methods, procedures, designs, documents, data, inventions, discoveries and works of authorship (in each case, whether or not patentable) known to WuXi from time to time other than confidential Customer Information and information in the
public domain. 
 1.1.25 “WuXi Patent Rights” means all patents and patent applications of any kind throughout the world
relating to WuXi Know-How or to the Process which from time to time WuXi is the owner of or is entitled to use 
 1.2 Use of
Definitions. Unless the context requires otherwise, words and phrases defined in any other part of the Agreement shall bear the same meanings in these Standard Terms and Conditions, references to the singular number include the plural and vice
versa, references to Technology Development Contracts are references to Technology Development Contracts to the Agreement, and references to Sections are references to sections of these Standard Terms and Conditions. 

1.3 Conflicting Definitions. In the event of a conflict between a term in any executed Technology Development Contract or any
supplemental or additional term agreed to in writing from time to time between the parties and these Standard Terms and Conditions, any Technology Development Contract and any supplemental or additional term agreed to in writing after the date
hereof shall prevail. 
 2. Applicability of Terms and Conditions 

These Terms and Conditions will not be effective until it (or a counterpart of it) has been signed on behalf of both Parties. Customer and
WuXi must complete and execute a Technology Development Contract before Services are provided. Each Technology Development Contract will include information relating to the specific Services agreed to by the Parties and price for Services. Once
signed, a Technology Development Contract becomes a part of the Agreement, although the terms in a Technology Development Contract will govern only Services described in that Technology Development Contract. A Technology Development Contract will
not change any term in the Agreement. In the event of any inconsistency between the Agreement and any Technology Development Contract, the Agreement will prevail unless the Technology Development Contract Specifies. No variation of or addition to
the Agreement or any part thereof shall be effective unless in writing and signed on behalf of both Parties. Notwithstanding the above, the Parties hereby confirm that amendments to the Specification shall be effective if reduced to writing and
signed by the quality and/or regulatory representative of both Parties, which quality and/or regulatory representative shall be nominated from time to time by each Party. Any such amendments to Specifications must also reflect, in writing, any
corresponding changes to the timing of the Services and any changes to the Pricing detailed in the applicable Technology Development Contract. 

3. Representations and Warranties 

3.1 WuXi Warranties. WuXi represents and warrants that: 

3.1.1 The Services will be performed in accordance with the Terms and Conditions of this Agreement; 

  
 3 

 

 
  

 3.1.2 It will use reasonable endeavors to keep the Cell Line and/or the Customer Materials
and/or the Customer Know-How secure and safe from loss and damage in such manner as WuXi stores its own material of similar nature; 

3.1.3 It will not part with possession of the Cell Line and/or the Customer Materials or the Product, save for the purpose of tests at any
third party Testing Laboratories that may be required and only with Customer’s written permission; and 
 3.1.4 It will use only
Testing Laboratories bound to obligations of confidence substantially similar to those obligations of confidence imposed on WuXi under these Standard Terms and Conditions. 

3.1.5 Subject to Section 13, unencumbered title to Product will be conveyed to Customer upon Delivery; 

3.1.6 As of the date of this Agreement, to the best of WuXi’s knowledge without independent investigation, the WuXi Patent Rights and
the WuXi Know-How are owned by WuXi or WuXi is otherwise entitled to use them for the purposes of providing Services under this Agreement and during the term of this Agreement WuXi shall not do or cause anything to be done which would adversely
affect their ownership or entitlement to use the same for those purposes. WuXi will notify Customer in writing immediately if it receives or is notified of a claim from a third party that the use by WuXi of the WuXi Know-How or the WuXi Patents
Rights for Services infringes any intellectual property rights vested in such third party; 
 3.1.7 WuXi has the necessary corporate
authorizations to enter into this Agreement; 
 3.1.8 WuXi has all necessary licenses from Life Technologies to use their host cell/vector
system to develop a Cell Line. WuXi has the right to grant Customer a royalty-free sublicense to use the Cell Line for development and commercial production upon payment of [***] to Life
Technologies. 
 3.1.9 To the best of WuXi’s knowledge, no taxes are payable to P.R.China in connection with the Services or
production and Delivery of Product. 
 3.2 DISCLAIMER. SECTION 3.1 IS IN LIEU OF ALL CONDITIONS, WARRANTIES AND STATEMENTS IN RESPECT
OF THE SERVICES AND/OR THE PRODUCT WHETHER EXPRESSED OR IMPLIED BY STATUTE, CUSTOM OF THE TRADE OR OTHERWISE (INCLUDING BUT WITHOUT LIMITATION ANY SUCH CONDITION, WARRANTY OR STATEMENT RELATING TO THE DESCRIPTION OR QUALITY OF THE PRODUCT, ITS
FITNESS OR SUITABILITY FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS WHETHER OR NOT KNOWN TO WUXI APPTEC) AND ANY SUCH CONDITION, WARRANTY OR STATEMENT IS HEREBY EXCLUDED AND DISCLAIMED. 

3.3 Representations and Warranties of Customer. Customer represents and warrants to WuXi that: 

3.3.1 Customer shall supply to WuXi the Customer Information, together with full details of any hazards relating to the Cell Line (if
applicable) and/or the Customer Materials, their storage and use. Upon review of this Customer Information, the Cell 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
 4

 

 
  

 
Line and/or the Customer Materials and/or the Customer Know-How will be provided to WuXi at WuXi’s reasonable request. The Cell Line and/or the Customer Materials and/or the Customer
Information and/or the Customer Know-How supplied to WuXi will remain the property of Customer. 
 3.3.2 Customer hereby grants WuXi the
non-exclusive right to use the Cell Line, the Customer Materials, the Customer Know-How and the Customer Information for the purpose of the Agreement. WuXi hereby undertakes not to use the Cell Line, the Customer Materials, the Customer Know-How or the Customer Information (or any part thereof) for any other purpose. 
 3.3.3 Customer has
the necessary corporate authority to enter into this Agreement; 
 3.3.4 To Customer’s knowledge without independent investigation, as
of the date of this Agreement, Customer has the right to supply the Cell Line (if applicable), the other Customer Materials and the Customer Information to WuXi and the necessary rights to license or permit WuXi to use the same for the purpose of
the Services; and Customer shall not do or cause anything to be done which would adversely affect their ownership or entitlement to use the same for those purposes; 

3.3.5 To Customer’s knowledge and belief without independent investigation, as of the date of this Agreement, the use by WuXi of the
Cell Line, other Customer Materials, Customer Information and Customer Patent Rights for the Services (including without limitation the manufacture of the Product) will not infringe in China any intellectual property rights of any third party; and
Customer shall not do or cause anything to be done which would adversely affect such use; 
 3.3.6 Customer will promptly notify WuXi in
writing if it receives or is notified of a claim from a third party that the Cell Line, other Customer Materials, Customer Information or the Customer Patent Rights or that the-use by WuXi thereof for the provision of the Services infringes any
intellectual property rights of such third party; 
 4. Provision of the Services 

4.1 Services. WuXi acknowledges and agrees that Customer commissioned WuXi to perform the Services, and all rights, title, interests and
benefits in and to the Customer Property, including all inventions therein, vest absolutely and exclusively in Customer from the moment of their creation or development. WuXi shall carry out the Services as provided in applicable Technology
Development Contracts and shall use reasonable efforts to achieve the estimated time schedule thereto or as agreed to by the Parties. Customer shall have the right to be present during manufacturing of Product, and the right to conduct periodic
routine GMP compliance audits or “for cause” audits of WuXi’s manufacturing facility. 
 4.2 Specification.
Specifications will be agreed to by the Parties prior to initiation of a manufacturing run or other Services, as appropriate. 
 4.3 Time
Limitations. Due to the unpredictable nature of discovery services, technical transfer, Cell Line development, process development, process scale-up, assay development, formulation and other related Services, the time schedule set down for the
performance of these Services is estimated only. Upon completion or near completion of these Services the project teams will work to finalize the pilot and cGMP manufacturing schedules. 

  
 5 

 

 
  

 4.4 Quality. Responsibility for quality assurance and quality control of Products shall be
allocated between Customer and WuXi as set forth in the Quality Agreement and in WuXi standard operating procedures. 
 5. Delivery,
Transportation of Product 
 5.1 Delivery. Product will be delivered Ex Works WuXi premises in Wuxi at the address set forth in
the first paragraph of this Agreement, which means (a) WuXi places Product at the disposal of Customer at WuXi’s premises not cleared for export and not loaded onto any collecting vehicle and (b) risk and title to Product pass to
Customer upon delivery (“Deliver,” “Delivery,” or “Delivered,” as appropriate). Subject to Section 5.2, WuXi shall deliver to Customer the Certificate of Analysis, the Certificate of Compliance (with GMP), and
BSE/TSE Certification for each Batch of Product not later than the date of Delivery. Transportation of Product, whether or not under any arrangements made by WuXi on behalf of Customer, shall be made at the sole risk and expense of Customer. 

5.2 Delivery Without Certificate of Analysis. At Customer’s request, WuXi will Deliver Product in quarantine prior to delivery of
the Certificate of Analysis. Such request shall be accompanied by Customer’s written acknowledgement that the Product has been Delivered without the transmittal to Customer of a Certificate of Analysis, that accordingly the Product cannot be
administered to humans until transmittal of the Certificate of Analysis, and that Customer nevertheless accepts full risk of loss, title and ownership of the Product. The Delivery of Product in quarantine will be subject to such testing requirements
as WuXi may reasonably require, and the forty-five (45) day period referred to in Section 5.8 will run from Delivery in quarantine by Customer of the Product. 

5.3 Packaging and Labeling. Unless otherwise agreed, WuXi shall package and label Product for Delivery in accordance with its standard
operating procedures and in accordance with required shipping conditions. It shall be the responsibility of Customer to inform WuXi in writing in advance of any special packaging and labeling requirements for Product. All additional costs and
expenses of whatever nature incurred by WuXi in complying with such special requirements must be agreed to in advance in writing and will be charged to Customer in addition to the Price. 

5.4 Insurance. If requested in writing by Customer, WuXi will (acting as agent for Customer) arrange for insurance of Product while
held by WuXi after Delivery (awaiting transportation) for a maximum of fourteen (14) days on terms equivalent to those under which WuXi insures product prior to Delivery. Third party expenses incurred by WuXi in arranging such insurance must be
agreed to in advance in writing and will be charged to Customer in addition to the Price. 
 5.5 Transportation. If requested in
writing by Customer, WuXi will (acting as agent of Customer for such purpose) arrange the transportation of Product from WuXi’s premises to the destination indicated by Customer together with insurance coverage for Product in transit at its
invoiced value. All additional costs and expenses of whatever nature incurred by WuXi in arranging such transportation and insurance must be agreed to in advance in writing and will be charged to Customer in addition to the Price. 

5.6 Additional Cost. Any other additional cost and expenses for this project need to be approved in writing by both parties including
both the contractor and the contractee. 
 5.7 Acceptance of Delivery. Where WuXi has made arrangements for the transportation of
Product, Customer shall diligently examine the Product as soon as practicable after receipt. Notice of all claims (time being of the essence) arising out of: 

  
 6 

 

 
  

 5.7.1 Visible damage to or total or partial loss of Product in transit will be given in
writing to WuXi and the carrier within five (5) working days of receipt by Customer; or 
 5.7.2 Non-delivery will be given in writing
to WuXi within ten (10) days after the receipt by Customer of WuXi’s dispatch notice. 
 5.8 Damage Claims. Customer shall
make damaged Product and associated packaging materials available for inspection and shall comply with the reasonable requirements of any insurance policy covering the Product, for which notification has been given by WuXi to Customer. WuXi shall
offer Customer all reasonable assistance in pursuing any claims arising out of the transportation of Product. 
 6. Non-Conforming
Product or Tests. 
 6.1 Non-Conforming Product. Within thirty (30) days following Delivery of Product and copies of the
relevant production batch records in English, including copies of the CoA, CoC, and BSE/TSE certification provided at Delivery, Customer shall determine whether the Product conforms to the Specifications and has been manufactured in material
accordance with such batch records. If Customer determines that the Product fails to meet Specification, or was not produced in material accordance with the batch records Customer shall give WuXi written notice within such 30 day period and shall
return such Product to WuXi’s premises, at WuXi’s expense, for further analysis. In the absence of such written notice, Product shall be deemed to have been accepted by Customer as meeting Specification and Customer has waived its right to
revoke acceptance. If Customer reasonably demonstrates to WuXi that Product returned to WuXi fails to meet Specification or was not manufactured in material accordance with the batch records and that such failure is due to the negligence of WuXi and
not due in whole or in part to the inherent property of the Product or Process, or acts or omissions of Customer or any third party after Delivery, WuXi shall at its option either refund that part of the Price that relates to the production of such
non-conforming Product, or initiate a manufacturing run within sixty (60) calendar days from the date it was determined that the Product was non-conforming to replace such Product at its own cost and expense. 

6.2 Non-Conforming Test. If, within fourteen (14) calendar days of receiving a result from a test conducted by WuXi, Customer
notifies WuXi in writing that the result is unexpected, WuXi will initiate a laboratory investigation of the result. The Customer and WuXi will agree on an appropriate course of action pending the results of the laboratory investigation. If WuXi
observes an Out Of Specification (OOS) result it will notify Customer as soon as reasonable but in any case within two (2) working days of learning of such result. Customer and WuXi will agree on the appropriate course of action to investigate
the OOS result. If WuXi determines that an unexpected, or OOS result is due to the inherent condition of the sample matrix, or to the act, omission, direction, or negligence of Customer or any third party outside of WuXi’s control, Customer
shall be liable to WuXi for the Price of the Services performed, including any additional testing or retests, and materials, reagents, expenses consumed, employed, or specially obtained during the course of the laboratory investigation. If the
unexpected or OOS result was caused by a combination of the inherent property of the sample matrix or the act, omission, direction, or negligence of Customer or any third party outside of WuXi’s control and WuXi error, or a reasonable
determination of cause cannot be ascertained, Customer shall be liable for 50% of the Price of the Services performed, including any additional testing or retests, and 50% of the cost of any materials or reagents specially obtained by WuXi during
the course of the laboratory investigation. Customer is not liable to WuXi for unexpected, or OOS results due to WuXi error and WuXi shall provide a refund of any payments made by Customer for the Services giving rise to the unexpected or OOS
results. Should Customer request a repeat or retest of such non-conforming Services Customer shall be liable for the Price of a successful repeat or retest of such non-conforming Services. 

  
 7 

 

 
  

 7. Records 

Records of Services are available for Customer review at the WuXi facility where the Services were performed. WuXi will retain Batch,
laboratory and other technical records (“Records”) of Services for the longer of ten (10) years or for the minimum period required by applicable law and consistent with FDA, EMA, or other relevant Competent Authority regulations and
guidance relating to the manufacture or testing of products intended to support an application for regulatory approval. Technology Development Contracts shall include copies of protocols, test methods, method qualification/validation reports. To the
extent that raw data from Services or descriptions of any of WuXi’s protocols, test methods, or SOPs are not included in the Customer-approved protocol Technology Development Contract, or Report pertaining to any particular Service and are
required by a competent regulatory authority, WuXi will upon written request by Customer provide a copy of such raw data or relevant portions of such protocols, test methods, or SOPs to be used solely for purposes of such regulatory submission under
the provisions of Confidentiality in accordance with Section 10. In the event WuXi proposes to dispose of Records WuXi shall provide Customer written notice thereof. If within thirty (30) days after such notice Customer requests any
Records, WuXi shall provide to Customer at Customer’s expense such Records rather than disposing thereof. WuXi may, however, retain copies of any Records as are reasonably necessary for regulatory or insurance purposes, subject to WuXi’s
obligation of confidentiality. 
 All the original lab notes will be in Chinese to meet Chinese regulatory requirements. All technical
reports and regulatory dossiers will be in both Chinese and English. 
 For the time specified in 5, 6, and 7, one party can ask for extension once upon
written request from the other party. Only a single extension is allowed. 
 8. Price and Terms of Payment 

8.1 Price. Customer shall pay the Price in accordance with the Price detailed in Technology Development Contracts attached hereto. 

8.2 Payment. Payment will be made in accordance with Technology Development Contracts attached hereto. Unless otherwise indicated in a
Technology Development Contract, all Prices and charges are exclusive of any applicable taxes, levies, duties and fees of whatever nature imposed by or under the authority of any government or public authority, which shall be paid by Customer (other
than taxes on WuXi’s income). Payment must be made within thirty (30) days of receipt by Customer of a correct invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim of any nature. Payment shall be made
in RMB by wire transfer to a Chinese bank account designated by WuXi. For uncontrollable reasons such as natural disasters, war, government control and bank errors that lead to payment delay, the client will notify WuXi and make corrections in a
reasonable timeframe. 
 8.3 No Additional Cost. WuXi acknowledges that it is duly compensated for all actions through being entrusted by
Customer with the performance of the Services under this Agreement, and WuXi agrees that it shall not be entitled to any additional fees, costs, reimbursement or other charges, unless otherwise agreed by the Parties in writing. WuXi represents and
warrants to Customer that all its employees, agents, consultants, and contractors who have contributed and will contribute to the Services have been and will be, as the case may be, properly remunerated, compensated and awarded for their
contributions. WuXi agrees that this Agreement does not create an employment relationship between Customer and any of WuXi employees, agents, consultants, or contractors, notwithstanding any agreements that a WuXi employee, agent, consultant, or
contractor may sign with Customer and/or WuXi from time to time. It is WuXi’s sole responsibility to compensate its 

  
 8 

 

 
  

 
employees, agents, consultants, and contractors as prescribed by applicable Chinese laws. Customer shall have no liability or responsibility for compensating any of WuXi employees, agents,
consultants, or contractors for any invention. 
 9. Indemnification and Limitation of Liability 

9.1 WuXi Indemnity. WuXi shall indemnify and hold Customer harmless against all claims, actions, costs, expenses (including court costs
and reasonable attorney’s fees) or other liabilities (collectively, “Losses”) whatsoever to, from or in favor of third parties, to the extent such Losses are in respect of WuXi’s material breach of any of the terms and conditions
of this Agreement, or the negligence or wrongful action of WuXi or any of its employees or agents in the provision of Services under this Agreement. 

9.2 Customer Indemnity. Customer shall indemnify and hold WuXi harmless against all claims, actions, costs, expenses (including court
costs and reasonable attorney’s fees) or other liabilities whatsoever to, from or in favor of third parties, in respect of 
 9.2.1
Customer’s storage, research, development, manufacture, distribution, use, sales or other disposition by Customer, or any distributor, collaborator, customer, sublicense, representative or agent of Customer, of the Product or other test
materials or any other substances upon which the Services of WuXi were performed; or 
 9.2.2 any claim that the use, sale, marketing, or
distribution of the Product by Customer or WuXi’s use of Customer-supplied information or materials violates any third party’s intellectual property or proprietary rights; or 

9.2.3 any negligent or willful act, omission, or breach of Customer in connection with this Agreement. 

9.3 Limitation. Except for the above indemnification obligations, neither Party shall be liable for any penalties, liquidated, special,
consequential, incidental or indirect damages arising out of or in connection with this Agreement (or the termination hereof), including, without limitation, loss of profits or anticipated sales to the fullest extent permitted by law, and the total
liability, in the aggregate, of either Party and its agents to the other Party and anyone claiming by or through the other Party, for any and all claims, losses, costs or damages, including without limitation, attorneys’ fees and costs and
expert-witness fees and costs of any nature whatsoever or claims expenses resulting from or in any way related to this Agreement from any cause or causes shall not exceed the fees paid or owed under this Agreement for the portion of the Services
under which such liability arises. Except as otherwise provided, it is intended that this limitation apply to any and all liability or cause of action however alleged or arising, including without limitation, negligence, professional errors and
omissions, breach of contract, unless otherwise prohibited by law. For the avoidance of doubt, the foregoing shall not limit either Party’s ability to obtain equitable relief of any type. 

9.4 Further Limitation. The obligation of WuXi under Section 9.1 and Customer under Section 9.2 is limited to one-hundred
thousand dollars ($100,000) per event, except that this limitation will not apply with respect to any indemnifiable claim arising out of or relating to gross negligence, fraud or willful misconduct by the indemnifying Party under this Agreement.
Except for claims arising under indemnities contained herein, any claim must be brought by either Party within one (1) year from the completion of Services under which such claim arises or such claim will be forever barred. 

  
 9 

 

 
  

 9.5 Limitation Exception. Nothing contained in these Standard Terms and Conditions
shall purport to exclude or restrict any liability for death or personal injury resulting directly from gross negligence by a Party in carrying out their obligations in breach of the terms of this Agreement. 

9.6 Waiver of Claims. WuXi represents only that it will use reasonable care in the provision of Services. WuXi makes no representation
or warranty, and Customer expressly waives all claims against WuXi and its Affiliates, and any of its respective agents or employees, arising out of or in connection with any claims relating to the stability, efficacy, safety, or toxicity of the
Product developed, formulated, packaged, or manufactured in accordance with the agreed upon Services. 
 9.7 For each party that is involved
in legal or administrative procedures due to this agreement, the other party shall provide reasonable support. 
 9.8 Survival. The
obligations of WuXi and Customer and under this Section 9 shall survive the termination or expiration of this Agreement. 
 10.
Confidentiality 
 10.1 Confidential Information. The Parties will exchange proprietary and confidential information during
the term of this Agreement, including without limitation, the existence and terms of this Agreement. The Parties will identify, in writing, such information as confidential and/or proprietary. Notwithstanding the foregoing, Customer Confidential
Information will also include Customer Information, Customer Materials, and Customer Know-How, and WuXi Confidential Information will include WuXi Know-How, study designs, pricing information, and test protocols. Customer acknowledges that WuXi
Confidential Information and WuXi AppTec acknowledges that Customer Confidential Information, with which it is supplied by the other pursuant to the Agreement is supplied subject to Sections 10.5 and 10.6 in circumstances imparting an obligation of
confidence. Each Party agrees to keep the other Party’s confidential information secret and confidential and to respect the other’s proprietary rights therein and not at any time for any reason whatsoever to disclose or permit the other
party’s confidential information to be disclosed to any third party save as expressly provided herein. Processes, formulations, SOPs, assays and test results developed by WuXi AppTec in the course of providing the Services and specific to
Customer Process and Product is the Confidential Information of Customer. 
 10.2 Obligations of Confidentiality. Customer and WuXi
AppTec shall each cause all their respective employees, consultants, contractors and persons for whom it is responsible having access to WuXi AppTec Confidential Information or Customer Confidential Information to be subject to the same obligations
of confidence as Customer and WuXi pursuant to Sections 10.1 and 10.3 and shall be bound by confidentiality agreements in support of such obligations. WuXi and Customer each undertake not to disclose or permit to be disclosed to any third party, or
otherwise make use of or permit to be made use of (a) any trade secrets or confidential information relating to the technology, business affairs or finances of the other, any subsidiary, holding company or subsidiary or any such holding company
of the other, or of any suppliers, agents, distributors, licensees or other customers of the other which comes into its possession under this Agreement, or (b) the commercial terms of this Agreement; except to the extent that the same is
required to be disclosed pursuant to subpoena, court order, judicial process or otherwise by law, provided the receiving party provides prompt notice to the disclosing Party of such requirement in order to give the disclosing party an opportunity to
timely seek a protective order or other appropriate judicial relief. In the event the disclosing Party is unable to obtain a protective order or other appropriate judicial relief, the receiving party shall disclose only that portion of the
disclosing Party’s confidential information which is legally required to be disclosed, and that the disclosing party shall be given an opportunity to review the confidential information prior to its disclosure. 

  
 10 

 

 
  

 10.3 Limitations. The obligations of confidentiality referred to in this
Section 10 shall not extend to any information which: 
 10.3.1 Is or becomes generally available to the public otherwise than by
reason of a breach by the recipient Party of the provisions of this Section 10; 
 10.3.2 Is known to the receiving Party and is at
its free disposal prior to its receipt from the disclosing Party, as established by written records; 
 10.3.3 Is subsequently disclosed to
the receiving Party without being made subject to an obligation of confidence by a third party, as established by written records; 

10.3.4 Is required to be disclosed by WuXi or Customer under any statutory, regulatory or similar legislative requirement, or is incorporated
into a regulatory submission, subject to the imposition of obligations of confidentiality wherever possible in that relation; or 
 10.3.5
Is developed by any servant or agent of the recipient Party without access to or use or knowledge of the information by the disclosing party, as established by written records. 

10.4 Remedies. Without prejudice to any other rights and remedies that the Parties may have, the Parties agree that the confidential
information is valuable and that damages may not be an adequate remedy for any breach of the provisions of Sections 10.1, 10.2, or 10.3. The Parties agree that the relevant party will be entitled to seek the remedies of an injunction and other
equitable relief for any actual or threatened breach by the other Party. 
 10.5 WuXi Confidential Information. Customer acknowledges
that Customer shall not at any time have any right, title, license or interest in or to WuXi Confidential Information the WuXi Patent Rights or any other intellectual property rights relating to the Services which are vested in WuXi or to which WuXi
is otherwise entitled. 
 10.6 Customer Confidential Information. WuXi acknowledges that save as provided herein WuXi shall not at
any time have any right, title, license or interest in or to the Customer Confidential Information, Customer Patent Rights, Customer Know-How, or any other intellectual property rights vested in Customer or to which Customer is entitled. 

10.7 Survival. The obligations of WuXi and Customer under this Section 10 shall survive the termination or expiration of this
Agreement. 
 11. Term and Termination 

11.1 Term. This Agreement will expire on the later of (a) two (2) years from the Effective Date or (b) the completion of
all Services under the last Technology Development Contract executed by the Parties prior to the second anniversary of the Effective Date. The Agreement may be extended by mutual agreement of the Parties or earlier terminated in accordance with
Section 11.2. or 11.3. 
 11.2 Termination without Cause. 

11.2.1 Customer may in its sole discretion terminate this Agreement at any time for any reason or no reason by giving not less than thirty
(30) days notice in writing to WuXi. In the event of termination pursuant to this Section 10.2.1 Customer shall pay WuXi for Services performed up to the date of termination. In addition, Customer shall reimburse WuXi for expenses incurred
or irrevocably committed to third parties in accordance with this Agreement 

  
 11 

 

 
  

 
and the Price for any cell banks, toxicology studies, or manufacturing Batches that are in-progress or that has an initiation date scheduled within forty-five (45) days of the receipt of
notice of termination. 
 11.2.2 WuXi may in its sole discretion terminate this Agreement or any Technology Development Contract at any
time for any reason or no reason by giving not less than one hundred eighty (180) days notice in writing to Customer. During such notice period, WuXi shall continue and complete all work in progress and both Parties shall remain liable to each
other for their respective obligations under this Agreement. In the event of termination pursuant to this Section 11.2.2 Customer shall pay WuXi for Services performed and for expenses incurred or irrevocably committed to third parties. 

11.3 Termination for Cause. WuXi and Customer may each terminate the Agreement forthwith by notice in writing to the other upon the
occurrence of any of the following events: 
 11.3.1 If the other commits a material breach of the Agreement which in the case of a breach
capable of remedy is not remedied to the reasonable satisfaction of the non-breaching Party within forty-five (45) days of the receipt by the other of written notice identifying the breach and requiring its remedy; or 

11.3.2 Any party may terminate this Agreement at any time by giving notice in writing to the other Party, if the other Party files a petition
of any type as to its bankruptcy, is declared bankrupt, becomes insolvent, makes an assignment for the benefit of creditors, goes into liquidation or receivership, otherwise loses legal control of its business or ceases to carry on its business.

 11.4 Rights and Obligations upon Termination. Upon the termination of the Agreement for whatever reason: 

11.4.1 Subject to Section 7, WuXi shall promptly return to Customer all Customer Know-How, Customer Information and shall dispose of or
return to Customer the Customer Materials (and where supplied by Customer the Cell Line) and any materials therefrom, as directed by Customer; 

11.4.2 Customer shall promptly return to WuXi all WuXi Know-How and WuXi Confidential Information it has received from WuXi; 

11.4.3 Subject to the terms of Section 13, Customer shall not thereafter use or exploit WuXi Confidential Information, the WuXi Patent
Rights or the WuXi Know-How in any way whatsoever; 
 11.4.4 WuXi shall not thereafter use or exploit the Customer Patent Rights, Customer
Know-How or the Customer Information in any way whatsoever; 
 11.4.5 WuXi and Customer shall do all such acts and things and shall sign
and execute all such deeds and documents as the other may reasonably require to evidence compliance with this Section 11.4. 
 12.
Force Majeure 
 12.1 Force Majeure Rights. If either Party is prevented or delayed in the performance of any of its
obligations under the Agreement by Force Majeure such Party shall give written notice thereof to the other Party specifying the matters constituting Force Majeure together with such evidence as reasonably can give and specifying the period for which
it is 

  
 12 

 

 
  

 
estimated that such prevention or delay will continue, the Party claiming Force Majeure shall be excused from the performance or the punctual performance of such obligations as the case may be
from the date of such notice for so long as such cause of prevention or delay shall continue. Notwithstanding the foregoing, if the Party claiming Force Majeure estimates that the delay will exceed 30 days, or if the delay has, in fact, exceeded 30
days, the other Party may terminate this Agreement for cause as set forth in Section 9.3, including an additional 30 days notice to remedy the breach. 

12.2 Force Majeure Definition. The expression “Force Majeure” shall be deemed to include any cause affecting the performance
by either Party of the Agreement arising from or attributable to acts, events, acts of God, omissions or accidents beyond the reasonable control of the Party claiming the Force Majeure. 

13. Inventions. WuXi hereby assigns to Customer all right, title, and interest in all inventions, improvements, designs, formulas,
methods, processes and writings, whether or not copyrightable or patentable that embodies Customer Materials and Customer Know-How provided hereunder and discovered solely as a result of using such Customer Materials and Customer Know-How
(collectively, the “Inventions”). WuXi agrees, upon Customer’s request and at Customer’s expense, to do all things reasonably necessary to obtain patents or copyrights on any Inventions discovered exclusively as a result of
performing Services and to execute any documents necessary to formalize the afore-mentioned assignments. Notwithstanding the foregoing, Customer acknowledges that WuXi possesses certain inventions, processes, know-how, trade secrets, other
intellectual property and assets, including but not limited to, discovery methods, production methods, test methods, viral clearance methods and expertise, controls, procedures, computer technical expertise and software which have been independently
developed by WuXi (collectively, the “WuXi Property”). Customer and WuXi agree that any WuXi Property or improvements thereto which are used, improved, modified or developed by WuXi under or during the term of this Agreement, are the
product of WuXi’s technical expertise possessed and developed by WuXi prior to or during the performance of this Agreement and are the sole and exclusive property of WuXi regardless if such WuXi Property or improvements thereto are incorporated
or embedded in any Inventions or Deliverable generated or due hereunder, except that Customer is granted a non-exclusive, world-wide, royalty-free license, sublicensable in conjunction with a license to Customer Know-How and Customer Patent Rights,
to portions of WuXi Property or improvements that are incorporated or embedded in Deliverables to the extent reasonably necessary to allow full lawful use of the Deliverables that incorporate it. Protocols, methods, controls, SOPs, Specifications,
or documents (other than Customer data, reports, and documents specific to Customer Process and Product) that are produced by WuXi for Services (collectively, “Service Instruments”) are furnished solely with respect to Services, and WuXi
will retain all common law, statutory, ownership, and other reserved rights in such Service Instruments. The assignment of inventions and other intellectual property rights shall include the right to apply for patent and the right to have patent
granted in the name of Customer (or its designee). Customer shall have sole discretion in the preparation, filing, prosecution, maintenance, and enforcement of patents arising from Inventions. WuXi agrees to cooperate with Customer during the
preparation, filing, prosecution, issuance and maintenance of patents and patent applications covering Inventions by promptly executing papers and providing assistance, information and records as needed, in a timely manner. 

14. Mediation, Arbitration, Governing Law, Jurisdiction, and Enforceability 

14.1 Mediation. In the event of any dispute, controversy or claim arising out of or relating to this Agreement, or the breach,
termination or invalidity thereof, each Party shall by written notice to the other have the right to have such dispute referred to the senior management of WuXi and Customer for attempted resolution by good faith negotiations within forty-five
(45) days after such notice is received. If such senior management are unable to resolve such dispute within the forty-five (45) day period, and before arbitration is initiated, the 

  
 13 

 

 
  

 
Parties shall participate in a mediation that will last no less than eight (8) hours unless the dispute is resolved before such time. Notwithstanding the requirement for the Parties to
submit to mediation for a minimum of eight (8) hours, neither party will be required to participate in mediation for longer than sixteen (16) hours. Any mediation will take place a mutually agreeable venue, and will be officiated by a
mutually agreeable mediator identified and engaged by the Parties, the cost and fees for whom shall be borne equally by the Parties. In the event the Parties’ efforts to reach an amicable resolution through mediation or other informal means are
unsuccessful, either party may invoke the provisions of Section 14.2. Any settlement reached by the Parties under this Section shall not be binding until reduced to writing and signed by the above-specified management of WuXi and Customer. When
reduced to writing, such agreement shall supersede all other agreements, written or oral, to the extent such agreements specifically pertain to the matters so settled. 

14.2 Arbitration. In the event of the failure to reach a resolution pursuant to Section 14.1, any dispute, controversy or claim
arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by binding arbitration in accordance with the complex rules of the Commercial Arbitration Rules of the Shanghai Arbitration
Association in effect on the date of this Agreement. The place of arbitration will be Shanghai China and the Parties shall share equally filing fees, arbitrator fees or other costs of such proceedings, except that each Party shall bear its own
attorney’s fees, and other out-of-pocket arbitration expenses, unless the arbitrators decides otherwise. 
 14.3 Governing Law and
Jurisdiction. The construction, validity and performance of the Agreement shall be governed by the laws of the State of California, without regard to its conflict of laws provisions. 

14.4 Waiver. No failure or delay on the part of either WuXi or Customer to exercise or enforce any rights conferred on it by the
Agreement shall be construed or operate as a waiver thereof nor shall any single or partial exercise of any right, power or privilege or further exercise thereof operate so as to bar the exercise or enforcement thereof at any time or times
thereafter. 
 14.5 Severability. The illegality or invalidity of any provision (or any part thereof) of the Agreement or these
Standard Terms and Conditions shall not affect the legality, validity or enforceability of the remainder of its provisions or the other parts of such provision as the case may be. The Parties shall replace the illegal or invalid provision with a
legal and valid provision that as closely as possible reflects the intent and economic effect of the illegal or invalid provision. 
 14.6
Agreement Language This agreement has both Chinese and English versions. If there is discrepancy, the Chinese version overrules. 
 15.
Miscellaneous 
 15.1 Assignment. Neither Party shall be entitled to assign, transfer, charge or in any way make over the
benefit and/or the burden of this Agreement without the prior written consent of the other which consent shall not be unreasonably withheld or delayed, save that either Party shall be entitled without the prior written consent of the other Party to
assign, transfer, charge, sub-contract, deal with or in any other manner make over the benefit and/or burden of this Agreement to an Affiliate or to any company with which such assigning Party may merge or to any company to which such assigning
Party may transfer its assets and undertakings. 
 15.2 Press Releases. The text of any press release or other communication to be
published by or in the media concerning the subject matter of the Agreement shall require the prior written approval of WuXi and Customer. 

  
 14 

 

 
  

 15.3 Entire Agreement. The Agreement, the Technology Development Contracts attached
hereto embody the entire understanding of WuXi and Customer and there are no promises, terms, conditions or obligations, oral or written, expressed on implied, other than those contained in the Agreement. The terms of the Agreement shall supersede
all previous agreements (if any) which may exist or have existed between WuXi and Customer relating to the Services. In the event the Parties desire to enter into a Commercial Manufacturing Agreement with each other, such Commercial Manufacturing
Agreement shall be on separate terms and conditions from this Agreement. 
 15.4 No Third Party Beneficiaries. The Parties to this
Agreement do not intend that any terms hereof should be enforceable by any person who is not a Party to this Agreement. 
 15.5
Counterparts. This Agreement may be executed in two or more counterparts, and each such counterpart shall be deemed an original thereof. 

  
 15 

 

 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by its duly authorized
representatives as of the Effective Date. 
  

									
	WuXi AppTec Biopharmaceuticals Co. Ltd.	 		 	Zhejiang Medicine Co. Ltd.
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 	  
	 		 	Title:	 	  

					
	Date:	 	  
	 		 	Date:	 	  

  

 

 
  

 Appendix 

[See Attached] 

  

 

 
  

 QUALITY AGREEMENT 

by and between 
  

Zhejiang Medicine Co. Ltd 

(“ZMC”) 
 and 

WuXi AppTec Biopharmaceuticals Co Ltd. (“WuXi”) 

Purpose 
 This Quality Agreement defines the quality
responsibilities of the Parties and their respective affiliates or approved contractors with respect to the services provided by WuXi to ZMC regarding the development, cGMP manufacture, labeling, packaging, testing, release, shipment, and storage of
the ZMC materials itemized in Exhibit A to this Agreement (“Products”). 
 The allocation of quality responsibilities is summarized in Exhibit B
to this Agreement. 
 This Quality Agreement may be amended from time to time and additional details concerning quality requirements may be provided in
addenda in writing signed by the parties to this Quality Agreement. By signing below, the parties acknowledge and agree to the provisions of this Quality Agreement. 
  

									
	Agreed and accepted for:	 	Agreed and accepted for:
	 WuXi App Tec

Biopharmaceuticals Co Ltd
	 	  
 Zhejiang Medicine Co Ltd

					
	By:	 	  
	 		 	By:	 	
		 		 		 	  

	Name:	 	James Ruan	 		 	Name:	 	
	Title:	 	Sr Director,	 		 	  
 Title:
	 	
		 	Quality Assurance	 		 	 	
					
	Date:	 		 		 	Date:	 	
	  
	 		 	  

 Effective Date: 

  

 

 
  

 Table of contents 

 

							
	1.	 	 BACKGROUND INFORMATION
	  	 	1	  
	2.	 	 SCOPE
	  	 	1	  
	3.	 	 DEFINITIONS
	  	 	1	  
	4.	 	 RESPONSIBILITIES
	  	 	4	  
	5.	 	 COMMUNICATION
	  	 	4	  
	6.	 	 BATCH DISPOSITION (PRODUCT RELEASE)
	  	 	5	  
	7.	 	 LABEL APPROVAL
	  	 	6	  
	8.	 	 QUALITY CONTROL
	  	 	6	  
	9.	 	 REFERENCE SAMPLES
	  	 	6	  
	10.	 	 RETENTION SAMPLES
	  	 	7	  
	11.	 	 RECEIVING, SHIPPING, STORAGE AND DESTRUCTION
	  	 	7	  
	12.	 	 CHANGE CONTROL
	  	 	7	  
	13.	 	 INVESTIGATIONS OF NONCONFORMANCES, DISCREPANCIES (PRE AND POST DISTRIBUTION NC’S)
	  	 	7	  
	14.	 	 AUDITS AND INSPECTIONS
	  	 	8	  
	15.	 	 DISPUTE RESOLUTION
	  	 	9	  
	16.	 	 PRODUCT COMPLAINTS
	  	 	9	  
	17.	 	 STOCK RECOVERY
	  	 	9	  
	18.	 	 RESPONSIBLE PERSONS: CONTACT INFORMATION
	  	 	9	  

  

 

 
  

	1.	BACKGROUND INFORMATION 

  

	 	1.1	WuXi AppTec Biopharmaceuticals Co Ltd. (“WuXi”) and Zhejiang Medicine Co Ltd. ( “ZMC”), (referred to individually as “the Party” or collectively as “the Parties”) have entered
into a Master Services Agreement (MSA) pursuant to which WuXi develops, manufactures, labels and packages various source materials and intermediates, clinical drug substance and drug product to supply clinical trials of an antibody-drug conjugate
(ADC). The MSA, effective date Jun 14 2013, stipulates the requirement that the Parties jointly develop and approve a Quality Agreement. 

  

	2.	SCOPE 

  

	 	2.1	This Quality Agreement defines the quality obligations of the Parties and their respective affiliates or approved contractors, with respect to the development, manufacture, labeling, packaging, testing, release,
shipment and storage of Products in accordance with the MSA and associated Work Orders. 

  

	 	2.2	The provisions of this Quality Agreement supplement the provisions of the MSA. The terms of the MSA shall remain in full force and effect. In the event of any conflict between this Quality Agreement and the MSA, in
matters of quality, the Quality Agreement shall govern. In matters of business, financial and legal nature, the MSA shall govern. 

  

	 	2.3	This Quality Agreement may be amended only by mutual written agreement of the Parties. 

  

	 	2.4	Exhibits to this Quality Agreement are intended to provide additional definition to the applicable topic and, as such, should be updated to reflect the current information and business process, as applicable. Amendment
of the Exhibits does not require re-approval of the Quality Agreement unless the Quality Agreement itself is affected. Exhibits and all amendments of Exhibits shall be approved by mutually written agreement by the Parties. 

 

	 	2.5	All activities under this Quality Agreement shall be performed in compliance with standard industry practices, regulatory agency guidelines, ZMC specifications, and all applicable laws and regulations, including,
without limitation, GMP requirements that are acceptable to the PRC SFDA, US FDA, EMA, and TGA. 

  

	 	2.6	This Quality Agreement shall expire at the termination, cancellation, or expiration, as the case may be, of the obligation under the MSA and any associated Work Order(s) to supply Products for clinical and non-clinical
use. 

  

	 	2.7	WuXi and ZMC quality assurance will jointly oversee compliance according to GMP requirements that are acceptable to the PRC SFDA, US FDA, EMA, TGA, and ICH. 

 

	 	2.8	Use of Products shall be limited to use in certain in vitro, animal, and clinical studies/trials approved jointly by WuXi quality assurance and by the ZMC Quality Manager as defined in the MSA. 

 

	3.	DEFINITIONS 

  

	 	3.1	All capitalized terms not otherwise defined in this Quality Agreement shall have the definitions set forth in the MSA. 

  

	 	3.2	As used in this Quality Agreement, the following terms shall have the following meanings: 

  

			
	CoA	  	Certificate of Analysis prepared by WuXi for Products representing the analytical results obtained for Products tested per the Quality Specifications.
	CoC	  	Certificate of Compliance prepared by WuXi for Products

  
 1 

 

 
  

			
		  	representing that the Products were manufactured according to applicable cGMP requirements and that any Deviations/investigations related to Products have been finalized.
	Deviation	  	Any departure from SOPs, methods, Quality Specifications, protocols, Batch Records, instructions, processes, process specifications or other documentation related to the Products.
	Disposition Manager	  	WuXi Quality Assurance staff member qualified to perform the comprehensive quality assessment and make the disposition decision.
	Disposition Package	  	Documentation set provided that represents the joint batch disposition of the Product.
	Drug Product	  	Final dosage form of [Anti-Her2 ADC] containing the [Anti-Her2 ADC Drug Substance] formulated with excipients.
	Drug Substance	  	The bulk active ingredient [Anti-Her2 ADC Drug Substance] that is formulated with excipients and processed to produce the Drug Product.
	Final Release	  	Release of Products by WuXi and ZMC in accordance with standard operating procedures (“SOPs”).
	cGMP	  	All applicable laws and regulations relating to current Good Manufacturing Practice(cGMP) as promulgated by the Chinese Food and Drug Administration (SFDA), US FDA, EMA, TGA and ICH.
	IPC	  	In-Process Control
	Lot Genealogy	  	A scheme depicting the origins of a Product Batch (Drug Substance or Drug Product) taking into consideration specific operations such as splitting and pooling.
	Manufacturer’s Release	  	Release of Products by WuXi according to its SOPs. Manufacturer’s Release signifies that Products have been produced using approved processes, in compliance with applicable cGMP regulations, and meet the specifications
established for the Product, as determined by review of all appropriate documentation.
	Material Change	  	A change which materially modifies the regulatory filing for the Product or is determined by ZMC and/or WuXi to have significant potential to materially affect the Safety, Quality, Identity, Potency, or Purity of the
Product.
	Major Deviation	  	A Deviation incurred during the manufacture, labeling, packaging, testing, storage or shipment of the Products, which on preliminary evaluation is determined to have the potential to impact the Safety, Quality, Identity, Potency, or
Purity of the Product, or regulatory commitments/submissions involving the Products.
	Minor Deviation	  	A Deviation which on preliminary evaluation is determined to have no potential to impact the Safety, Quality, Identity, Potency, or Purity of the Product, or regulatory commitments/submissions involving the Products.
	OOS (Out Of Specification) Result	  	An examination, measurement or test result that does not conform with pre-established Specifications.
	Packaging Materials	  	All materials employed in the packaging of Products, excluding any outer packaging used for transportation or shipment. Packaging Materials are designated as primary or secondary
Packaging

  
 2 

 

 
  

			
		  	Materials according to whether or not they are intended to be in direct contact with Products.
	Process	  	A single operation or number of operations employed in the preparation of the Products.
	Process Description	  	A controlled document, approved by authorized technical and quality representatives of both Parties, that documents the general outline of a specific Process. It includes all relevant Process parameters to be met and equipment and
Raw Materials to be used.
	Products	  	The ZMC materials listed in Exhibit A to this Quality Agreement.
	Raw Materials	  	All materials and components (with the exception of Packaging Materials) used by WuXi in the production of Products under the MSA and associated Work Orders.
	Regulatory Authority	  	A public authority or government agency responsible for protecting and promoting public health through regulation or rulemaking (codifying and enforcing rules and regulations and imposing supervision or oversight for the benefit of
the public at large).
	Reserve Sample	  	Sample collected from the manufacture of Products for the purpose of being analyzed, should the need arise, to support investigations.
	Retention Samples	  	A fully packaged unit from a batch of finished Product stored for identification purposes.
	Specifications	  	A mutually agreed and approved set of tests and acceptance criteria used to judge the identity, quality, purity, potency and safety of all source materials, Raw Materials, and Products.
	Stock Recovery	  	The removal or correction of a non-marketed Drug Product used in a clinical trial for reasons related to product Safety, Quality, Identity, Potency, or Purity, that has not left the direct control of WuXi.

  
 3 

 

 
  

	4.	RESPONSIBILITIES 

  

	 	4.1	Without limiting any other provision of this Quality Agreement, the Parties agree that this Quality Agreement is intended to carry out the following guiding principles: 

 

	 	4.1.1	The Parties’ quality obligations with respect to the manufacture, labeling, packaging, testing, release, shipment and storage of Products are as set forth in this Quality Agreement and the MSA and associated work
orders. 

  

	 	4.1.2	The Parties shall comply with all Applicable Laws in the conduct of activities under this Quality Agreement. 

  

	 	4.1.3	The Parties acknowledge that the Parties shall each have the right to perform responsibilities hereunder through their affiliates and contractors, subject to the requirements outlined in Section 6.1.

  

	 	4.1.4	The Parties shall collaborate to address any disagreements. 

  

	5.	COMMUNICATION 

  

	 	5.1	The Parties agree to provide verbal communication to one another, in a timely manner, as necessary or appropriate for a given issue. Both Parties also agree to follow-up and clarify promptly in writing those important
verbal communications to ensure clarity of issues. All official communications and documentation between the Parties will be conducted in Chinese. 

  

	 	5.1.1	WuXi shall forward any written communication from the Chinese Regulatory Agency concerning the Products within three (3) business days of the time of receipt by WuXi in Chinese. 

 

	 	5.1.2	The forwarding of any oral communication from the Chinese Regulatory Agency concerning the Product outlined in this document shall be done within three (3) business days in Chinese. 

 

	 	5.2	Routine verbal and written communications required herein shall be delivered to the individuals indicated in EXHIBIT B or their delegates. 

 

	6.	SUBCONTRACTING 

 6.1 Any subcontracting related to manufacture and testing of Products requires
the prior approval of ZMC, a contractual agreement between WuXi and the respective contractor, and qualification of the contractor by WuXi quality assurance. Upon request by ZMC, WuXi shall provide documentation of the qualification of the
contractor for ZMC review. 
  

	7.	FACILITIES AND EQUIPMENT 

 7.1 WuXi will operate all equipment, systems, and facilities related
to manufacturing, testing, packaging, and storage of Products according to WuXi’s written procedures. 
 7.2 WuXi shall perform
equipment qualification, preventive maintenance, instrument calibration, computer system validation, and cleaning validation according to WuXi’s written procedures. 

7.3 WuXi is responsible for maintaining records of equipment usage, cleaning and any maintenance/calibration performed. 

  
 4 

 

 
  

	8.	RAW MATERIALS AND PACKAGING MATERIALS 

  

	 	8.1	WuXi shall use raw materials and raw material vendors and components that have been jointly agreed by ZMC and WuXi. 

  

	 	8.2	Raw Materials and Packaging Materials provided or procured by WuXi shall be obtained from qualified or specified vendors. 

  

	 	8.3	Wuxi shall maintain a vendor assurance program. 

  

	 	8.4	WuXi shall ensure that a Certificate of Analysis or equivalent is obtained with each lot of Raw Materials or Packaging Materials purchased. 

 

	 	8.5	Specifications for Critical Raw Materials will be agreed to by ZMC. 

  

	 	8.6	WuXi will store all Raw Materials and Packaging Materials and Products in a secure location under appropriate conditions. 

  

	9.	PRODUCTION SYSTEMS 

  

	 	9.1	Manufacture of Products will be done at WuXi’s pharmaceutical manufacturing facilities on a campaign basis, using procedures for manufacturing and control of Products set forth in Master Batch Records according to
Process Descriptions approved by ZMC. 

  

	10.	BATCH DISPOSITION (PRODUCT RELEASE) 

  

	 	10.1	WuXi Quality Responsibility 

  

	 	10.1.1	WuXi shall be responsible for release of Product batches to ZMC (Manufacturer’s Release) confirming that each Batch supplied is in full accordance with the relevant Specifications. ZMC and WuXi will mutually
approve in writing all IPC, Manufacturer’s Release, and stability Specifications for Products. 

  

	 	10.1.2	WuXi shall prepare a Certificate of cGMP Compliance (CoC) and a Certificate of Analysis (CoA) for each batch of Product and a BSE/TSE statement. 

 

	 	10.1.3	WuXi shall provide to ZMC’s Quality Manager a Disposition Package for each batch of Product consisting of the CoC, CoA, Lot Genealogy, copy of the Executed Batch Record and Deviation Summary. The Disposition
Package will be prepared and reviewed by a Disposition Manager to confirm completeness of the package and determine the batch disposition based on a comprehensive quality assessment of the batch. 

 

	 	10.1.4	The Deviation Summary for the batch will list all Deviations incurred during the manufacture, labeling, packaging, testing, or storage of the Products along with confirmation of satisfactory review and approval of each
Deviation. Deviations shall be categorized as Major (determined to have potential to adversely impact the Safety, Quality, Identity, Potency, or Purity of the Products or compliance with regulatory filings regarding the Products, and subject to
formal investigation and resolution according to WuXi procedures) or Minor (determined to have no adverse impact as described above). 

  
 5 

 

 
  

	 	10.2	ZMC and WuXi Joint Quality Responsibility 

  

	 	10.2.1	ZMC and WuXi shall be responsible for the Final Release of the Products for further manufacturing use, animal studies, or clinical distribution following joint review of the Disposition Packages provided by WuXi. ZMC
and WuXi agree to reasonable review periods and completion of document requests. 

  

	11.	LABEL APPROVAL 

  

	 	11.1	Physical Label Creation and Approval 

  

	 	11.1.1	Physical labels for Product will be generated and approved according to established GMP procedures of WuXi for any such activities performed for toxicology or clinical studies. 

 

	 	11.1.2	Label Application 

  

	 	11.1.2.1	WuXi is responsible for labeling and bulk packaging of the toxicology and clinical supplies. 

  

	 	11.1.2.2	WuXi shall apply physical labels to Product prior to all shipments. 

  

	12.	QUALITY CONTROL 

  

	 	12.1	WuXi Quality Control Laboratory Testing Responsibility 

  

	 	12.1.1	WuXi will conduct testing of Products according to the relevant Specifications and its approved, qualified or validated methods, policies and procedures. All Specifications relating to Products will be jointly approved
by WuXi and ZMC quality assurance. 

  

	 	12.2	WuXi Importation and Testing Responsibility 

  

	 	12.2.1	WuXi shall be responsible for preparing all documents required for import clearance and entry of shipment with reasonable cooperation from ZMC. 

 

	 	12.2.2	WuXi is responsible for sampling upon receipt and conducting testing, as required. 

  

	 	12.2.3	ZMC must consent to WuXi using a contract laboratory for raw material/component release testing. Such consent is subject to the requirements outlined in Section 6.1. 

 

	 	12.2.4	In the case of OOS, an investigation will be performed per Section 13 (INVESTIGATION OF NONCONFORMANCES, DISCREPANCIES) of this Quality Agreement and WuXi should notify and obtain consent from ZMC quality assurance
immediately. 

  

	 	12.3	Stability Tesing 

  

	 	12.3.1	WuXi will conduct stability testing of Products according to WuXi’s clinical stability program requirements. 

  

	 	12.3.2	WuXi will communicate the expiration/retest date of each Product lot in the Disposition Package. 

  

	 	12.3.3	WuXi shall notify ZMC within five (5) business days of any confirmed stability failure of Products and provide periodic updates on the OOS or Out of Trend investigations. 

 

	 	12.3.4	WuXi will provide ZMC with periodic Stability Summary Reports, including trending not to exceed six (6) month intervals. 

  

	13.	REFERENCE/RESERVE SAMPLES 

 13.1 WuXi shall retain Reference/Reserve Samples for each lot of
Products produced and released for further manufacturing use, or for use in toxicology and clinical studies for the longer of five (5) years after the lot’s expiration period or two (2) years after the completion (as determined by
issuance of a non-clinical or clinical study report) of a non-clinical or clinical study conducted using the lot. 

  
 6 

 

 
  

 13.2 Each Reference/Reserve Sample will consist of at least twice the quantity necessary to
determine whether the Product meets its established Specifications, except for sterility and pyrogen testing. 
  

	14.	RETENTION SAMPLES 

  

	 	14.1	WuXi shall retain Retention Samples for 1 year after the expiration date of the Product for each packaged lot of Product released for clinical distribution per established WuXi procedure. 

 

	15.	RECEIVING, SHIPPING, STORAGE and DESTRUCTION 

  

	 	15.1	WuXi is responsible for adequate storage of the raw materials, components and Product throughout the supply chain to meet any temperature or special storage conditions. 

 

	 	15.2	Shipping excursions will be investigated by WuXi. 

  

	 	15.3	WuXi shall be responsible for the destruction of any unused and partially used Product in accordance with Applicable Laws and regulations. 

 

	16.	CHANGE CONTROL 

  

	 	16.1	WuXi will have a change control procedure in place to address changes to WuXi’s systems, facilities, Processes, Process Descriptions, Master Batch/Labeling/Packaging Records, Raw Materials and Packaging Materials
(and associated specifications. 

  

	 	16.2	Both Parties shall jointly agree and both Parties’ quality assurance personnel approve any material changes of manufacturing of the Product, specifically impacting the following documents, if applicable:
(1) Analytical Methods, (2) Master Batch/Labeling/Packaging Records, (3) Primary Packaging Components Specifications, (4) Product Specifications, (5) Raw Material/Component Specifications, and (6) Major Facility of
Manufacture Changes. 

  

	 	16.3	Within fourteen (14) calendar days after the receipt of such notification both Parties will meet and determine collaboration requirements. 

 

	 	16.4	If a Material Change requires the approval of a Governmental Authority in China, then, WuXi shall use reasonable efforts to file for such approval. 

 

	 	16.5	WuXi shall provide updates to ZMC of any regulatory submissions relating to said changes. 

  

	17.	INVESTIGATIONS OF DEVIATIONS, NONCONFORMANCES, OOS RESULTS, DISCREPANCIES ( Pre and POST DISTRIBUTION Deviations) 

  

	 	17.1	WuXi will maintain a documented system for handling Deviations, Deviation Investigations, OOS Results, and Corrective and Preventive Actions. 

 

	 	17.2	It is the responsibility of WuXi to ensure that all Deviations are investigated, documented, and approved prior to release of Products. 

 

	 	17.3	Prospective (planned) Deviations shall be provided to ZMC for review and approval. 

  

	 	17.4	If a Deviation is identified after a Product lot has been Released and shipped to a clinical site and/or patients have been administered the Product, then WuXi will notify ZMC immediately of such Deviation.

  

	 	17.5	Each Party shall inform the other Party as soon as reasonably possible of issues which may adversely impact Product quality, safety, efficacy or adverse events relating to any batch of Product. 

  
 7 

 

 
  

	18.	AUDITS AND INSPECTIONS 

  

	 	18.1	WuXi Audits 

  

	 	18.1.1	ZMC shall be entitled to perform yearly routine audits of WuXi facilities engaged in the provision of contracted services relating to Products. All facilities and areas involved in manufacturing, testing, filling,
labeling, packaging, storage of Products, intermediates, raw materials and components, document review and storage facilities are within the scope of an ZMC audit. Audit scope, agenda, and timing will be approved by both Parties prior to each audit.

  

	 	18.1.2	All audits of WuXi facilities will be conducted during regular business hours in the presence of WuXi representatives. Audits shall be conducted by not more than three (3) ZMC representatives at each WuXi facility,
and, unless otherwise agreed upon by WuXi, for not more than four (4) business days at each site. ZMC shall provide WuXi written notification of such audit in a reasonable time period. The written notification must clearly state the scope of
the audit. 

  

	 	18.1.3	In case of serious events (e.g. receipt of an FDA Warning Letter or its equivalent from another Regulatory Authority, recall of clinical Product or series of clinical Product complaints), WuXi shall host ZMC “For
Cause” audits. The scheduling of For Cause audits will be mutually agreed and take into consideration the critical and/or urgent nature of the precipitating event(s). 

 

	 	18.2	Audit Findings 

  

	 	18.2.1	ZMC shall provide WuXi a copy of the audit report within thirty (30) calendar days of completion of an audit. After delivery of the audit report, WuXi shall provide ZMC with a written response to such report within
thirty (30) calendar days from WuXi’s receipt of the report from ZMC. All information in the audit report and subsequent follow up is considered confidential information between both Parties. 

 

	 	18.3	Regulatory Agency Inspections 

  

	 	18.3.1	WuXi shall notify ZMC of any inspection by a Regulatory Authority related to a facility involved in (i) manufacture, labeling, packaging, testing, release, shipment, or storage of the Product within one
(1) business days of the initiation of the inspection. 

  

	 	18.3.2	WuXi shall provide ZMC with a copy of the final response immediately after submission to the Regulatory Authority. 

  

	 	18.3.3	WuXi shall provide the document in the language provided along with a reasonable translation into English. 

18.3.4 WuXi shall provide a list and/or copies of all documents directly related to Products shared with a Regulatory Authority during any
inspection. 

  
 8 

 

 
  

	19.	DISPUTE RESOLUTION 

  

	 	19.1	Disputes relating to non-compliance or nonconformance of Products with the product specifications shall be governed by the terms set forth in the MSA. 

 

	20.	PRODUCT COMPLAINTS 

  

	 	20.1	Any information related to product complaints (i.e., communication that alleges deficiencies relating to the identity, quality, durability, reliability, safety, effectiveness, or performance of a drug, condition of
labeling, or packaging, after it is released by WuXi for toxicology or clinical studies) shall be forwarded to ZMC within one (1) business day after WuXi first becomes aware of such information. 

 

	 	20.2	WuXi shall investigate according to WuXi’s applicable policy and procedures. 

  

	 	20.3	WuXi shall provide ZMC with periodic updates on any outstanding product complaints and complete a final report within sixty (60) calendar days. 

 

	21.	STOCK RECOVERY 

  

	 	21.1	If any problems are discovered and identified as recall/stock recovery issues related to the Products, the discovering Party shall notify the other immediately. 

 

	 	21.2	WuXi shall notify ZMC within three (3) business days if it becomes aware that any Product is alleged or proven to be the subject of a recall or stock recovery in China. 

 

	 	21.3	The Parties shall meet to discuss the circumstances that merit the Product recall or stock recovery and to determine the appropriate course of action. Such course of action shall be consistent with the WuXi internal
SOP. 

  

	 	21.4	If either Party proposes to initiate a Stock Recovery or other corrective action with respect to the Product in the Collaboration Territory, the Parties will promptly discuss such proposed action. Any decisions by the
Parties shall be governed by the terms of the Collaboration Agreement. The Parties shall cooperate, as reasonably necessary, in the implementation of such actions. 

 

	 	21.5	The Parties shall cooperate and promptly perform investigations into the root causes leading up to the Product Stock Recovery, when appropriate. Investigation reports regarding the defect or cause for such regulatory
reporting shall be provided to the corresponding Party within an appropriate timeframe dependent on regulatory reporting requirements. 

  

	 	21.6	The Parties shall each maintain complete and accurate records of any Stock Recovery it has the right to control pursuant to this section of the Quality Agreement for such periods as may be required by legal
requirements, but in any event for no less than three (3) years from the date of Stock Recovery. 

  

	22.	RESPONSIBLE PERSONS: CONTACT INFORMATION 

 22.1 The individuals listed in EXHIBIT C shall be
the key points of contact between WuXi and ZMC relating to the rights and obligations of the Parties in this Quality Agreement. The responsible individuals, or their respective delegates, must be notified in official communications as required by
this Quality Agreement. 

  
 9 

 

 
  

 Exhibit A 

List of Products 
 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  

 Exhibit B 
  

									
	 Definition of Quality Duties and Responsibilities

	 	  	 	  	 	  	[***]	  	 
	 	  	 	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
					
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  

									
	 Definition of Quality Duties and Responsibilities

	 	  	 	  	 	  	[***]	  	 
	 	  	 	  	[***]	  	[***]	  	[***]
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  

									
	 Definition of Quality Duties and Responsibilities

	 	  	 	  	 	  	[***]	  	 
	 	  	 	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
	  	  		  		  	[***]
		  	[***]	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
	  		  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
					
		  	[***]	  		  	[***]	  	
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
	  	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  

									
	 Definition of Quality Duties and Responsibilities

	 	  	 	  	 	  	[***]	  	 
	 	  	 	  	[***]	  	[***]	  	[***]
		  	[***]	  		  		  	[***]
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  		  	[***]
	[***]	  	[***]	  		  		  	
		  	[***]	  		  	[***]	  	
		  	[***]	  		  	[***]	  	

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
  

 EXHIBIT C 

Responsible Persons and Contact Information 
  

							
	 WuXi

	 Name
	  	 Email Address
	  	 Contact Number
	  	 Responsibility

				
	James Ruan	  	[***]	  	[***]	  	Sr. Director, Quality Assurance
				
	Bob Coldreck	  	[***]	  	[***]	  	VP, Quality
		  		  		  	
	
	 ZMC

	 Name
	  	 Email Address
	  	 Contact Number
	  	 Responsibility

		  		  		  	
		  		  		  	

 Exhibit C Version Date: Jun 14 2013 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 4 

Work Plan 
 [***] 
  

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 [***] 

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 Exhibit 5 

Joint Steering Committee 
  

					
	Chairperson:	 	Feng Tian, Ph.D, AMBRX Inc.	 	
			
	Members	 		 	

  

									
	 Name
	  	 Affiliation
	  	 Title
	  	 Email
	  	 Work Phone

	Feng Tian, Ph.D	  	AMBRX Inc.	  	Director, EuCode Technology	  	[***]	  	[***]
	Ho Cho, Ph.D	  	AMBRX Inc.	  	Chief Technology Officer	  	[***]	  	[***]
	Scott Geyer, Ph.D	  	AMBRX Inc.	  	Vice president, CMC	  	[***]	  	[***]
	Xuejun Liang	  	ZMC	  	Manager, Biopharmaceutical	  	[***]	  	[***]
	Baoquan Zhu	  	Shanghai Institute of Pharmaceutical Industry	  	Chair, Academic Committee	  	[***]	  	[***]
	Hong Qian, Ph.D	  	Novo Biotech Corp.	  	CEO/BOD	  	[***]	  	[***]

  
 ***Certain information on this page has
been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 6 

Joint Press Release 
 Ambrx and
Zhejiang Medicine Co. Ltd. Form Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugate for Breast Cancer 
 San Diego and
Shanghai, June 14, 2013 — Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) today announced that they have formed a collaboration to develop and commercialize ARX788, Ambrx’s most advanced internally developed site-specific antibody drug
conjugate (ADC) targeting Her2-positive breast cancer. 
 Under the agreement, Ambrx and ZMC will continue the development of ARX788, with ZMC bearing the
ongoing development cost. ZMC will receive commercial rights in China while Ambrx retains commercial rights outside of China and receives royalties on sales of the product in China. ZMC will manufacture the product to world-class standards for
clinical and commercial supplies on a global basis. WuXi PharmaTech will provide integrated services for ARX788, including the development and manufacturing of the toxin, antibody and ADC, pre-clinical development and clinical trials. 

“We are excited to initiate this unique collaboration with ZMC and WuXi, which allows us to team up with China’s leading pharmaceutical and CRO
companies to efficiently develop ARX788, our most advanced ADC therapeutic candidate for both breast cancer and gastric cancer indications,” said Lawson Macartney, Ph.D., Chief Executive Officer of Ambrx. This collaboration allows Ambrx to
further extend our pipeline of ADCs and gain access to the China market through our partnership with ZMC. Our experience with site-specific ADC technology has shown that we have the potential to create best-in-class therapeutic candidates, and we
look forward to advancing ARX788 into the clinic to understand its full potential.” 

 Chunbo Li, Chairman of Zhejiang Medicine, commented, “We are honored to partner with Ambrx, a leading
biotech company, in ADC drugs. We will work with WuXi PharmaTech to accelerate the development and commercialization of ARX788 in China to bring benefits to Her2-positive cancer patients. The partnership will help ZMC undertake pioneering work in
the development of monoclonal antibodies and ADCs. The partnership will also help ZMC establish long-term and mutually beneficial relationships with leading global companies and advance our position in the biopharmaceutical industry. “ 

“Our collaboration with Ambrx and ZMC on ARX788 is another example of how WuXi’s comprehensive, integrated, open-access R&D services platform
enables our partners to develop innovative products efficiently and cost-effectively to benefit the world’s patients,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “We are very pleased to offer our partners integrated
services at global standards ranging from toxins to antibodies, from CMC development to pre-clinical studies, from regulatory strategy to clinical trials.” 

About Ambrx 
 Ambrx Inc. is a clinical stage
biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including ADCs, bispecific antibodies and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth
hormone that has successfully completed Phase 2b clinical trials. in addition to its most recent ADC collaborations with Merck, Astellas and Bristol-Myers Squibb, Ambrx has collaborations to discover and develop products incorporating Ambrx
technology with Bristol-Myers Squibb, Eli Lilly and several undisclosed companies. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas. 

For additional information, visit www.ambrx.com. 

 About Zhejiang Medicine Co. Ltd. 

Zhejiang Medicine Co. Ltd. (ZMC) is a major China-based pharmaceutical company listed on the Shanghai stock exchange. It is a leading global manufacturer of
fat-soluble vitamins and bacteria-resistant antibiotics. ZMC’s products are exported to the United States and many EU countries. In 2012, total revenue reached 5.3 billion RMB and total profit reached 855 million RMB. ZMC has strong
capabilities in technology innovation and new drug R&D and has received the National High-Tech Enterprise and Model Innovation Enterprise awards in China. ZMC has a national-level R&D center and post-doctorate R&D sponsorship. Three ZMC
research projects were awarded second prize in the National Technology Advancement competition and one was awarded second prize in the National Technology Innovation competition. To date, ZMC has 126 issued patents, including 15 global patents, and
has four class 1 drugs in clinical trials. 
 For more information, please contact: 

ZhuJun Yu or Jing Zhu (Investor Relationship) 
 Phone:
+86-571-87213883 
 email: sunny_0517@163.com 
 About WuXi
PharmaTech 
 WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the
United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug
and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners shorten the cycle and lower the cost of drug and 

 
medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. 
 For
more informaiton, please contact 
 Ambrx 
 Ian Stone

 (619) 308-6541 
 WuXI PharmaTech 

Ronald Aldridge (for investors) 
 (201) 585-2048 

ir@wuxiapptec.com 
 Aaron Shi (for the media) 

+86-21-5046-4362 
 aaron_shi@wuxiapptec.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]